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Chapter 1 General introduction
In the next section, an overview of current clinically available topical hemostatic 
agents is provided in which the main advantages and shortcomings of these products 
are discussed in more detail.
1.2 Natural hemostats
The main class of hemostatic products is composed of polymeric materials of 
biological origin such as starch17, chitosan18, oxidized regenerated cellulose 
(ORC)19, 20, collagen and gelatin21, 22. These biocompatible and biodegradable 
products accelerate the natural coagulation cascade by providing a sealing matrix 
where blood platelets can aggregate, thereby facilitating the formation of a blood 
clot. The products are available in various forms (powder, sponges, dressings) and 
are widely used in the clinic. In Figure 1, scanning electron microscopy (SEM) images 
of selected natural hemostats are displayed, revealing the fibrous structure of ORC-
fibers (Figure 1A and 1B) and the porous nature of both collagen (Figure 1C and 
1D) and gelatin sponges (Figure 1E and 1F). These products have the capacity to 
absorb blood due to their large surface area and permeabilility, and subsequently 
induce blood coagulation by providing a physical matrix for blood clot formation. 
The hemostatic efficacy of these materials is, however, limited for i) large areas 
of profuse bleedings, ii) patients suffering from bleeding disorders or iii) patients 
receiving anticoagulants (such as heparin) during surgery.
 A promising class of natural hemostats involves biologically derived carriers which 
are coated with fibrinogen and thrombin.  These proteins facilitate the final stage of 
the coagulation cascade, i.e., the formation of a fibrin clot23. As a result, the addition 
of these proteins to a collagen sponge results in reduced time to hemostasis (TTH) 
compared to collagen without these proteins, which has been reported by Chapman 
et al24. Tachosil® is such a collagen-based carrier coated with human-derived 
fibrinogen and thrombin which is considered a ‘gold standard’ due to its widespread 
use in many fields including liver resection25-28. Tachosil is covered with thrombin and 
fibrinogen (Figure 2A, 2B and 2D) on the active side, which is yellow colored due to 
the presence of riboflavin (E101) as a coloring agent (Figure 2C). The uncoated side 
displays a porous structure (Figure 2E and 2F). Tachosil has been tested in a wide 
range of surgical procedures. For liver resection procedures, Tachosil performed 
significantly better than electocautery29, 30 regarding TTH, but not better than ORC31. 
In addition, this study also demonstrated that postoperative complications (e.g. 
bile leakage) were still observed - although at a lesser extent - in patients treated 
with Tachosil. Despite the favorable efficacy, Tachosil is still associated with several 
drawbacks. Recently, it was reported that Tachosil can cause undesired adhesion 
between organs32. Other drawbacks include a high cost price and the use of human- 
as well as animal-derived materials, which have a known risk of disease transmission 
1. Hemostatic biomaterials
Insufficient control over bleeding remains one of the biggest challenges in trauma 
surgery of soft tissues. This limited control is especially problematic during surgical 
procedures on highly venous organs (kidney, liver and spleen), particularly during 
removal of part of an organ (e.g. due to the presence of tumorous tissue), which 
compromises the veins close to the tissue surface.  These bleedings cannot be treated 
by invasive methods like suturing or stitching, since this would create additional 
bleeding.  Due to the severity of these bleedings, other methods like electrocautery1 
and ultrasonic sealing2 often do not suffice during surgical treatment of these 
organs. Consequently, an alternative approach to control bleeding is required. As a 
result, a wide range of topical hemostatic agents has been developed3-5, which are 
defined as materials which facilitate localized wound closure without compromising 
underlying tissues during their mechanism of action.
 Two major surgeries which often require the use of topical hemostatic agents are 
partial nephrectomy6 and liver resection7, since both procedures are accompanied 
with severe blood loss8, 9. According to a survey among Japanese surgeons, 60% of 
the respondents indicated that topical hemostatic agents are standard treatment 
in case of a liver resection10. Another survey among Dutch surgeons indicated 
that 87% of the surgeons used topical hemostatic agents after liver resection. 
Moreover, 45% of the respondents were convinced that topical hemostats could 
aid in reducing complications during liver resection11. Nevertheless, liver resection 
remains a complex surgical procedure which often proceeds with the development 
of postoperative complications such as bile leakage12, abscess formation13, 14 and 
post-operative bleedings15. As a result, successful control over bleedings and 
postoperative management both remain a challenge in liver resection.
 Although the quality of topical hemostatic agents has improved considerably 
over the past decades, the success rates of hemostatic agents are often not only 
determined by the efficacy of the agent, but also by external factors such as the type 
of surgical procedure, the severity of the procedure, the experience of the surgeon 
and the medical condition of the patient. Therefore, it is hard to predict a priori 
whether a specific topical hemostatic agent is effective for a specific procedure. 
Despite a large amount of studies on topical hemostatic agents3, comparative studies 
are often performed for a limited number of products per study and often only few 
outcome parameters are considered. As a result, many studies on hemostatic agents 
are either inconclusive or offer contradictory results16. Evidently, extensive research 
is needed to improve the current generation of topical hemostatic agents and avoid 
the above-mentioned clinical complications.
1514
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1.3 Synthetic hemostats
Recently, synthetic polymer sealants33 have been developed which act independently 
of the natural coagulation cascade due to their ability to seal the wound surface, 
thereby stopping the blood flow. Although the efficacy of these products is reported 
to be superior over naturally derived hemostats, the unknown biodegradability or 
excretability of some of these polymers as well as their toxicity (e.g. for cyano-
acrylates)34 are specific drawbacks of this class of materials.  
 A recently emerging approach entails the development of hybrid products, 
which combine the beneficial properties of both synthetic and natural polymers. 
A particularly interesting example of such a hybrid product is Veriset35, which 
is an oxidized regenerated cellulose sheet impregnated with tri-lysine and 
N-hydroxysuccinimide ester-functional 4-arm poly(ethylene glycol) (NHS-PEG) 
(Figure 3). As can be observed from the SEM images, this product is composed of 
a coated side (Figure 3A&B), which is the tissue-reactive side due to application 
of NHS-PEG, and an uncoated side (Figure 3D), which shows the woven character 
of the ORC. The product has to be applied in dry state with the coated side facing 
the bleeding surface, whereafter blood penetrates through the product to allow 
fixation to the tissue. This fixation is achieved since NHS-PEG is reactive towards 
amines present in tissue, thereby sealing the wound site. Veriset has been tested in 
various model systems, for example in liver resection36. It was observed that Veriset 
performed better than Tachosil in terms of TTH, while both products had a similar 
Figure 2 Overview of Tachosil. Images were recorded using SEM of the biologically active top side 
(A+B), cross section (D) and back side (E). Scale bars correspond to 1 mm (A&E), 100 µm (D) and 10 µm 
(B). Images were taken with a digital camera from top (C) and bottom (F).  
via viral or prion agents. Moreover, biologically derived hemostatic materials are only 
effective to a limited extent for patients receiving anticoagulants (such as heparin) 
during surgery. Since these factors are intrinsically connected to biologically derived 
hemostatic agents, many research groups have focused on the development of 
alternative hemostatic products based on synthetic polymers.  
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Figure 1 SEM images of hemostats composed of oxidized regenerated cellulose (ORC) (Snow®) (A&B), 
collagen (Hemotese®) (C&D) and porcine gelatin (E&F). Scale bars correspond to 1 mm (C&E), 100 µm 
(A, D&F) and 10 µm (B)
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Figure 4 Overview of Hemopatch. Images were recorded using SEM of the protein-reactive side (A+B), 
cross section (D) and back side (E). Scale bars correspond to 1 mm (A) and 100 µm (B, D & E). Images 
were taken with a digital camera from protein-reactive top side (C) and back side (F). 
1.4 Advantages and disadvantages of current hemostats
Traditionally, hemostatic products have been developed which rely on the natural 
coagulation cascade as mechanism of action and these products are generally used 
in view of their biocompatibility and biodegradability. However, the limited efficacy 
for complex surgical scenarios (e.g. in case of profuse bleedings) and drawbacks 
related to the use of biologically derived materials (e.g. transmission of animal-
diseases) have led to an increased interest for synthetic alternatives. 
 These synthetic alternatives (in particular PEG-based systems) have specific 
benefits over their biological counterparts due to their highly tunable structure and 
mechanism, which has led to faster hemostasis compared to methods purely based 
on the natural coagulation cascade. Although favorable efficacy has been reported 
for the NHS-PEG based products Veriset and Hemopatch, the intrinsically fast 
crosslinking of NHS-PEG (in case of Hemopatch) might lead to irregular sealing of 
the wound site (by inhomogeneous crosslinking with tissue) or poor fixation to tissue 
(in case limited crosslinking with the collagen carrier is achieved), thereby rendering 
these hemostats less effective for some surgical bleedings. Moreover, PEG based 
materials are known to swell which can cause e.g. compression of neighbouring blood 
vessels or nerves. These potential drawbacks might be solved by modifying and fine-
tuning the polymer architecture and properties. However, PEG has limited options 
for tailoring the degree of functionalization (only via the end groups) and polarity, 
which prompts further research on alternative polymers with hemostatic activity.
occurrence of adverse effects35. In another study, in a cardiovascular model, Veriset 
outperformed ORC without NHS-PEG (Surgicel®) in terms of TTH, demonstrating 
the benefit of the sealing effect of the tissue-reactive coating37.
Figure 3 Overview of Veriset. Images were recorded using SEM of the protein-reactive top side (A&B), 
back side (D) and cross section (E). Scale bars correspond to 1 mm (A) and 100 µm (B, D&E). Images 
were taken with a digital camera from top (C) and bottom (F). 
Another product in this class is Hemopatch38-40, a flexible porous collagen carrier 
coated with NHS-PEG (Figure 4). Similar to Veriset, Hemopatch contains a tissue-
reactive coated side (Figure 4A-C), which is partially coated with NHS-PEG, and a 
non-coated side (Figure 4E and 4F) which shows the porous nature of the collagen 
carrier. The mechanism of action of Hemopatch is based on instantaneous covalent 
crosslinking between NHS-PEG and amines present in tissue, blood proteins and 
the collagen carrier. This reaction seals the wound site and allows firm fixation of 
the patch to the tissue. Hemopatch has been thoroughly tested in the field40, for 
example in liver resection where Hemopatch performed better than Tachosil41 in 
terms of TTH. In this work, the authors claim that this phenomenon is related to 
the faster crosslinking reaction of NHS-PEG compared to the enzymatic conversion 
of fibrinogen to fibrin (forming a fibrin clot) in case of Tachosil. Moreover, a lower 
incidence of hematoma formation was observed for Hemopatch compared to 
Tachosil. However, a recent study reported that Tachosil and Hemopatch performed 
equally effective regarding TTH42. In another study, Hemopatch demonstrated 
shorter TTH compared to a product based on pure ORC39, which also confirmed the 
beneficial effect of the NHS-PEG-coating. 
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common reagents which are used for the respective steps. For a more detailed 
discussion on the mechanism, the reader is referred to an excellent review on this 
topic53.
Figure 5 Simplified mechanism of CROP of 2-oxazolines. Reprinted with permission53
2.2.1 Initiation
During initiation, an electrophilic initiator forms a complex with the nucleophilic 
oxazoline (with initiation rate constant ki) leading to the formation of an oxazolinium 
salt (Figure 6A). This cation is the reactive species, which is susceptible to nucleophilic 
attack of the oxazoline monomers, resulting in chain extension (propagation). 
However, this oxazolinium salt is in equilibrium with the covalently bound counter-
ion, which limits successful propagation54. Experimentally, the occurrence of the 
reactive cationic species (determined by the equilibrium kcovalent/kcation) is strongly 
determined by the type of initiator55, counter-ion56 and the experimental conditions 
(e.g. concentration57, solvent58, reaction temperature59). Common initiators 
employed for CROP include alkylating agents (triflates60, 61, tosylates55), acid halides62 
and Lewis acids43, but also multivalent initiator species (such as tetravalent triflates) 
have been employed for the design of star-shaped POx-architectures63, 64.    
2.2.2 Propagation
After the reactive cationic species is formed, nucleophilic attack of the oxazolines 
on this reactive species will result into chain extension, which is entropically driven 
by the formation a more stable tertiary amide from the cyclic oxazoline species 53. 
Similar to the initiation process, chain extension (determined by propagation rate 
constant kp) is dependent on the equilibrium between the cationic and covalent 
species54 (Figure 6B). Additional factors which influence the propagation rate 
constant are the type of counter-ion65, type of solvent66, 67, concentration57 and 
nucleophilicity of the incoming monomer68-70. 
In summary, it remains a major challenge to develop a hemostatic device which is 
capable of both i) treating large areas of profuse bleedings in a non-invasive way 
and ii) reducing postoperative complications which improves surgical outcome and 
reduce hospitalization.  
To this end, the ideal topical hemostatic agent should:
• seal large areas of profuse bleedings (including the wound site)
• attach to tissue in a non-invasive way
• be effective without adverse reactions
• prevent undesired adhesion between organs
• in dry state to  be suitable for laparoscopic procedures
• be flexible in terms of folding 
• be able to absorb sufficient amounts of blood
• be fully resorbable
• display favorable excretability
To achieve these requirements, novel polymeric materials with improved hemostatic 
efficacy should be developed that can be functionalized in a more versatile manner 
than currently available hemostatic products. A highly interesting class in this 
respect are the poly(2-alkyl-2-oxazolines).
2. Poly(2-oxazoline)s
2.1 Introduction
Poly(2-alkyl-2-oxazoline)s or POx are polymers, which were independently discovered 
in the 1960s by various research groups43-46. Due to their structural resemblance 
to peptides, versatile synthesis and excellent functionalization possibilities these 
polymers have gained increasing interest in many fields47 including the development 
of responsive materials48, 49, drug delivery50, 51 and polymer therapeutics52. In the 
following section, the mechanism of cationic ring opening polymerization (CROP), 
the most common way of synthesizing POx, will be discussed. Moreover, various 
possibilities how POx functionalities can be introduced, the basic physicochemical 
properties of POx, as well as a current overview of the use of POx in biomedical 
applications will be described.
2.2 Mechanism
CROP is the most common method in the field for synthesizing POx. This 
polymerization method involves three consecutive steps: i) initiation, ii) propagation 
and iii) termination (Figure 5). The three steps will be discussed individually including 
2120
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Figure 7 Detailed overview of the termination at either the 2-position (illustrated by water) or at the 
5-position (illustrated by piperidine).
2.3 Functionalization possibilities
One of the most attractive features of POx-based polymers relates to the ease of their 
functionalization at either the polymer chain ends and/or the side chains79-81, which 
is not possible for e.g. PEG where only functional end groups can be introduced.     
2.3.1 Chain end functionalization
Functionalities can be introduced onto POx via initiation agents containing 
functional moieties which can be modified afterwards. Examples of initiators which 
have been reported include alkyne82-84 and alkene (allyl85, vinyl83) functional moieties. 
Initiators bearing amine86, hydroxyl87 and carboxylic acid groups85, 88 have been used 
as well. However, because of their incompatibility with CROP, they require suitable 
protecting groups during CROP, which can be deprotected after synthesis.
 Another possibility to introduce functional end groups onto POx is by using 
functional terminating agents. In principle, any nucleophilic species can be 
introduced, but the functionalization efficacy varies depending on the site of 
termination (2 or 5 position) and the compatibility with functional side chains. 
A selection of functional groups, which have been reported using functional 
terminating agents include primary amines (e.g. by ethylene diamine89), secondary 
amines (piperazine derivatives90), carboxylic acids91 and azides92, 93. 
Various kinetic studies55, 61, 71 have shown (by measuring the monomer concentration 
in time by size exclusion chromatography (SEC) and 1H-NMR spectroscopy) 
that the propagation of POx follows  pseudo first-order kinetics, thereby being 
solely dependent on the propagating cationic species. The polymerization can be 
considered a ‘living’ polymerization72, 73, if e.g. i) linear increase in molecular weight 
with conversion is observed, ii) complete and immediate initiation is achieved and 
iii) side reactions during polymerizations are circumvented72, 73. However, in practice, 
meeting these criteria is not trivial, since especially at higher conversions and when 
synthesizing high molecular weight polymers,  chain transfer74 and β-elimination75 
are commonly observed side reactions leading to chain branching.   
Figure 6 Detailed view of the initiation (A) and propagation steps (B) of CROP of 2-oxazolines: 
formation of the oxazolinium salt and the equilibrium between cationic and covalent species. 
Reprinted with permission53
2.2.3 Termination
After monomer consumption has been achieved, termination can be performed by end 
capping the polymer chains via addition of a nucleophile which will form a covalently 
bound end capped polymer and disables further propagation. 
 Termination can be achieved at the 2-position of the oxazoline ring (yielding a 
terminal ester)76 or on the 5-position (yielding the terminating moiety next to the 
ethylene group) (Figure 7). The termination position (2 or 5) is dependent on the 
type of nucleophile used (hard or soft), the type of counter-ion and the identity of the 
reactive charged polymer end77. Termination at the 5-position is often preferred due to 
the higher selectivity, especially if a specific functional end group is desired. It is also 
evident that the reaction mixture should be free from nucleophilic impurities during 
CROP as this would lead to termination of the polymer chains during propagation 
resulting into ill-defined polymers.  A wide range of termination agents has been 
studied, of which piperidine77, water77 and KOH/methanol78 are most commonly used.   
A                                           B
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2.4 Solubility in aqueous solutions
The facile functionalization of POx has led to POx-based materials with a wide range 
of different physico-chemical properties97, 106. As an example, POx exhibits intriguing 
solubility behavior in aqueous solutions, which is mainly determined by the side 
chains of the polymer (Figure 8). While incorporation of 2-methyl-2-oxazoline 
(MeOx) groups renders these polymers polar and water-soluble, 2-n-butyl-2-
oxazoline (nButOx) or longer alkyl side chains yield apolar and water-insoluble POx. 
Interestingly, the incorporation of specific monomers such as 2-ethyl-2-oxazoline 
(EtOx), 2-n-propyl-2-oxazoline (nPropOx), 2-cyclo-propyl-2-oxazoline (cPropOx), 
2-iso-propyl-2-oxazoline (iPropOx), 2-methoxycarbonylethyl-2-oxazoline (MestOx) 
or 2-methoxycarbonylpropyl-2-oxazoline (C3-MestOx) in the polymer structure 
results in polymers with so-called lower critical solution temperature (or LCST)49, 
97, 107-109. These thermosensitive polymers are water-soluble below their so-called 
cloud point (CP), but insoluble above this critical temperature. This LCST-behavior 
is reported for other polymer systems as well, such as poly(N-isopropylacrylamide) 
(PNIPAm)110. This LCST behavior has been proven an interesting material 
characteristic for applications such as drug delivery111 and a useful tool for the 
purification of e.g. pharmaceutical proteins in case of polymer-protein conjugates112.
Figure 8 Schematic overview of the influence of side chain architecture on LCST behavior of POx-
based polymers108, 113.  
2.5 POx in biomedical applications
In view of their structural resemblance to peptides and their excellent 
functionalization possibilities, POx has gained increasing interest for biomedical 
applications52, 114-116.  Its use has been explored in areas such as gene delivery117, drug 
delivery118 and the development of antimicrobial polymers86, 89, 119.  Various studies 
have been performed to test the biocompatibility of POx. In these studies, POx-
based polymers were shown to be cyto- and hemocompatible50, 89, 120-123. Furthermore, 
it was observed that the polymers did not provoke an undesired immune response118, 
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2.3.2 Side chain functionalization
Functionalization of POx side chains is particularly interesting since the number 
of functional groups can be precisely tuned by mixing oxazoline monomers with 
the desired functional group in the reaction mixture. To avoid compromised 
polymerization using CROP, nucleophilic species (amines, hydroxyl groups) and 
some electrophilic species (e.g. aldehydes) should be introduced in a protected 
manner, while other functional groups are compatible with CROP (alkynes, alkenes 
and azides). The protected groups can be deprotected after the polymer has been 
formed, revealing the masked functional group. In Table 1, an overview of selected 
functional oxazoline monomers is listed including most common functionalities and 
their deprotection strategies.  For a complete overview, the reader is referred to 
extensive reviews on this topic80, 81. Alternative strategies to modify side chains of 
POx after polymerization are discussed in more detail in Chapter 2. 
Table 1 Selection of functional oxazoline monomers 
# Oxazoline Deprotection conditions 
after polymerization
Masked 
functionality
Reference
1
O
O
O
N
0.1M NaOH in methanol hydroxyl 94
2 H
N O
O
O
N
TFA/DCM (v/v, 1:1) primary amine 95
3
S
O
O
N
Anisole/TFA (v/v, 7:93) thiol 96
4
O
On
n=1, 2
O
N
1M NaOH in water carboxylic acid 68, 71, 97-99
5
O
OO
N
TFA/water (v/v, 5:95) aldehyde 100
6 O
N
- - 101
7 O
N
- - 102, 103
8
N3
O
N
- - 104
9 O
N N3
- - 105
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POx is a promising class of biomaterials which can be functionalized both at the end 
groups and side chains. In addition, various POx have been shown to be e.g. cyto- 
and hemocompatible, which paves the way for its use in biomedical applications. 
As a result, we envision that NHS-ester functionalized POx (NHS-POx) is a strong 
candidate material for hemostatic applications, since the hemostatic efficacy of this 
polymer could be tuned by controlling the amount of amine-reactive NHS-ester 
groups. Moreover, in comparison to PEG, POx does not only allow the introduction 
of more functional groups than PEG, but also enables the introduction of various 
additional polar functionalities. These additional functionalities could be used to 
tune the water solubility of the polymers, which could also contribute to a higher 
reactivity towards amines and, as a result, an improved hemostatic efficacy.
 In this work, we aim to develop a topical hemostatic agent based on NHS-ester 
functionalized POx for the non-invasive treatment of profuse bleedings in soft 
tissues. To this end, the most relevant steps of this development are discussed in 
separate chapters:
 In Chapter 2, we will discuss various synthetic routes towards NHS-POx by CROP 
and post-modification polymerization strategies.  Herein, we will investigate the 
most suitable and scalable strategy towards synthesis of NHS-POx both regarding 
the synthesis method and the properties of the final polymers.  
 In Chapter 3, the pH and thermoresponsive behavior of nPropOx based copolymers 
will be studied by turbidimetry. By introduction of various molar percentages of 
amine and carboxylic acid functionalities on these polymers, we aim to gain deeper 
insight into the thermoresponsive behavior of these materials.
 In Chapter 4, we will study the hemostatic performance of various NHS-POx 
polymers (synthesized in Chapter 2) both in vitro as well as in vivo in comparison to 
commercially available controls.
 In order to gain insight in the mechanism of action of NHS-POx as a synthetic 
hemostatic material, we will investigate the crosslinking of both NHS-POx and 
NHS-PEG with bovine serum albumin (BSA) using rheometry in Chapter 5. 
 In Chapter 6, we will study the degradation of NHS-POx in physiologically 
relevant media and study the excretion pathway of the degradation products after 
intravenous injection in a rat model. We will analyse the excretion of these polymers 
after radiolabeling using Single Photon Emission Computed Tomography (SPECT/
CT) and by testing the radioactivity of dissected organs using an automated γ 
counter. 
 Finally, in Chapter 7, a summary of this thesis is provided as well as a perspective 
view on the future of POx-based hemostatic products.  
123, 124. Moreover, several biodistribution studies50, 51, 88, 90, 91, 125-127 have demonstrated 
that POx-based materials can be excreted from animals after intravenous 
administration. Biodistribution studies on polymers consisting entirely of POx 
revealed that the excretion process was strongly controlled by the hydrodynamic 
volume and molecular weight distribution of the polymer128. 
 Nevertheless, POx remains a relatively new candidate material in the field 
of polymer therapeutics. Although several companies have filed patents for the 
development of POx-based drug therapeutics129, 130 and biomedical devices131-134, the 
use of POx has only been approved by the FDA for indirect food-contacting agents 
(e.g. materials used for food packaging)135 and drug delivery systems (Phase 1 clinical 
trial)118. Therefore, new formulations have to be thoroughly investigated and comply 
with regulatory requirements for clinical usage. Nevertheless, the possibilities for 
technology transfer and clinical translation seem numerous for POx as both the 
academic world and industry are looking into the possibilities of developing POx-
based therapeutics.
3. Objectives of this thesis
Despite the fact that considerable progress has been made regarding the 
development of topical hemostatic agents, blood loss during surgery on soft tissue 
(e.g. liver resection) remains challenging, as these procedures are still associated 
with a high risk of hemorrhage and postoperative complications. As discussed in 
section 1.3, a promising class of hemostatic products is comprised of NHS-ester 
functionalized PEG. However, the limited possibilities of end-group functionalization 
as well as the limited opportunities in changing the polarity of the polymer restrict 
major improvements based on the polymer structure (Figure 9).
Figure 9 Overview of the differences in architecture between PEG (A) and POx (B).
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2Chapter 2: 
Synthesis of NHS-ester functionalized 
poly(2-oxazoline)s (NHS-POx)  
Abstract
In this chapter, we aim to develop a robust method for the preparation of NHS-ester functional 
poly(2-oxazoline)s (NHS-POx). Particular attention was paid to the application potential in 
hemostatic devices, solubility and scalability of the procedures. We discuss three different synthetic 
routes (A-C). In route A, we first hydrolyzed commercially available POx and then used post-
polymerization modification strategies to introduce NHS-esters onto the polymers. In routes B and 
C, cationic ring opening polymerization (CROP) was employed to create copolymers with methyl 
ester side chains, which were further modified via post-polymerization strategies based on either 
hydrolysis, (route B) or amidation (route C) to develop NHS-POx polymers with different polarities. 
Synthesis of NHS-POx appeared to be most feasible via routes B and C since these routes proved 
robust, reproducible and scalable. Moreover, the polymers were obtained with good control over 
the number of functional groups and polymer dispersity. Finally, these polymers showed favorable 
solubility in both aqueous and organic media.
2
3534
Chapter 2 Synthesis of NHS-ester functionalized poly(2-oxazoline)s (NHS-POx)
2
use of functional monomers is less preferred if the desired monomer is difficult to 
synthesize14 or to purify, which is the case if the side chain consists of a labile moiety. 
Also, the kinetic profile and the incorporation rate can strongly differ between 
oxazolines bearing different side chains (e.g. due to electronic effects15), which has 
to be taken into account if a specific distribution of monomers within the polymer 
is desired16. Therefore, several alternative strategies have been developed for the 
introduction of functionalities into POx.     
 A first approach utilizes hydrolysis of the tertiary amide groups in POx, yielding 
linear poly(ethylene imine) (l-PEI) moieties. These nucleophilic l-PEI moieties 
are reactive towards electrophilic species like acyl chlorides17, 18 and anhydrides, 
which allows reintroduction of the tertiary amide groups. If electrophilic reagents 
containing functional groups are used, these are introduced onto the polymer. 
Hydrolysis of the POx-amides can be achieved using a wide range of reagents, 
including HCl19, NaOH20, and HCl under microwave irradiation21, 22. Moreover, the 
kinetics of the hydrolysis of poly(2-ethyl-2-oxazoline) P(EtOx) at various elevated 
temperatures has been described23, which allows for precise tuning of the number of 
secondary amines created, and thus the number of functional groups.
 Another way to introduce functionalities into POx is by making use of post-
polymerization modification strategies on copolymers containing modifiable side 
chains24. Using this method, a polymer is synthesized containing a specific number 
of functional groups, which can be chemically modified after the polymer structure 
has been synthesized. This strategy can be advantageous if the desired functional 
group is incompatible with the polymerization method, as can be the case for CROP. 
This concept was pioneered by the work of Hermann Staudinger in the 1930s25, 26, 
and is nowadays a widely-applied approach in the field of polymer science27. To date, 
several groups have reported the use of post-polymerization modification strategies 
for the design of POx, e.g. by thiol-ene28-30 or click chemistry31-34.
 Since NHS-esters are not compatible with CROP, these functional groups need to be 
introduced by post-modification functionalization strategies. A particularly interesting 
functional group in this respect is the methyl ester. This moiety can be effectively 
modified by hydrolysis or amidation which offers opportunities for the introduction of 
a wide range of functionalities17, 35-38. It has been demonstrated that the methyl ester 
group can be introduced into POx  by reaction of l-PEI with methyl succinyl chloride or 
via  copolymerization of 2-methoxycarbonyl-ethyl-2-oxazoline (MestOx) as functional 
monomer in CROP17, 39. The latter route has already been investigated with various 
monomers including 2-methyl-2-oxazoline (MeOx)40, 2-ethyl-2-oxazoline (EtOx)40 and 
2-n-propyl-2-oxazoline (nPropOx)41, which allows for the design of a great variety of 
MestOx-containing polymers with different polarities42.  
1. Introduction
Poly(2-oxazoline)s or POx1-4 are a promising class of polymers which are interesting 
for  biomedical applications due to their biocompatibility5-7 as well as easy and 
versatile functionalization possibilities8-10. In this thesis, we aim to functionalize 
POx with activated esters for application in hemostatic devices11.  One of the most 
commonly used activated esters to date is the N-hydroxy succinimide (NHS) ester12, 
13, which forms a stable amide bond upon reaction with primary amines. Since 
primary amines are widely present in soft tissue and blood, polymers equipped with 
NHS-esters are intrinsically able to form crosslinks with these tissues and induce the 
formation of artificial blood clots. As a result, polymers equipped with NHS-esters 
are excellent candidates for hemostatic applications. However, these polymers 
should meet a number of requirements for application in hemostatic devices. 
 First of all, the polymer should have sufficient reactive moieties for covalent 
crosslinking (e.g. with blood proteins). Secondly, the polymer composition should 
be soluble in both water (beneficial for their biological activity) and volatile organic 
solvents (beneficial for processing of the polymer). Moreover, the reactive moieties 
should be available for crosslinking, which requires reactive side chains of sufficient 
flexibility and length as well as an overall polymer polarity which allows for effective 
wetting under physiological conditions. To achieve this, the synthetic procedures 
towards these polymers should be robust, scalable and high yielding to guarantee 
constant quality. To meet these demands for both the polymer structure and the 
corresponding synthetic procedures, design criteria can be formulated in order to 
achieve optimal hemostatic performance (Table 1).  
Table 1 Design criteria for NHS-POx and corresponding synthetic procedures
NHS-POx Synthetic procedures
• Solubility in water 
• Solubility in volatile organic solvents
• Degree of polymerization (DP=100) 
• Functional group ratio 
• Dispersity values (Đ < 1.3)
• Purity (>95%)
• Scalable synthetic steps
• Common and affordable reagents
• Robustness of procedures
• Scalable purification steps  
• Environmentally benign 
• High yield
As discussed in Chapter 1, the most common way to introduce functionalities in 
POx involves introduction of i) functional end groups (via initiation or termination 
agents) or ii) functional side chains by using monomers bearing functional moieties 
in cationic ring opening polymerization (CROP). However, in certain conditions the 
use of functional reagents for CROP is impractical or undesired. As an example, the 
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Figure 1 Synthetic routes (A-C) towards NHS-ester functionalized POx (NHS-POx). A) Hydrolysis 
approach and introduction of NHS-ester groups, B) CROP followed by introduction of NHS-ester 
groups, C) CROP followed by introduction of hydrophilic groups and NHS-ester groups.  
In this chapter, we investigate three different synthetic strategies towards NHS-
ester functionalized POx (NHS-POx) (Route A-C) in order to select the most 
robust synthetic procedure towards these polymers (Figure 1). Subsequently, the 
advantages and disadvantages of these three routes as well as the physico-chemical 
properties (e.g. aqueous solubility) of the synthesized polymers are discussed.
 In route A, we use selective hydrolysis of commercially available P(EtOx) (Aquazol 
50®)43, whereafter we first introduce the methyl ester moiety via the appropriate 
acyl chloride, and subsequently the  NHS-ester group via a post-polymerization 
modification strategy. In route B and C, we synthesize copolymers based on MestOx 
with nPropOx and EtOx and use a similar approach to introduce the NHS-ester 
onto the polymers from the methyl ester side chains. A difference between routes 
B and C is the way the hydrophilic part of the polymer is introduced. In route B 
the hydrophilic groups (EtOx) are incorporated via copolymerization, whereas the 
hydrophilic groups are introduced by post-modification polymerization strategies in 
route C. Additionally, polymers prepared using route C bear a biodegradable ester 
linker in the side chain to facilitate hydrolytic degradation of crosslinked POx-based 
networks. 
2. Results and discussion
2.1 Route A: Hydrolysis of P(EtOx) followed by NHS-ester 
modification
In this route, we used selective hydrolysis of the POx-backbone to yield linear l-PEI 
moieties. These secondary amines in the polymer backbone were post-modified 
towards NHS-esters yielding NHS-POx. Aquazol 5043, a commercially available 
P(EtOx) (Mn 50 kDa, Ð 3-4), was applied. Using this approach, three types of NHS-
ester functionalized polymers were prepared (A1-A3) (Scheme 1).
 In route A1 the preparation of polymer P4 started with the partial hydrolysis of 
the alkyl side chains of POx to obtain polymer P1.  By means of time-dependent 
heating in 6M HCl at 73°C, the desired degree of hydrolysis (11% l-PEI) was obtained 
as confirmed by 1H-NMR spectroscopy. Subsequently, methyl succinyl chloride was 
coupled, resulting in the formation of a methyl ester functional polymer P2. These 
methyl ester groups were subsequently hydrolyzed using LiOH, yielding polymers 
containing carboxylic acid moieties (P3). In a final step, these carboxylic acid groups 
were converted to the desired NHS-esters (P4) as was characterized by 1H NMR 
spectroscopy. It was observed that this polymer was soluble in both water and 
organic solvents (20 mg/mL). However, route A1 proved to have certain limitations. 
First of all, coloration of the polymer occurred during the coupling of methyl 
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obtain polymers which were fully functionalized with methyl esters (P6). Subsequently, 
it was attempted to partially hydrolyze these methyl esters into carboxylic acid groups 
using sub-stoichiometric amounts of LiOH (0.25 eq. compared to methyl ester groups), 
which could be activated into NHS-esters afterwards. However, the partial hydrolysis 
was not reproducible and therefore this route (A2) was considered not feasible.
 In a third l-PEI-based synthesis route (A3), succinic anhydride was employed 
in the presence of tri-ethylamine (Et3N) to fully convert P5 into a carboxylic acid-
functional polymer (P7). After overnight reaction, the characteristic 1H-NMR signal 
of the ethylene units next to the secondary amine (2.8 ppm) disappeared, indicating 
full conversion of the l-PEI moieties into tertiary amide groups of POx. After multiple 
precipitation steps to remove the excess of reagents, the polymer was obtained as a 
white powder in a good yield (80 %). In contrast to the hydrolysis-based routes A1 and 
A2, no color change was observed during this procedure, which was caused most likely 
due to the use of anhydrides instead of acyl chlorides in this route.
 Polymer P7 was partially functionalized with NHS-ester by reaction with 0.25-1 
equivalents of N-hydroxysuccinimide in the presence of di-isopropylcarbodiimide 
(DIC) (P8-P11). The polymers were obtained with good control over the NHS-ester 
content, as demonstrated by 1H-NMR spectroscopy. However, these polymers proved 
hygroscopic upon storage and were not soluble in volatile organic solvents, which 
renders processing of the material difficult. The analytical data of the synthesized 
polymers via routes A1-A3 are listed in Table 2.  
Table 2 Analytical data of NHS-POx polymers synthesized via route A
Route # Chemical structure % funct. % NHS Yielda Solubility (Dis)advantages
x 1H-NMR g %
A1 P4 N N
∗
O
m x
O O
O
N
O
O
10 11 1.9 7
• DMF
• DMSO
• CHCl3
-Insoluble polymers were 
obtained when x >20
A2 - N N
∗
O
m x
O O
O
O
O
N
O
O
25 16 (COOH) - - -
-Ester hydrolysis was not 
reproducible
-No NHS-ester functionalized 
polymers were obtained
A3
P8
N
N
∗
O
m x
O O
OH
O
O
N
O
O
25 29 1.3 58 • DMF
• DMSO
• Water
+ Degree of functionalization
- Polymers are not soluble in 
volatile organic solvents
P9 50 44 0.9 50
P10 75 80 1.9 43
P11 N
∗
O
m
O
O
N
O
O 100 98 0.9 36
• DMF
• DMSO
+ Degree of functionalization
- Only soluble in non-volatile 
organic solvents
a Overall yield   
succinyl chloride and residual salts (probably related to the use of Et3N) could not 
be removed by precipitation.  Furthermore, attempts to synthesize polymers with 
a higher number of functional NHS-esters (>20%) was not possible due to limited 
solubility of the intermediate products in organic solvents.
In route A2, Aquazol 50 was fully hydrolyzed to create linear 100% l-PEI (P5). This 
was achieved in quantitative yield and high purity (>99%). Similar to the procedure 
described for A1, P5 was reacted with an excess of methyl succinyl chloride in order to 
Scheme 1 Overview of synthetic routes A1-A3 starting from Aquazol 50®. Reagents: i) HCl 6M, reflux, 
ii) methyl succinyl chloride, Et3N, DCM, 0°C,  iii) succinic anhydride, Et3N, rt,  iv) LiOH, MeOH, rt, v) 
NHS/DIC, DMF, rt.  
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by vacuum distillation using conventional laboratory equipment. In addition, for 
some substituted 2-oxazolines like MestOx, short path distillations (Kugelrohr) 
were advocated as a preferred distillation procedure. However, the scale of this 
equipment is mainly limited to small volumes (<100 mL). Therefore, we utilized 
wiped film evaporation (WFE), a purification approach which has proven its value in 
many applications, for example the purification of essential oils47 and the removal 
of volatile components from polymer melts48. For our purpose, we used WFE for 
selective distillation of nPropOx and MestOx from the higher boiling impurities, 
which were still present after the washing workup steps. An additional benefit of 
WFE over other purification methods is that it allows for constant supply of crude 
amounts of monomer during distillation, thereby making it a continuous process. 
 Using this approach, the crude products (1-3) were distilled. An overview of the 
process, which involved several steps, is shown schematically in Figure 2. In the first 
step, the crude mixture was added dropwise (Figure 2A) from the feed onto the 
heated mantle equipped with a rotating blade (Figure 2B). Here, an agitated thin 
film was spread over the heated mantle, thereby creating a homogeneous surface 
for distillation. After optimizing the conditions for distillation (pressure, oil and 
condenser temperature), only the desired lower boiling products condensed on the 
internal condenser unit (based on cooling water), thereby separating them from the 
higher boiling contaminants (Figure 2C). As a result, the higher boiling contaminants 
were collected in the residual fraction (Figure 2D), while the product of interest 
(monomer) was collected separately (Figure 2E). It proved important to remove 
traces of volatile solvents from the crude mixture prior to distillation, since these 
were otherwise co-distilled together with the desired monomer. The experimental 
conditions of the distillation are listed in Table 3. 
 Both monomers 1 and 3 were purified twice by wiped film evaporation and were 
kept under argon atmosphere to ensure dry conditions for polymerization. Both 
monomers were obtained in large amounts, 168 g (26% yield) and 86 g (80% yield) 
for 1 and 3 respectively, demonstrating the scalability of both the synthesis route 
and the used distillation method.
2.2 Route B: CROP followed by NHS-ester modification
In route B, cationic ring opening polymerization (CROP) and post-polymerization 
modification strategies were used to synthesize NHS-POx. A great advantage of 
this approach as compared to route A is the precise control over polymerization 
parameters (e.g. monomer ratios, degree of polymerization (DP) and sequence 
of monomer addition), thereby facilitating excellent control over the polymer 
architecture10, 44.  Additionally, the combination of functionalizable (MestOx) and 
non-functionalizable monomers (EtOx and nPropOx), allowed good control over the 
amount of incorporated functional groups in the side chains and overall polarity of 
the polymers. Using this route, we synthesized both copolymers containing nPropOx 
and NHS-ester groups (P(nPropOx-NHS), P12-P20) and copolymers containing 
nPropOx, EtOx and NHS-ester groups (P(nPropOx-EtOx-NHS), P21-P24). Similar 
reaction conditions were applied to convert methyl esters to NHS-esters, as reported 
for route A1. 
2.2.1 Monomer synthesis
Since both nPropOx and MestOx are not commercially available, both monomers 
had to be synthesized, via procedures described in literature45, 46. In short, nPropOx 
(1) was obtained by refluxing butyronitrile and ethanolamine with zinc acetate 
(Zn(OAc)2) as a catalyst (Scheme 2). For MestOx, a two-step approach was followed, 
because of the labile character of the methyl ester side chain. First, a monomer 
precursor (2) was formed, after which ring closure was facilitated by reaction with 
Na2CO3, which resulted in the formation of MestOx (3). This reaction was performed 
on the rotary evaporator to drive the reaction to completion by removal of the 
formed water and CO2. After workup via washing steps, both crude monomers were 
obtained. 
Scheme 2 Overview of monomer synthesis nPropOx (1) and MestOx (3). Conditions: i) Zn(OAc)2 (cat.), 
120°C, overnight, ii) Et3N, DCM, 0°C, iii) Na2CO3 (0.9 eq.), 60°C, 20 mbar, overnight.
Monomer purity is crucial for successful cationic ring opening polymerization 
(CROP), since traces of residuals (solvent or other impurities) can terminate this 
reaction, resulting in ill-defined polymers. On smaller scale this can be achieved 
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were mixed in the desired ratios to form statistical copolymers with close to random 
monomer distribution as previously reported40. In these experiments, methyl 
tosylate was used as an initiator and piperidine as a terminating agent which 
prevents saponification of the methyl ester side chains of MestOx.  After threefold 
precipitation in ether, P12a-P24a were obtained in multigram scale at high yields 
(>70%). Subsequently, these polymers were post-functionalized by hydrolysis of the 
methyl ester side chains to carboxylic acid moieties using 1M NaOH yielding P12b-
P24b  (Scheme 3, ii). 
 For the workup of these polymers (P12b-P24b), we exploited the lower critical 
solution temperature (or LCST-behavior) of nPropOx-containing polymers50. Since 
these polymers contained both nPropOx and carboxylic acid groups, these polymers 
were both temperature- and pH-responsive. The workup of these polymers was 
performed by decreasing the pH of the solution from 12 to 4 in order to protonate 
the carboxylate side chains, and subsequent heating, which caused the polymers 
to precipitate. After multiple cycles of i) dissolving the polymers in water, ii) 
precipitating the polymers by heating the polymer solution and iii) redissolving the 
polymer in water, the water-soluble impurities were separated from the polymers. 
Subsequently, polymers P12b-P24b were obtained as pure white powders in multigram 
quantities. It must be noted that syntheses of P19b and P20b (with 20 and 10 molar 
percent of nPropox groups, respectively) proceeded at low yield due to the low amount 
of thermoresponsive nPropOx groups. Nevertheless, the above-mentioned procedure 
confirms that the thermoresponsive behavior of these copolymers can be exploited for 
the purification of a wide range of nPropOx-containing polymers. A systematic study of 
the LCST-behavior of nPropOx-containing polymers is described in Chapter 3.
 The purified polymers were further modified using DIC and NHS towards NHS-
ester functional polymers. After workup by precipitation, they were obtained with 
good control over the number of functional groups, based on analysis by 1H-NMR-
spectroscopy. All polymers (except for P19 and P20) were synthesized in multigram 
quantities using this route at overall yields (over three steps) ranging from 18-60% 
and with control over the dispersity values (Ð 1.1-1.3, Table 4). 1H-NMR spectra of the 
assigned resonances of P21 and the intermediate products can be found in Figure 3. 
Figure 2 Overview of various stages of WFE purification. A) Addition of the crude mixture from the 
feed, B) Creation of a homogeneous film over the heated mantle, C) Schematic of the distillation 
process, D) Residue after distillation, E) Monomer obtained after distillation  
Table 3 Experimental conditions during WFE-purification
# Tfeed Tcondenser Toil pressure Yield
(°C) (°C) (°C) (mbar) (g) (%)
1 nPropOx 30 20 44 1.5*10-1 167.7 26
2 MestOx-precursor 40 45 87 4.4*10-2 186.5 53
3 MestOx 40 27 60 2.3*10-1  86.3 80
2.2.2 Polymer synthesis
After successfully synthesizing the monomers, the polymers were prepared by 
cationic ring opening polymerization (CROP) using microwave reaction conditions49 
(Scheme 4). For the copolymerization, the monomers (EtOx, nPropOx and MestOx) 
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Table 4 Analytical data of the synthesized polymers (P12-P24)
# Chemical structure %func.
(theor.)
% funct. (1H-NMR) SEC (PMMA)a Yieldb
P(nPropOx-NHS) x MestOx COOH NHS Mn (kDa) Đ g %
P12 10 10 8 10 29.6 1.16 6.1 52
P13 20 21 20 21 c c 6.4 54
P14 30 30 30 27 29.6 1.19 1.8 15
P15 40 42 39 42 34.5 1.23 1.3 23
P16 50 49 49 50 27.7 1.13 4.9 30
P17 60 60 60 54 30.8 1.29 1.4 62
P18 70 72 65 65 31.8 1.32 1.0 42
P19 80 79 75 d 21.0 1.24 c c
P20 90 89 85 d 24.1 1.40 c c
P(nPropOx-EtOx-NHS) m-n-x
P21 40-50-10 9 10 11 12.5 1.18 2.9 22
P22 50-40-10 11 11 12 12.3 1.16 5.6 42
P23 40-35-25 24 24 28 16.8 1.22 4.7 18
P24 50-25-25 23 20 24 14.6 1.18 4.5 35
a  SEC was calibrated against PMMA standards, eluent: 0.1 % LiCl in DMA.  SEC measurements were 
performed on NHS-POx, except for P19 and P20,  which were performed on COOH-functionalized POx
b Yield over 3 steps
c not determined
d not synthesized
Scheme 3 Synthesis scheme of P12-P24. Conditions: i) methyl tosylate, 140°C, MeCN, ii) 0.1 M NaOH, 
rt, iii) NHS-OH, DIC, DMF/DCM (v/v, 1:9)), rt
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polymers prepared via routes A and B. This gives this class of polymers more mobile 
crosslinking groups, which can be beneficial in terms of crosslinking efficacy.
Scheme 4 Synthesis of P26-P28. Reaction conditions: i) methyl tosylate, 140°C, MeCN, ii) ratio of 
functional amines, 60°C, 300 mbar, rt (P26a, amine used: 2-amino-ethanol , 7 eq.; P27a, amines used: 
2-amino-ethanol /2-methoxy-ethylamine (1:1), 7 eq. ; P28a, amines used: 2-amino-ethanol/N1,N1-
dimethyl-1,2-ethylene diamine (1:3), 14 eq.),  iii) succinic anhydride, DMAP, DMF/DCM (v/v, 1:9, rt), iv) 
acetic acid, NHS-OH, DIC, DCM, rt.
First, P(nPropOx-c-MestOx) (P25) was synthesized similar to route B. Subsequently, 
the methyl ester groups on the polymer were amidated by heating the polymer 
(60°C) in 2-amino-ethanol under reduced pressure (300 mbar), thereby driving the 
reaction to completion by favoring the release of methanol. As a consequence, a 
hydroxyl-functional polymer was obtained (P26a).  
 For P27a and P28a, we converted half of the ester groups to the hydroxyl moiety 
for further modification towards NHS-ester moieties, and half of the ester groups 
to a hydrophilic component (OMe for P27 and N(CH3)2 for P28). To this end, we 
screened various ratios of functional amines to obtain the desired incorporation 
onto the polymer. An equimolar ratio of 2-amino-ethanol and 2-methoxyethylamine 
was needed for incorporation of a 1:1 molar ratio of functional groups into P27a. For 
P28a, a 3:1 molar ratio of N1,N1-dimethyl-1,2-ethylene diamine and 2-amino-ethanol 
was needed to achieve this. Subsequently, the hydroxyl-functionalized side chains 
of these polymers (P26a-P28a) were converted to carboxylic acid moieties, yielding 
P26b-P28b.
Figure 3 Representative 1H-NMR spectra of P(nPropOx-c-EtOx-c-NHS) (P21) and intermediate 
products. A) Structural formulas of I (P21a), II (P21b) and III (P21), B) Assigned 1H-NMR signals of P21 
and intermediate products.
2.3 Route C: CROP followed by post-polymerization modification 
and NHS-ester modification
Via route C, we synthesized a series of NHS-POx containing groups of different 
polarity, but in contrast to route B, post-polymerization modification strategies were 
used to introduce the hydrophilic moieties. To this end, we prepared copolymers 
consisting of nPropOx and MestOx, as described in route B.  Since the methyl 
ester groups can be modified by direct amidation17 using a wide range of functional 
amines, we utilized this to introduce a wide range of hydrophilic groups (hydroxyl, 
methyl ether and dimethylamine) on the polymer (Scheme 4). Subsequently, via 
the hydroxyl groups, we introduced carboxylic acid groups by reaction with succinic 
anhydride. In a final step, we activated the carboxylic acid groups to NHS-esters 
using the reaction conditions as used for routes A and B.  This route offered several 
advantages over previously described routes.  Firstly, we created polymers equipped 
with hydrolytically sensitive ester groups in the side chains, which should allow 
faster degradation than the polymers prepared in routes A and B. Moreover, the 
polymers prepared via this route (A26-A28) are equipped with an extended spacer 
length between the polymer backbone and the crosslinking group, compared to the 
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Figure 4 1H-NMR spectrum indicating the partial conversion of the hydroxy-terminal side chains into 
carboxylic acid-functionalized side chains by a shift of protons a (3.3 ppm) into b (4.2 ppm). (n = molar 
percentage of OH functionalized side chains)
Table 5 Reactions conditions optimization for P26b
Succinic anhydride T %mol COOHa
# eq. towards OH catalyst (eq.) Solvent (°C) Theor. 1H-NMRb
1 0.32 - MeCN 100 10 4
2 0.45 - MeCN 100 14 8
3 0.7 - MeCN 100 21 10
4 0.85 - MeCN 100 26 12
5 0.5 - MeCN 100c 15 5
6 0.5 DBU (1) MeCN (20 v% DMF) rt 15 d
7 0.5 Et3N (1) MeCN (20 v% DMF) rt 15 17
8 0.5 DMAP  (0.7) DCM (10v% DMF) rt 15 12
9 0.67 DMAP  (0.7) DCM (10v% DMF) rt 20 18
Conditions: All screening reactions (#1-#9) were performed on P26a using the reaction conditions 
described above using a reaction molarity of 1M. Theoretical amount % COOH= molar percentage of 
carboxylic acid groups on polymer at full conversion of succinic anhydride.    
a Based on P26a (P(nPropOx-c-OH) 70-30 (n=30 hydroxyl groups))
b Samples were measured in D2O.
c Sample was heated for 30 minutes under microwave irradiation
d No conversion was observed by 1H-NMR spectroscopy.
For P26b, we aimed to partially convert the hydroxyl groups into carboxylic acid 
moieties, thereby retaining half of the hydroxyl groups as hydrophilic component in 
the final polymer. Several conditions were screened for optimization of this reaction. 
Different equivalents of succinic anhydride (with respect to hydroxyl groups) were 
investigated and different catalysts were used, namely (I) tri-ethylamine (Et3N), 
(II) 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and (III) 4-dimethylaminopyridine 
(DMAP). The reactions were monitored by 1H-NMR spectroscopy (Figure 4), since 
the protons next to the hydroxyl group at 3.3 ppm (a) shift downfield to 4.2 ppm (b) 
upon esterification of the side chains, thereby making a clear distinction between 
unreacted and reacted side chains, which allowed easy determination of the 
conversion. The reaction conditions and the results of these screening reactions are 
listed in Table 5.     
 As can be observed from Table 5, the reactions in which no base was utilized 
(Entries 1-5) resulted in poor control over the incorporation of functional groups since 
physical gels were formed during these reactions. In the screening reaction where 
DBU was used (Entry 6), the reaction mixture turned deep red and no conversion was 
observed by 1H-NMR spectroscopy. Although conversion was observed using Et3N 
(Entry 7), the reaction mixture turned pink and it was difficult to remove Et3N using 
the consecutive precipitation steps in acetone and Et2O. The reactions using DMAP 
proved most effective since precise incorporation of carboxylic acid groups could 
be achieved by adding a slight excess of succinic anhydride over the desired ratio of 
functional groups. Although most of the DMAP could be removed by precipitation 
steps, removal of the remaining traces required an additional filtration step over 
propylsulfonic acid bonded silica particles (SCX-2). This procedure resulted into the 
synthesis of P(nPropOx-c-OH-c-COOH) copolymer in good purity and therefore we 
selected the conditions used in Entry 9 for synthesis of P26b.
 For P26b, the addition of DMAP as a catalyst resulted into a desired (1:1 molar) 
incorporation of functional groups (18 mol% COOH). For both P27b and P28b, all 
hydroxyl moieties needed to be converted to carboxylic acids. Therefore, an excess 
of succinic anhydride was used to drive the reaction to completion, which yielded 
polymers with the desired incorporation of carboxylic acid groups. Subsequently, 
these carboxylic acid moieties were fully converted to NHS-ester functional polymers 
thereby yielding P26-P28 with the desired incorporation of functional groups 
as determined using 1H-NMR spectroscopy (Figure 5). The analytical data of the 
synthesized polymers (P26-P28) and intermediate products are listed in Table 6.  
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3. Discussion
After synthesis of the polymers, the three different routes (A-C) can be compared 
with respect to the various design criteria which have been set for both the polymer 
structure and synthetic procedures (see Table 1). 
 In route A, we prepared several polymers by both partial and complete hydrolysis 
of Aquazol 50, yielding l-PEI units, which were subsequently converted into NHS-
esters, resulting in NHS-POx polymers P1-P4. Using this route, P4 (P(EtOx-c-NHS) 
90-10) was the only polymer which was obtained with sufficient control over the 
number of functional groups. Additionally, this polymer was soluble in both aqueous 
and organic solvents. However, attempts to increase the number of NHS-groups on 
this polymer resulted in insoluble polymers. Moreover, the total yield for P4 was 
low (7%).  Although polymers were obtained with the desired number of functional 
groups using route A3, none of these polymers displayed desired solubility 
characteristics (in both water and volatile organic solvents). In general, all reaction 
steps in this route proved scalable. However, the use of acyl chlorides resulted in 
undesired coloration of the polymers, which could not be resolved during workup. 
In summary, it was concluded that route A offered limited freedom to functionalize 
the polymers. Moreover, the majority of the polymers were poorly soluble in water 
and/or organic media. As a result, this route was not considered feasible for our 
purposes.
 Using route B, different series of NHS-POx (P(nPropOx-c-NHS) (P12-P18) and 
P(nPropOx-c-EtOx-c-NHS) (P21-P24) based copolymers were prepared by CROP 
and post-polymerization modification strategies. It was demonstrated that both 
P(nPropOx-c-COOH) and P(nPropOx-c-EtOx-c-COOH) could be purified in a scalable 
way by exploiting the intrinsic LCST behavior of these polymers through consecutive 
heating and cooling cycles in water, thereby omitting the use of organic solvents. 
The polymers were obtained with good control over the ratio of functional groups. 
All synthesized NHS-POx polymers (P12-P24) were soluble in volatile organic 
solvents. The water solubility of P12 was equal to 10 mg/mL at room temperature, 
while P21-P24 were soluble up to 40 mg/mL at room temperature, indicating that 
incorporation of ethyl groups in the polymer structure renders the polymers more 
water soluble. In conclusion, this route offered the possibility to synthesize a series of 
different nPropOx-containing polymers by employing scalable workup procedures. 
No notable drawbacks were encountered using this synthetic route. Consequently, 
route B was considered feasible for synthesis of NHS-POx polymers.
 In route C, three different polymers (P26-P28) were synthesized by CROP and 
post-polymerization modification strategies (amidation of the methyl esters side 
chains). The polymers were obtained with good control over the number of functional 
Table 6 Analytical data of synthesized polymers (P26-P28) and intermediate products
# Polymer 1H-NMR (mol%) Mn (kg/mol)
R=OH MestOx OH R COOH NHS Theor. SECa Ða
P25 P(nPropOx-c-MestOx) 31 - - - - 12.7 11.3 1.12
P26a P(nPropOx-c-OH) - 31 - - - 13.6 13.9 1.11
P26b P(nPropOx-c-OH-c-COOH) - 13 - 18 - 15.1 - -
P26 P(nPropOx-c-OH-c-NHS) - 14 - - 17 16.5 18.8 1.25
OMe
P27a P(nPropOx-c-OMe-c-OH) - 15 16 - - 13.6 12.4 1.16
P27b P(nPropOx-c-OMe-c-COOH) - - 17 14 - 15.1 - -
P27 P(nPropOx-c-OMe-c-NHS) - - 17 - 14 16.5 21.1 1.35
N(CH3)2
P28a P(nPropOx-c- N(Me)2-c-OH)) - 14 17 - - 13.6 11.0 1.15
P28b P(nPropOx-c- N(Me)2-c-COOH) - - 16 15 - 15.1 - -
P28 P(nPropOx-c- N(Me)2-c-NHS) - - 16 - 15 16.5 22.1 1.33
 a SEC was calibrated against PMMA standards, eluent: 0.1 % LiCl in DMA
Figure 5 Overview of 1H-NMR spectra of P26-P28.   A) Structural formulas of P26 (I), P28 (II),  P27 III, B) 
Assigned signals of P26 (I)(recorded in CD3CN),  P28 (II) (recorded in D2O),  P27 (III) (recorded in D2O).
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6. Experimental procedures
6.1 Materials
All reagents (synthesis grade) for the synthesis of the monomers were purchased 
at Sigma Aldrich and used without further purification, unless stated otherwise. 
All reagents for the synthesis of the polymers were distilled twice before use in 
the polymerizations. Acetonitrile (obtained from Actu-all Chemicals) was dried and 
dispensed under nitrogen atmosphere by using an MBraun MB SPS-800 solvent 
dispersing system. 
6.2 Characterization
1H-NMR and 13C-NMR spectra were recorded on a Bruker Avance III 500MHz 
spectrometer using the solvents D2O, MeOD, CDCl3 or DMSO-d6. FT-IR measurements 
were performed on a Bruker Tensor 27 IR ATR spectrometer. Microwave-assisted 
polymerizations were performed in a Biotage Initiator+, equipped with an 
autosampler. Size exclusion chromatography (SEC) was performed on an Agilent 
1260 - series HPLC system equipped with a 1260 online degasser, a 1260 ISO-pump, 
a 1260 automatic liquid sampler, a thermostatted column compartment, a 1260 
diode array detector (DAD) and a 1260 refractive index detector (RID). Analyses 
were performed on two Mixed-D and a guard column in series at 50 °C. As an 
eluent, N,N-dimethyl acetamide (DMA), containing LiCl (concentration 50 mM), 
was used at a flow rate of 0.593 ml min-1. The SEC traces were analyzed using the 
Agilent Chemstation software with the GPC add on. Number average molecular 
weights (Mn), weight average molecular weights (Mw), and dispersity (Ð) values were 
calculated against poly(methyl methacrylate) (PMMA) standards. Monomers were 
distilled using a KDL-1 Wiped film evaporation setup (UIC GmbH) containing both an 
oil pump and an oil diffusion pump.  
6.3 Synthesis route A
Synthesis of these polymers was based on a procedure described in literature39.
Note: since highly polydisperse Aquazol 50® was used in this study as a starting 
groups according to 1H-NMR spectroscopy. During the consecutive reaction steps 
only a minor increase in polymer dispersity was observed by SEC, which indicates 
that cross coupling between polymer chains is neglegible. The polymers prepared via 
route C were soluble in both organic and aqueous solvents (10 mg/mL). An additional 
benefit of these functionalized polymers is the presence of a hydrolytically cleavable 
linker which facilitates degradation in vivo. On the other hand, the synthesis of route 
C involves an additional reaction step compared to route B, which can be considered 
a minor drawback of this procedure. Nevertheless, this route offers the possibility 
to introduce a wide range of hydrophilic functionalities in addition to NHS-esters, 
thereby offering superior control over the reactivity of medical devices based on 
NHS-POx.   
4. Conclusion
In this chapter, various synthetic routes (A-C) towards NHS-ester functionalized POx 
have been described. The main objective of this study was the development of a 
robust procedure, which would give much freedom in the choice and amounts of 
functional side chains on the polymers. The route based on hydrolysis of POx into 
l-PEI units and further postmodification into NHS-POx (route A) was not considered 
feasible since the synthetic procedures did not allow for easy functionalization. 
Moreover, most polymers prepared via this route lacked solubility in e.g. volatile 
organic solvents.  Using route B, we prepared a series of P(nPropOx-c-NHS) and 
P(nPropOx-c-EtOx-c-NHS) polymers by CROP and post polymerization modification 
strategies. Using this route, polymers were prepared with good control over the 
number of functional groups. Moreover, the prepared polymers were soluble in 
volatile organic solvents and aqueous media. The synthesis procedures were scalable 
and applicable for the majority of polymers. Using route C, polymers were prepared 
by CROP and post-polymerization modification strategies with good control over 
the ratio of incorporated functional groups. The post modification was not only used 
to introduce the NHS esters, but also side chains with different polarities, which 
makes this route probably the most versatile of the three approaches reported.
 Taken all factors into account, from a synthesis perspective, only route B and 
route C have proven to be viable routes for the development of NHS-POx.  This 
provides us with a robust platform to prepare functional POx systems for application 
in hemostatic devices.      
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in MeOH (300 mL), dried over anhydrous Na2SO4 and subsequently filtered. The solvent 
was evaporated under reduced pressure.  P3 was obtained as a brown powder (11.3. g, 
60% yield). 1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCO-CH2CH2N), δ 2.80-
2.60 (b,x•4H, CO-CH2-CH2-CO),  2.50-2.25 (b, m•2H, CO-CH2-CH3), 1.15-1.00 (b, m•3H, 
CO-CH2-CH3). Experimentally determined monomer ratio (m/x): 89/11
P4 P(EtOx-c-NHS) 90-10 - P3 (11.3 g, 0.36 mmol, 10.9 
mmol functional groups, 1 eq.), EDC·HCl (4.7 g, 24.5 
mmol, 2.2 eq.) and NHS-OH (2.82 g, 24.5 mmol, 2.2 eq.) 
were dissolved in DMA (141 mL) and the reaction mixture 
was stirred overnight.  Next, the reaction mixture was 
concentrated under reduced pressure. Subsequently, the 
polymer was dissolved in DCM (300 mL) and the organic phase was washed with 
water (100 mL, 2x) and brine (100 mL, 2x), dried over anhydrous Na2SO4 and filtered. 
The solvent was evaporated under reduced pressure, yielding a sticky brown foam. 
Subsequently, the polymer was dissolved in DCM (100 mL) and precipitated in cold 
ether (1 L). This was performed 4 times.  P4 was obtained as a brown powder (1.9. 
g, 15% yield). 1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCO-CH2CH2N), δ 
3.00-2.45 (b,x•4H, CO-CH2-CH2-CO+ (b,x•4H,  CO-CH2-CH2-CO (NHS)),  2.50-2.25 (b, 
m•2H, CO-CH2-CH3), 1.15-1.00 (b, m•3H, CO-CH2-CH3). Experimentally determined 
monomer ratio (m/x): 88/12
 P5 l-PEI - P5 was synthesized similar as P1 using identical 
amounts of reagents but different hydrolysis conditions (16 
hrs at 110°C). P5 was obtained as a white powder (9.2 g, 
85% yield). 1H NMR (500 MHz, MeOD) δ 2.73 (s,x•4H, NH-
CH2-CH2-  NH).Experimentally determined monomer ratio 
(m/x): 0/100
 P6 P(MestOx) - The reaction was performed similar to P3 
using P5 (3.0 g, 0.14 mmol, 70 mmol functional groups, 1 
eq.), methyl succinyl chloride (23.8 mL, 29.8 g, 195 mmol, 
2.8 eq.) and Et3N (24.2 mL, 17.7 g,  174 mmol, 2.5 eq.) in 
DMA (200 mL). P6 was obtained as a dark brown foam (7.3 
g, 67% yield). 1H NMR (500 MHz, MeOD) δ 3.70 (br,m•3H, 
OCH3), δ 3.70-3.50 (b,m•4H, NCO-CH2CH2N), δ 2.80-2.60 (b,m•4H, CO-CH2-CH2-
CO). Experimentally determined monomer ratio (m/x): 100/0
 P7 P(COOH) - P5 (5.0 g, 0,23 mmol, 116.2 mmol 
functional groups, 1 eq.), succinic anhydride (23.2 g, 232.4 
mmol, 2 eq) and Et3N (40.3 mL, 29.4 g, 290.5 mmol, 2.5 eq.) 
were dissolved in DMSO (140 mL). The reaction mixture 
was stirred overnight. Next, the reaction mixture was 
polymer (Đ 3-4), SEC measurements were not performed.  End group functionality was 
furthermore not defined.
 P1 P(EtOx-c-l-PEI) 90-10 - P(EtOx) (25 g, 0.50 mmol) was 
dissolved in a 6M-HCl-solution (525 ml) and heated in a pre-
heated oil bath (73°C) for 2 hours and 20 minutes.  Afterwards, 
the reaction mixture was evaporated to dryness. A 4M-NaOH-
solution (600 mL) was added. The pH of the solution turned 
10. The polymer was extracted from the aqueous layer twice 
with DCM (500 mL). The combined organic fractions were dried over anhydrous Na2SO4 
and subsequently filtered.  The solvent was evaporated under reduced pressure. P1 
was obtained as a white foam (21.4 g, 92% yield). 1H NMR (500 MHz, MeOD) δ 3.70-
3.50 (b,m•4H, NCO-CH2CH2N), δ 2.73 (s,x•4H, NH-CH2-CH2-NH), 2.40-2.20 (b, m•2H, 
CO-CH2-CH3), 1.10-1.00 (b, m•3H, CO-CH2-CH3). Experimentally determined monomer 
ratio (m/x): 89/11
 P2 P(EtOx-c-MestOx) 90-10 - P1 (21.4 g, 0.53 mmol, 
26.3 mmol functional groups, 1 eq.) was added to a flame 
dried Schlenk-flask and subsequently dissolved in DCM (135 
mL) under a flow of argon. Next, the solution was cooled 
using an ice bath (0°C) and methyl succinyl chloride (5.95 
mL, 0.10 mol, 4 eq.) and Et3N (9.1 mL, 0.13 mol, 5 eq.) were 
added dropwise. Next, the reaction mixture was stirred overnight and turned brown. 
Afterwards, the organic layer was washed twice with a 5% Na2CO3-solution (50 mL). 
The combined organic fractions were dried over anhydrous Na2SO4 and subsequently 
filtered.  The solvent was evaporated under reduced pressure. Since residual Et3N was 
present (observed by 1H-NMR spectroscopy), the polymer was dissolved in toluene, 
and Et3N was co-evaporated with this organic solvent (100 mL). Subsequently, the 
polymer was dissolved in DCM (100 mL) and precipitated in Et2O (2 L). The precipitate 
was redissolved in DCM (100 mL) and finally the solvent was evaporated under reduced 
pressure.  P2 was obtained as a brown foam (19.2. g, 79% yield). 1H NMR (500 MHz, 
MeOD) δ 3.70 (br,x•3H, OCH3), δ 3.70-3.50 (b,(m+x)•4H, NCO-CH2CH2N), δ 2.80-2.60 
(b,x•4H, CO-CH2-CH2-CO),  2.40-2.20 (b, m•2H, CO-CH2-CH3), 1.10-1.00 (b, m•3H, CO-
CH2-CH3). Experimentally determined monomer ratio (m/x): 89/11
 P3 P(EtOx-c-COOH) 90-10 - P2 (19.1 g, 0,36 mmol, 18.1 
mmol functional groups, 1 eq.) was dissolved in MeOH (505 
mL). Subsequently, water (505 mL) and LiOH (17.8 g, 0.43 
mol, 24 eq) were added and the reaction mixture was stirred 
for 3 hrs. Next, the reaction mixture was concentrated under 
reduced pressure. Subsequently, the polymer was dissolved in 
MeOH (300 mL) and precipitated in cold acetone (2 L). The precipitate was redissolved 
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6.4 Route B
6.4.1 Monomer synthesis
nPropOx (1) was synthesized using a modified literature procedure51. Butyronitrile 
(500 mL, 5.75 mol, 1 eq.), 2-amino ethanol (520 mL, 8.61 mol, 1.5 eq.) and Zn(OAc)2·2 
H2O (24.7 g; 0.11 mol, 0.02 eq.) as a catalyst were mixed and heated to reflux (~130°C) 
overnight. The resulting yellow-orange reaction mixture was cooled down to room 
temperature. Afterwards DCM (1000 mL) was added and the organic layer was 
washed with water (2x 500 mL) and brine (500 mL). The organic phase was dried over 
anhydrous Na2SO4 and subsequently filtered. The solvent was evaporated under 
reduced pressure, yielding a yellow oil (256.8 g). This oil was distilled twice (1.5·10-2 
mbar) using the KDL-1. nPropOx (1) was obtained as a colorless liquid (167.74 g, 26% 
yield). 1H NMR (500 MHz, CDCl3) δ 4.13 (t, J = 9.5 Hz, 2H, CH2-O), 3.74 (t, J = 10 Hz, 2H, 
CH2N), 2.16 (m, 2H, CH2-CH2-CH3), 1.58 (m, 2H, CH2-CH2-CH3), 0.89 (t, J = 7.4 Hz, 3H, 
CH2-CH2-CH3) 
13C NMR (500 MHz, CDCl3) δ 167.96, δ 66.66, δ 53.94, δ 29.43, δ 18.98, 
δ 13.30 TLC Rf = 0.82, (MeOH/DCM, v/v, 9:1) 
 MestOx-precursor (2) was synthesized following a modified literature procedure40 
- Methyl succinyl chloride (271.8 g, 1.805 mol, 1 eq.) was dissolved in DCM (2.00 
L) and 2-chloroethylamine.HCl (209.2 g, 1.804 mol, 1 eq.) was added. The reaction 
mixture was cooled to 0°C and Et3N (535 mL, 3.84 mol, 2.13 eq.) was added drop 
wise over 2 hours. The reaction mixture was stirred for 4 days. The reaction mixture 
turned orange and a precipitate (Et3N-HCl) was formed.  Subsequently, the reaction 
mixture was filtered and divided into three equal parts. Each part was washed twice 
with water (2 x 80 mL) and brine (1 x 80 mL). The organic layers were combined and 
dried over anhydrous Na2SO4 and subsequently filtered. The mixture was evaporated 
under reduced pressure yielding a brown oil (323.7 g). The oil was distilled twice 
(4.4·10-3 mbar) using the KDL-1. MestOx-precursor (2) was obtained as a colorless oil 
which solidified in time (186.5 g, 53% yield). 1H NMR (500 MHz, CDCl3) δ 6.32 (s, 1H, 
NHCO), 3.70 (s, 1H, CH3-O-CO), 3.66 (t, J = 7.4 Hz, 2H, CH2-Cl), 3.54 (t, J = 7.4 Hz, 2H, 
CH2-NH-CO), 2.69 (t, J = 7.4 Hz, 2H, NH-CO-CH2), 2.59 (t, J = 7.4 Hz, 2H, CH2-CO-O) 
 MestOx (3) was synthesized following a modified literature procedure40. 
MestOx-precursor 2 (132.3 g, 0.68 mol, 1 eq.) was heated to 45°C to melt the solid. 
Subsequently, sodium carbonate (70.62 g, 0.67 mol, 1 eq.) was added gently, which 
caused the formation of CO2. The reaction mixture was heated and stirred overnight 
(60°C, 20 mbar) using a rotary evaporator. After overnight reaction, the absence of 
CO2 formation indicated full conversion. The reaction mixture was diluted with Et2O 
(500 mL) and the resulting viscous suspension was filtered. The solvent was removed 
under reduced pressure yielding a yellow oil (104.7 g). This oil was distilled twice 
(2.3·10-2 mbar) using the KDL-1. MestOx (3) was obtained as a colorless oil which 
solidified over time. (86.3 g, 80% yield). 1H NMR (500 MHz, CDCl3) δ 4.20 (t, J = 9.5 
precipitated in cold acetone (2 L) and subsequently triturated for 2 hrs. Next, the 
precipitate was filtered off and subsequently washed on a glass filter with acetone 
(100 mL, 3x) and with Et2O (100 mL, 3x). In a final step, the polymer was dried under 
reduced pressure.  P7 was obtained as a white powder (13.2 g, 80% yield).1H NMR 
(500 MHz, D2O) δ 3.70-3.30 (b, m•4H, NCO-CH2CH2N), δ 2.60-2.45 (b,m•4H, CO-CH2-
CH2-CO). Experimentally determined monomer ratio (m/x): 100/0
 P8 P(COOH-c-NHS) 75-25 - P7 (1.3 g, 0.018 mmol, 9 
mmol functional groups, 1 eq.), NHS-OH (0.26 g, 2.2 mmol, 
0.25 eq.), DIC (2.81 mL, 2.27 g, 18 mmol, 2 eq.) and DMAP 
(112 mg, 0.9 mmol, 0.1 eq) were dissolved in DMSO (15 
mL). The reaction mixture was stirred overnight. Next, the 
reaction mixture was precipitated in cold THF (500 mL). 
Subsequently, the precipitate was dissolved in DMF (30 mL) and precipitated in cold 
Et2O (500 mL). The precipitate was filtered off and subsequently washed on a glass 
filter with DCM (100 mL, 3x), acetone (100 mL, 3x) and Et2O (100 mL, 3x). In a final 
step, the polymer was dried under reduced pressure.  P8 was obtained as a grey 
powder (1.32 g, 86% yield). 1H NMR (500 MHz, D2O) δ 3.70-3.30 (b, (m+x)•4H, NCO-
CH2CH2N), δ 3.00-2.45 (b,(m+x)•4H, CO-CH2-CH2-CO+ (b,x•4H,  CO-CH2-CH2-CO 
(NHS)). Experimentally determined monomer ratio (m/x): 71/29
 P9  P(COOH-c-NHS) 50-50 -  The reaction was performed similar to P8 using P7 (1.0 
g, 0.02 mmol, 6.9 mmol functional groups, 1 eq.), NHS-OH (0.40 g, 3.5 mmol, 0.50 eq.), 
DIC (2.15 mL, 1.74 g, 13.8 mmol, 2 eq.) and DMAP (84.3 mg, 0.69 mmol, 0.1 eq).  P9 was 
obtained as a white powder (0.9 g, 74% yield). 1H NMR (500 MHz, D2O) δ 3.70-3.30 (b, 
(m+x)•4H, NCO-CH2CH2N), δ 3.00-2.45 (b,(m+x)•4H, CO-CH2-CH2-CO+ (b,x•4H,  CO-
CH2-CH2-CO (NHS)). Experimentally determined monomer ratio (m/x): 56/44
 P10  P(COOH-c-NHS) 25-75 -  The reaction was performed similar to P8 using P7 
(2.0 g, 0.028 mmol, 13 mmol functional groups, 1 eq.), NHS-OH (1.12 g, 9.75 mmol, 
0.75 eq.), DIC (4.30 mL, 3.48 g, 27.6 mmol, 2 eq.) and DMAP (168.6 mg, 1.3 mmol, 0.1 
eq).  P10 was obtained as a white powder (1.9 g, 63% yield). 1H NMR (500 MHz, D2O) 
δ 3.70-3.30 (b, (m+x)•4H, NCO-CH2CH2N), δ 3.00-2.45 (b,(m+x)•4H, CO-CH2-CH2-CO+ 
(b,x•4H,  CO-CH2-CH2-CO (NHS)). Experimentally determined monomer ratio (m/x): 
20/80
 P11 P(COOH-c-NHS) 0-100 - The reaction was performed similar to P8 using P7 (1.0 
g, 0.014 mmol, 6.9 mmol functional groups, 1 eq.), NHS-OH (1.59 g, 13.8 mmol, 2 eq.), 
DIC (2.15 mL, 1.74 g, 13.8 mmol, 2 eq.) and DMAP (84.3 mg, 0.69 mmol, 0.1 eq).  P11 
was obtained as a white powder (0.9 g, 53% yield). 1H NMR (500 MHz, D2O) δ 3.70-3.30 
(b, (m+x)•4H, NCO-CH2CH2N), δ 3.00-2.45 (b,(m+x)•4H, CO-CH2-CH2-CO+ (b,x•4H, 
CO-CH2-CH2-CO (NHS)). Experimentally determined monomer ratio (m/x): 2/98
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P15a  P(nPropOx-c-MestOx) 60-40  - P15a  was synthesized according to protocol 
1 with a monomer ratio of m/x of 60/40. P15a was obtained as a white foam (1.9 g, 
76% yield). 1H NMR (500 MHz, D2O) δ 3.60 (b, x•3H, OCH3), 3.60-3.40 (b,(m+x)•4H, 
NCH2CH2N), 2.70-2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-2.10 (b, m•2H, CO-CH2-CH2-
CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b,m•3H, CO-CH2-CH2-CH3). 
Experimentally determined monomer ratio (m/x): 58/42. SEC (PMMA) Mn 21.6kg/
mol, Đ 1.31
 P16a  P(nPropOx-c-MestOx) 50-50  - P16a  was synthesized according to protocol 
1 with a monomer ratio of m/x of 50/50. P16a was obtained as a white foam (2.4 g, 
96% yield). 1H NMR (500 MHz, D2O) δ 3.60 (b, x•3H, OCH3), 3.60-3.40 (b,(m+x)•4H, 
NCH2CH2N), 2.70-2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-2.10 (b, m•2H, CO-CH2-CH2-
CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). 
Experimentally determined monomer ratio (m/x): 51/49. SEC (PMMA) Mn 23.5 kg/
mol, Đ 1.29
 P17a  P(nPropOx-c-MestOx) 40-60  - P17a  was synthesized according to protocol 
1 with a monomer ratio of m/x of 40/60. P17a was obtained as a white foam (2.4 g, 
96% yield). 1H NMR (500 MHz, D2O) δ 3.60 (b, x•3H, OCH3), 3.60-3.40 (b,(m+x)•4H, 
NCH2CH2N), 2.70-2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-2.10 (b, m•2H, CO-CH2-CH2-
CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). 
Experimentally determined monomer ratio (m/x): 40/60. SEC (PMMA) Mn 24.8 kg/
mol, Đ 1.25
 P18a  P(nPropOx-c-MestOx) 30-70  - P18a  was synthesized according to protocol 
1 with a monomer ratio of m/x of 30/70. P18a was obtained as a white foam (2.7 g, 
quant. yield). 1H NMR (500 MHz, D2O) δ 3.60 (b, x•3H, OCH3), 3.60-3.40 (b,(m+x)•4H, 
NCH2CH2N), 2.70-2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-2.10 (b, m•2H, CO-CH2-CH2-
CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). 
Experimentally determined monomer ratio (m/x): 28/72. SEC (PMMA) Mn 24.1 kg/
mol, Đ 1.32
 P19a  P(nPropOx-c-MestOx) 20-80  - P19a  was synthesized according to protocol 
1 with a monomer ratio of m/x of 20/80. P19a was obtained as a white foam (2.5 g, 
quant. yield). 1H NMR (500 MHz, D2O) δ 3.60 (b, x•3H, OCH3), 3.60-3.40 (b,(m+x)•4H, 
NCH2CH2N), 2.70-2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-2.10 (b, m•2H, CO-CH2-CH2-
CH3), 1.60-1.40 (b,m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). 
Experimentally determined monomer ratio (m/x): 21/79. SEC (PMMA) Mn 23.1 kg/
mol, Đ 1.36
 P20a  P(nPropOx-c-MestOx) 10-90  - P20a  was synthesized according to protocol 
1 with a monomer ratio of m/x of 10/90. P20a was obtained as a white foam (2.5 g, 
quant. yield). 1H NMR (500 MHz, D2O) δ 3.60 (b, x•3H, OCH3), 3.60-3.40 (b,(m+x)•4H, 
NCH2CH2N), 2.70-2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-2.10 (b, m•2H, CO-CH2-CH2-
Hz, 1H, CH2O), 3.78 (t, J = 9.4 Hz, 1H, CH2N), 3.66 (s, 3H, CH3-OCO), 2.64 (t, J = 9.5 Hz, 
2H, CH2CH2COO),  2.55 (t, J = 7.5 Hz, 2H, CH2CH2COO). 
13C NMR (500 MHz, CDCl3) δ 
172.67, δ 166.97, δ 67.45, δ 54.35, δ 51.73, δ 30.01, δ 23.04. LCQ MS: m/z 158.1 [M+H]+ 
(calc. 158.1)
6.4.2 Route B: Polymer synthesis
Protocol 1: General procedure polymerization (P12a-P24a)
Methyl tosylate (1 eq.), nPropOx (m eq.), EtOx (n eq.), MestOx (x eq.) and 
acetonitrile were mixed in the desired ratios in a dry microwave vial (concentration 
4M) under inert atmosphere (argon). The polymerization was heated for 30 min 
under microwave irradiation (140°C) after which dry piperidine (5 eq.) was added to 
the reaction mixture, which was stirred for three hours.  The polymer was dissolved 
in DCM and precipitated in diethylether (DCM/Et2O, v/v, 1:20). This procedure was 
performed two times. The resulting suspension was filtered and the residue dissolved 
in DCM (100 mL). The solvent was evaporated under reduced pressure yielding the 
MestOx-functionalized polymers (P12a-24a) as white powders.
 P12a  P(nPropOx-c-MestOx) 90-10  - P12a  was 
synthesized according to protocol 1 with a monomer ratio 
of m/x of 90/10. P12a was obtained as a white foam (1.9 
g, 76% yield). 1H NMR (500 MHz, D2O) δ 3.60 (b, x•3H, 
OCH3), 3.60-3.40 (b,(m+x)•4H, NCH2CH2N), 2.70-2.50 (b, 
x•4H, CO-CH2-CH2-CO),  2.40-2.10 (b, m•2H, CO-CH2-CH2-
CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). 
Experimentally determined monomer ratio (m/x): 90/10. SEC (PMMA) Mn 19.1 kg/
mol, Đ 1.23
 P13a  P(nPropOx-c-MestOx) 80-20  - P13a  was synthesized according to protocol 
1 with a monomer ratio of m/x of 80/20. P13a was obtained as a white foam (9.1 g, 
87% yield). 1H NMR (500 MHz, D2O) δ 3.60 (b, x•3H, OCH3), 3.60-3.40 (b,(m+x)•4H, 
NCH2CH2N), 2.70-2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-2.10 (b, m•2H, CO-CH2-CH2-
CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). 
Experimentally determined monomer ratio (m/x): 79/21. 
 P14a  P(nPropOx-c-MestOx) 70-30  - P14a  was synthesized according to protocol 
1 with a monomer ratio of m/x of 70/30. P14a was obtained as a white foam (4.5 g, 
90% yield). 1H NMR (500 MHz, D2O) δ 3.60 (b, x•3H, OCH3), 3.60-3.40 (b,(m+x)•4H, 
NCH2CH2N), 2.70-2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-2.10 (b, m•2H, CO-CH2-CH2-
CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b,m•3H, CO-CH2-CH2-CH3). 
Experimentally determined monomer ratio (m/x): 70/30. SEC (PMMA) Mn 21.0 kg/
mol, Đ 1.24
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(0.1 M). The reaction mixture was stirred in a heated water bath (45°C) which caused 
precipitation of the polymer as a sticky white precipitate. This precipitate was 
dissolved in cold water (100 mL) and the reaction mixture was stirred again in the 
heated water bath, which caused the polymer to precipitate again. The pH of the 
resulting solution was 4. The sticky white precipitate was either (1) dissolved again 
in DCM (100 mL) and concentrated under reduced pressure or (2) precipitated from 
DMF (20 mL) into diethyl ether (2000 mL) and subsequently filtered and dried under 
high vacuum, yielding the COOH-functionalized polymers (P12b-P24b) as white 
fluffy powders.
P12b  P(nPropOx-c-COOH) 90-10  - P12b was synthesized 
according to protocol 2 starting from P12a (10.2 g). P12b 
was obtained as a white foam (6.8 g, 69% yield). 1H NMR 
(500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCH2CH2N), 2.60-
2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-2.20 (b, m•2H, CO-
CH2-CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-
0.80 (b, m•3H, CO-CH2-CH2-CH3). Experimentally determined monomer ratio (m/x): 
92/8. SEC (PMMA) Mn 20.5 kg/mol, Đ 1.16
 P13b  P(nPropOx-c-COOH) 80-20  - P13b  was synthesized according to protocol 
2 starting from P13a (9.05 g). P13b was obtained as a white foam (7.0 g, 79% yield). 
1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCH2CH2N), 2.60-2.50 (b, x•4H, 
CO-CH2-CH2-CO),  2.40-2.20 (b, m•2H, CO-CH2-CH2-CH3), 1.60-1.40 (b, m•2H, CO-
CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3).  Experimentally determined 
monomer ratio (m/x): 80/20. 
 P14b  P(nPropOx-c-COOH) 70-30  - P14b  was synthesized according to protocol 
2 starting from P14a (10 g). P14b was obtained as a white foam (2.4 g, 25% yield). 
1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCH2CH2N), 2.60-2.50 (b, x•4H, 
CO-CH2-CH2-CO),  2.40-2.20 (b, m•2H, CO-CH2-CH2-CH3), 1.60-1.40 (b, m•2H, CO-
CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3).  Experimentally determined 
monomer ratio (m/x): 70/30. SEC (PMMA) Mn 24.8 kg/mol, Đ 1.16
 P15b  P(nPropOx-c-COOH) 60-40  - P15b  was synthesized according to protocol 
2 starting from P15a (1.60 g). P15b was obtained as a white foam (0.5 g, 33% yield). 
1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCH2CH2N), 2.60-2.50 (b, x•4H, 
CO-CH2-CH2-CO),  2.40-2.20 (b, m•2H, CO-CH2-CH2-CH3), 1.60-1.40 (b, m•2H, CO-
CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). Experimentally determined 
monomer ratio (m/x): 61/39. SEC (PMMA) Mn 23.5 kg/mol, Đ 1.17
 P16b  P(nPropOx-c-COOH) 50-50  - P16b  was synthesized according to protocol 
2 starting from P16a (2.2 g). P16b was obtained as a white foam (0.3 g, 14% yield). 
1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCH2CH2N), 2.60-2.50 (b, x•4H, 
CO-CH2-CH2-CO),  2.40-2.20 (b, m•2H, CO-CH2-CH2-CH3), 1.60-1.40 (b, m•2H, CO-
CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). 
Experimentally determined monomer ratio (m/x): 11/89. SEC (PMMA) no signal 
could be obtained
 P21a P(nPropOx-c-EtOx-c-MestOx) 40-50-10  - P21a  was 
synthesized according to protocol 1 with a monomer ratio 
of m/n/x of 40/50/10. P21a was obtained as a white foam 
(7.5 g, 78% yield). 1H NMR (500 MHz, D2O) δ 3.60 (b, x•3H, 
OCH3), 3.60-3.40 (b,(m+n+x)•4H, NCH2CH2N), 2.70-2.50 (b, 
x•4H, CO-CH2-CH2-CO),  2.40-2.10 (b, (m+n)•2H, CO-CH2-
CH2-CH3+ CO-CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 1.15-1.05 (b, n•3H, 
CO-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). Experimentally determined 
monomer ratio (m/n/x): 40/51/9. 
 P22a  P(nPropOx-c-EtOx-c-MestOx) 50-40-10  - P22a  was synthesized according 
to protocol 1 with a monomer ratio of m/n/x of 50/40/10. P22a was obtained as 
a white foam (7.8 g, 79% yield). 1H NMR (500 MHz, D2O) δ 3.60 (b, x•3H, OCH3), 
3.60-3.40 (b,(m+n+x)•4H, NCH2CH2N), 2.70-2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-
2.10 (b, (m+n)•2H, CO-CH2-CH2-CH3+ CO-CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-
CH2-CH3), 1.15-1.05 (b, n•3H, CO-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). 
Experimentally determined monomer ratio (m/n/x): 40/51/9.
 P23a  P(nPropOx-c-EtOx-c-MestOx) 40-35-25  - P23a  was synthesized according 
to protocol 1 with a monomer ratio of m/n/x of 40/35/25. P23a was obtained as a 
white foam (18.9 g, 93% yield). 1H NMR (500 MHz, D2O) δ 3.60 (b, x•3H, OCH3), 
3.60-3.40 (b,(m+n+x)•4H, NCH2CH2N), 2.70-2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-
2.10 (b, (m+n)•2H, CO-CH2-CH2-CH3+ CO-CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-
CH2-CH3), 1.15-1.05 (b, n•3H, CO-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). 
Experimentally determined monomer ratio (m/n/x): 41/35/24. SEC (PMMA) Mn 11.1 
kg/mol, Đ 1.19
 P24a  P(nPropOx-c-EtOx-c-MestOx) 50-25-25  - P24a  was synthesized according 
to protocol 1 with a monomer ratio of m/n/x of 50/25/25. P24a was obtained as 
a white foam (8.2 g, 78% yield). 1H NMR (500 MHz, D2O) δ 3.60 (b, x•3H, OCH3), 
3.60-3.40 (b,(m+n+x)•4H, NCH2CH2N), 2.70-2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-
2.10 (b, (m+n)•2H, CO-CH2-CH2-CH3+ CO-CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-
CH2-CH3), 1.15-1.05 (b, n•3H, CO-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). 
Experimentally determined monomer ratio (m/n/x): 51/26/23.
Protocol 2: General procedure methyl ester hydrolysis (P12b-P24b)
Polymers P12a-P24a  were dissolved in a NaOH solution (0.1 M)  to a polymer 
concentration of 1 M and this reaction mixture was stirred overnight.  Afterwards, 
the reaction mixture was acidified to pH 4 by dropwise addition of an HCl solution 
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CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 1.15-1.05 (b, n•3H, CO-CH2-CH3) 
0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). Experimentally determined monomer ratio 
(m/n/x): 40/49/11
 P23b  P(nPropOx-c-EtOx-c-COOH) 40-35-25  - P23b  was synthesized according 
to protocol 2 starting from P23a (18.4 g). P23b was obtained as a white foam (10.0 
g, 54% yield). 1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+n+x)•4H, NCH2CH2N), 2.60-
2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-2.20 (b, (m+n)•2H, CO-CH2-CH2-CH3 + CO-
CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 1.15-1.05 (b, n•3H, CO-CH2-CH3) 
0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). Experimentally determined monomer ratio 
(m/n/x): 40/36/24
 P24b  P(nPropOx-c-EtOx-c-COOH) 50-25-25  - P24b  was synthesized according 
to protocol 2 starting from P24a (8.2 g). P24b was obtained as a white foam (4.3 g, 
54% yield). 1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+n+x)•4H, NCH2CH2N), 2.60-
2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-2.20 (b, (m+n)•2H, CO-CH2-CH2-CH3 + CO-
CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 1.15-1.05 (b, n•3H, CO-CH2-CH3) 
0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). Experimentally determined monomer ratio 
(m/n/x): 50/30/20
Protocol 3: General procedure NHS activation (P12-P24)
Polymers P12b-P24b, N,N’-Diisopropylcarbodiimide (DIC) (1.1 eq. compared to 
COOH) and N-hydroxysuccinimide (NHS) (1.1 eq. compared to COOH) were dissolved 
in a mixture of solvents (DMF/DCM, v:v, 1:9) yielding a 0.1 M solution. This mixture 
was stirred overnight. A white precipitate (urea byproduct of DIC) was formed 
which was removed by filtration of the reaction mixture over celite.  Afterwards, the 
reaction mixture was concentrated to dryness under reduced pressure. Subsequently, 
the polymers were dissolved in DCM  (100 mL) and precipitated in Et2O (250 mL). 
This procedure was performed three times.  After the final precipitation step, the 
polymers were collected by filtration and dried under high vacuum yielding the 
NHS-ester functionalized polymers (P12-P24) as white fluffy powders.
P12  P(nPropOx-c-NHS) 90-10 - P12  was synthesized 
according to protocol 3 starting from P12b (6.5 g). P12 was 
obtained as a white foam (6.2 g, 87% yield). 1H NMR (500 
MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCH2CH2N), 3.00-2.60 
(b, (m+x)•4H, CO-CH2-CH2-CO + (b, x•4H, CO-CH2-CH2-CO 
(NHS)),  2.40-2.20 (b, m•2H, CO-CH2-CH2-CH3), 1.60-1.40 
(b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). Experimentally 
determined monomer ratio (m/x): 90/10. SEC (PMMA) Mn 29.6 kg/mol, Đ 1.16
 P13  P(nPropOx-c-NHS) 80-20  - P13  was synthesized according to protocol 3 
starting from P13b (7.0 g). P13 was obtained as a white foam (6.4 g, 79% yield). 1H 
CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). Experimentally determined 
monomer ratio (m/x): 51/49. SEC (PMMA) Mn 18.4 kg/mol, Đ 1.20
 P17b  P(nPropOx-c-COOH) 40-60  - P17b  was synthesized according to protocol 
2 starting from P17a (2.1 g). P17b was obtained as a white foam (1.9, 80% yield). 
1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCH2CH2N), 2.60-2.50 (b, x•4H, 
CO-CH2-CH2-CO),  2.40-2.20 (b, m•2H, CO-CH2-CH2-CH3), 1.60-1.40 (b, m•2H, CO-
CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). Experimentally determined 
monomer ratio (m/x): 40/60. SEC (PMMA) Mn 18.7 kg/mol, Đ 1.21
 P18b  P(nPropOx-c-COOH) 30-70  - P18b  was synthesized according to protocol 
2 starting from P18a (2.2 g). P18b was obtained as a white foam (1.4 g, 66% yield). 
1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCH2CH2N), 2.60-2.50 (b, x•4H, 
CO-CH2-CH2-CO),  2.40-2.20 (b, m•2H, CO-CH2-CH2-CH3), 1.60-1.40 (b, m•2H, CO-
CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). Experimentally determined 
monomer ratio (m/x): 35/65. SEC (PMMA) Mn 19.2 kg/mol, Đ 1.25
 P19b  P(nPropOx-c-COOH) 20-80  - P19b  was synthesized according to protocol 
2 starting from P19a (2.1 g). P19b was obtained as a white foam (0.2 g, 10% yield). 
1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCH2CH2N), 2.60-2.50 (b, x•4H, 
CO-CH2-CH2-CO),  2.40-2.20 (b, m•2H, CO-CH2-CH2-CH3), 1.60-1.40 (b, m•2H, CO-
CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). Experimentally determined 
monomer ratio (m/x): 25/75. SEC (PMMA) Mn 21.1 kg/mol, Đ 1.24
 P20b  P(nPropOx-c-COOH) 10-90  - P20b  was synthesized according to protocol 
2 starting from P20a (2.1 g). P20b was obtained as a white foam (0.3 g, 10% yield). 
1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCH2CH2N), 2.60-2.50 (b, x•4H, 
CO-CH2-CH2-CO),  2.40-2.20 (b, m•2H, CO-CH2-CH2-CH3), 1.60-1.40 (b, m•2H, CO-
CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). Experimentally determined 
monomer ratio (m/x): 15/85. SEC (PMMA) Mn 23.7 kg/mol, Đ 1.40
 P21b  P(nPropOx-c-EtOx-c-COOH) 50-40-10  - P21b  was 
synthesized according to protocol 2 starting from P21a 
(7.5 g). P21b was obtained as a white foam (4.0 g, 52% 
yield). 1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+n+x)•4H, 
NCH2CH2N), 2.60-2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-
2.20 (b, (m+n)•2H, CO-CH2-CH2-CH3 + CO-CH2-CH3), 
1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 1.15-1.05 (b, n•3H, CO-CH2-CH3) 0.90-0.80 
(b, m•3H, CO-CH2-CH2-CH3). Experimentally determined monomer ratio (m/n/x): 
50/40/10
 P22b  P(nPropOx-c-EtOx-c-COOH) 40-50-10  - P22b  was synthesized according 
to protocol 2 starting from P22a (7.8 g). P22b was obtained as a white foam (6.5 g, 
83% yield). 1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+n+x)•4H, NCH2CH2N), 2.60-
2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-2.20 (b, (m+n)•2H, CO-CH2-CH2-CH3 + CO-
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P19 + P20 could not be synthesized because of limited solubility
 P21  P(nPropOx-c-EtOx-c-NHS) 40-50-10  - P21  was 
synthesized according to protocol 3 starting from P21b 
(4.0 g). P21 was obtained as a white foam (2.9 g, 53% 
yield). 1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+n+x)•4H, 
NCH2CH2N), 3.00-2.60 (b, (m+n+x)•4H, CO-CH2-CH2-CO + 
(b, x•4H, CO-CH2-CH2-CO (NHS)),  2.40-2.20 (b, (m+n)•2H, 
CO-CH2-CH2-CH3  + CO-CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 
(b, n•3H, CO-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). Experimentally 
determined monomer ratio (m/n/x): 40/49/11. SEC (PMMA) Mn 12.5 kg/mol, Đ 1.18 
FT-IR (cm-1) 1626 (C=O amide), 1738 + 1785 + 1815 (NHS-ester). 
 P22  P(nPropOx-c-EtOx-c-NHS) 50-40-10  - P22  was synthesized according to 
protocol 3 starting from P22b (6.5 g). P22 was obtained as a white foam (5.6 g, 
65% yield). 1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+n+x)•4H, NCH2CH2N), 3.00-
2.60 (b, (m+n+x)•4H, CO-CH2-CH2-CO + (b, x•4H, CO-CH2-CH2-CO (NHS)),  2.40-
2.20 (b, (m+n)•2H, CO-CH2-CH2-CH3  + CO-CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-
CH2-CH3), 0.90-0.80 (b, n•3H, CO-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). 
Experimentally determined monomer ratio (m/n/x): 49/39/12. SEC (PMMA) Mn 12.3 
kg/mol, Đ 1.16 FT-IR (cm-1) 1626 (C=O amide), 1738 + 1785 + 1815 (NHS-ester). 
 P23  P(nPropOx-c-EtOx-c-NHS) 40-35-25  - P23 was synthesized according to 
protocol 3 starting from P23b (10 g). P23 was obtained as a white foam (4.7 g, 35% 
yield). 1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+n+x)•4H, NCH2CH2N), 3.00-2.60 
(b, (m+n+x)•4H, CO-CH2-CH2-CO + (b, x•4H, CO-CH2-CH2-CO (NHS)),  2.40-2.20 
(b, (m+n)•2H, CO-CH2-CH2-CH3  + CO-CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-
CH3), 0.90-0.80 (b, n•3H, CO-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). 
Experimentally determined monomer ratio (m/n/x): 39/33/28. SEC (PMMA) Mn 16.8 
kg/mol, Đ 1.22 FT-IR (cm-1) 1626 (C=O amide), 1738 + 1785 + 1815 (NHS-ester). 
 P24  P(nPropOx-c-EtOx-c-NHS) 50-25-25  - P24 was synthesized according to 
protocol 3 starting from P24b (5.4 g). P24 was obtained as a white foam (4.5 g, 
83% yield). 1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+n+x)•4H, NCH2CH2N), 3.00-
2.60 (b, (m+n+x)•4H, CO-CH2-CH2-CO + (b, x•4H, CO-CH2-CH2-CO (NHS)),  2.40-
2.20 (b, (m+n)•2H, CO-CH2-CH2-CH3  + CO-CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-
CH2-CH3), 0.90-0.80 (b, n•3H, CO-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3). 
Experimentally determined monomer ratio (m/n/x): 50/26/24. SEC (PMMA) Mn 14.6 
kg/mol, Đ 1.18 FT-IR (cm-1) 1626 (C=O amide), 1738 + 1785 + 1815 (NHS-ester). 
6.5 Route C
P25 P(nPropOx-c-MestOx) 70-30 - P25 was synthesized according to protocol 
1 with a monomer ratio of m/x of 70/30 and by using 2-amino-ethanol (5 eq.) as a 
NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCH2CH2N), 3.00-2.60 (b, (m+x)•4H, 
CO-CH2-CH2-CO + (b, x•4H, CO-CH2-CH2-CO (NHS)),  2.40-2.20 (b, m•2H, CO-CH2-
CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-
CH3).  Experimentally determined monomer ratio (m/x): 79/21. 
 P14  P(nPropOx-c-NHS) 70-30  - P14  was synthesized according to protocol 3 
starting from P14b (2.1 g). P14 was obtained as a white foam (1.8 g, 69% yield). 1H 
NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCH2CH2N), 3.00-2.60 (b, (m+x)•4H, 
CO-CH2-CH2-CO + (b, x•4H, CO-CH2-CH2-CO (NHS)),  2.40-2.20 (b, m•2H, CO-CH2-
CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-
CH3). Experimentally determined monomer ratio (m/x): 73/27. SEC (PMMA) Mn 29.6 
kg/mol, Đ 1.19
 P15  P(nPropOx-c-NHS) 60-40  - P15  was synthesized according to protocol 3 
starting from P15b (0.5 g). P15 was obtained as a white foam (0.3 g, 46% yield). 1H 
NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCH2CH2N), 3.00-2.60 (b, (m+x)•4H, 
CO-CH2-CH2-CO + (b, x•4H, CO-CH2-CH2-CO (NHS)),  2.40-2.20 (b, m•2H, CO-CH2-
CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-
CH3). Experimentally determined monomer ratio (m/x): 58/42. SEC (PMMA) Mn 34.5 
kg/mol, Đ 1.23
 P16  P(nPropOx-c-NHS) 50-50  - P16  was synthesized according to protocol 3 
starting from P16b (0.3 g). P16 was obtained as a white foam (0.2 g, 46% yield). 1H 
NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCH2CH2N), 3.00-2.60 (b, (m+x)•4H, 
CO-CH2-CH2-CO + (b, x•4H, CO-CH2-CH2-CO (NHS)),  2.40-2.20 (b, m•2H, CO-CH2-
CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-
CH3). Experimentally determined monomer ratio (m/x): 50/50. SEC (PMMA) Mn 27.7 
kg/mol, Đ 1.13
 P17  P(nPropOx-c-NHS) 40-60  - P17  was synthesized according to protocol 3 
starting from P17b (1.4 g). P17 was obtained as a white foam (1.3 g, 81% yield). 1H 
NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCH2CH2N), 3.00-2.60 (b, (m+x)•4H, 
CO-CH2-CH2-CO + (b, x•4H, CO-CH2-CH2-CO (NHS)),  2.40-2.20 (b, m•2H, CO-CH2-
CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-
CH3). Experimentally determined monomer ratio (m/x): 36/64. SEC (PMMA) Mn 30.8 
kg/mol, Đ 1.29
 P18  P(nPropOx-c-NHS) 30-70  - P18  was synthesized according to protocol 3 
starting from P18b (1.0 g). P18 was obtained as a white foam (1.0 g, quant yield). 1H 
NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, NCH2CH2N), 3.00-2.60 (b, (m+x)•4H, 
CO-CH2-CH2-CO + (b, x•4H, CO-CH2-CH2-CO (NHS)),  2.40-2.20 (b, m•2H, CO-CH2-
CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-
CH3). Experimentally determined monomer ratio (m/x): 35/65. SEC (PMMA) Mn 31.8 
kg/mol, Đ 1.32
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mL). The solution was stirred overnight at room temperature under argon.  After 
overnight reaction, a white precipitate (urea of DIC) was formed. Subsequently, the 
precipitate was filtered off over cotton wool. Next, the solvent was concentrated 
under reduced pressure. Subsequently, the polymer was precipitated twice from 
DCM (2.5 mL) into acetone (25 mL) and once from DCM (2.5 mL) into Et2O (25 mL). 
The white fluffy precipitate was filtered off, dried under high vacuum. P26 was 
obtained as a white powder (0.2 g, 42% yield). 1H NMR (400 MHz, D2O): δ 4.23-
4.14 (b, x•2H, O=CNHCH2CH2OC=O), δ 3.60 (b, n•2H, NHCH2CH2OH), δ 3.60-3.40 
(b, (m+n+x)•4H, NCH2CH2N), δ 3.40 (b, x•2H, O=CNHCH2CH2OC=O), 3.35-3.28 
(b, n•2H, NHCH2CH2OH), 3.08-2.99 (b, x•2H, O=CCH2CH2COON), 3.01-2.90 (b, 
x•4H, ONO=CCH2CH2C=ONO), 2.88-2.80 (b, x•2H, O=CCH2CH2COON), 2.76-2.48 
(b, (n+x)•4H, O=CCH2CH2C=ONH + x•4H, O=CCH2CH2C=O), 2.43-2.20 (b, m•2H, 
CH2CH2CH3), 1.65-1.50 (b, m•2H, CH2CH2CH3), 0.98-0.85 (b, m•3H, CH2CH2CH3). 
Experimentally determined monomer ratio (m/n): 69/15/16. SEC (PMMA) Mn 18.8 
kg/mol, Đ 1.25
 P27a  P(nPropOx-c-OMe-c-OH) 70-15-15  - P27a was synthesized similar to 
P26a starting from P25 (8 g, 0.63 mmol polymer,  20 mmol OH) using a mixture 
of 2-amino-ethanol (4.2 mL, 4.2 g, 69 mmol, 3.5 eq.) and 2-methoxyethylamine 
(6.0 mL, 5.1 g, 69 mmol, 3.5 eq.). P27a was obtained as a white foam (8.5 g, 97% 
yield). 1H NMR (500 MHz, D2O): δ 3.60 (b, x•2H, NHCH2CH2OH), δ 3.70-3.40 (b, 
(m+n+x)•4H, NCH2CH2N), 3.40 (b, n•3H, NHCH2CH2OCH3),  3.35-3.28 (b, x•2H, 
NHCH2CH2OH + n•2H, NHCH2CH2OCH3 ), 2.76-2.48 (b, n•4H, O=CCH2CH2C=ONH), 
2.43-2.20 (b, m•2H, CH2CH2CH3), 1.65-1.50 (b, m•2H, CH2CH2CH3), 0.98-0.85 (b, 
m•3H, CH2CH2CH3). Experimentally determined monomer ratio (m/n/x): 69/16/15. 
SEC (PMMA) Mn 12.4 kg/mol, Đ 1.16
 P27b  P(nPropOx-c-OMe-c-COOH) 70-15-15  - P27b was synthesized similar to 
P26a starting from P27a (6.4 g, 0.46 mmol polymer,  6.9 mmol ester, 1 eq.). P27b 
was obtained as a white solid (2.2 g, 30% yield). 1H NMR (400 MHz, D2O): δ 4.23-
4.14 (b, x•2H, O=CNHCH2CH2OC=O), δ 3.60 (b, n•2H, NHCH2CH2OCH3), δ 3.60-
3.40 (b, (m+n+x)•4H, NCH2CH2N), 3,45 (b, n•3H, NHCH2CH2OCH3), δ 3.40 (b, x•2H, 
O=CNHCH2CH2OC=O), 3.35-3.28 (b, n•2H, NHCH2CH2OCH3), 2.76-2.48 (b, (n+x)•4H, 
O=CCH2CH2C=ONH + x•4H, O=CCH2CH2C=O), 2.43-2.20 (b, m•2H, CH2CH2CH3), 
1.65-1.50 (b, m•2H, CH2CH2CH3), 0.98-0.85 (b, m•3H, CH2CH2CH3). Experimentally 
determined monomer ratio (m/n/x): 69/17/14. SEC (PMMA) no signal could be 
obtained
 P27  P(nPropOx-c-OMe-c-NHS) 70-15-15  - P27 was synthesized similar 
to P26 starting from P27b (2.1 g, 2.0 mmol polymer,  29 mmol COOH). P27 was 
obtained as a white foam (0.3 g, 15% yield). ). 1H NMR (400 MHz, D2O): δ 4.23-
4.14 (b, x•2H, O=CNHCH2CH2OC=O), δ 3.60 (b, n•2H, NHCH2CH2OCH3), δ 3.60-
terminating agent. P25 was obtained as a white foam (27.0 g, 71% yield). 1H NMR 
(500 MHz, D2O) δ 3.60 (b, n•3H, OCH3), 3.60-3.40 (b,(m+n)•4H, NCH2CH2N), 2.75-
2.50 (b, x•4H, CO-CH2-CH2-CO),  2.40-2.15 (b, m•2H, CO-CH2-CH2-CH3), 1.70-1.50 
(b, m•2H, CO-CH2-CH2-CH3), 1.00-0.85 (b,m•3H, CO-CH2-CH2-CH3). Experimentally 
determined monomer ratio (m/x): 69/31. SEC (PMMA) Mn 11.3 kg/mol, Đ 1.12
 P26a  P(nPropOx-c-OH) 70-30  - P25 (8 g, 0.63 mmol polymer,  20 mmol ester, 
1 eq.) was dissolved in 2-amino-ethanol (8.35 mL, 8.4 g, 138 mmol, 7 eq.) and the 
reaction mixture was allowed to reflux overnight at 60°C under reduced pressure 
(300 mbar). After this, 2-amino-ethanol was removed under reduced pressure and 
the polymer was precipitated twice from isopropanol (100 mL) into Et2O (2 L). 
Subsequently, the precipitate was dissolved in isopropanol (100 mL) and the solvent 
was evaporated under reduced pressure. Since residual 2-amino-ethanol and 
isopropanol were present (1H-NMR), the polymer was precipitated from methanol 
(100 mL) into Et2O (2 L) and subsequently filtered off and dried overnight under 
vacuum. P26a was obtained as a white foam (5.09 g, 59% yield). 1H NMR (500 
MHz, D2O): δ 3.60 (b, n•2H, NHCH2CH2OH), δ 3.60-3.40 (b, (m+n)•4H, NCH2CH2N), 
3.35-3.28 (b, n•2H, NHCH2CH2OH), 2.76-2.48 (b, n•4H, O=CCH2CH2C=ONH), 2.43-
2.20 (b, m•2H, CH2CH2CH3), 1.65-1.50 (b, m•2H, CH2CH2CH3), 0.98-0.85 (b, m•3H, 
CH2CH2CH3). Experimentally determined monomer ratio (m/n): 69/31 . SEC (PMMA) 
Mn 13.9 kg/mol, Đ 1.11
 P26b  P(nPropOx-c-OH-c-COOH) 70-15-15  - P26a (3.43 g, 0.21 mmol polymer, 
6.5 mmol OH, 1 eq.) and  succinic anhydride (0.53 g, 5.08 mmol, 0.78 eq) and DMAP 
(0.48 g, 3.93 mmol, 0.6 eq)  were dissolved in DCM (30 mL) and the reaction mixture 
was stirred at room temperature overnight under inert atmosphere.  Next, the 
reaction mixture was evaporated under reduced pressure to dryness. Subsequently, 
the polymer was precipitated twice from DCM (20 mL) into acetone (200 mL). 
Hereafter, the resulting white solid was dissolved in methanol (50 mL) and charged on 
an SCX-2 column (1.4 g, 0.69 mmol/g) and the loaded column was flushed twice with 
methanol (50 mL). After this, the combined fractions of methanol were concentrated 
to dryness under reduced pressure. P26b was obtained as a white solid (0.52 g, 13% 
yield). 1H NMR (400 MHz, D2O): δ 4.23-4.14 (b, x•2H, O=CNHCH2CH2OC=O), δ 3.60 
(b, n•2H, NHCH2CH2OH), δ 3.60-3.40 (b, (m+n+x)•4H, NCH2CH2N), δ 3.40 (b, x•2H, 
O=CNHCH2CH2OC=O), 3.35-3.28 (b, n•2H, NHCH2CH2OH), 2.76-2.48 (b, (n+x)•4H, 
O=CCH2CH2C=ONH + x•4H, O=CCH2CH2C=O), 2.43-2.20 (b, m•2H, CH2CH2CH3), 
1.65-1.50 (b, m•2H, CH2CH2CH3), 0.98-0.85 (b, m•3H, CH2CH2CH3). Experimentally 
determined monomer ratio (m/n): 69/13/18. SEC (PMMA) no signal could be obtained 
 P26  P(nPropOx-c-OH-c-NHS) 70-15-15  - P26b (0.5 g, 32 µmol polymer,  0.5 
mmol COOH, 1 eq.)), DIC (0.3 mL, 2.0 mmol; 3.5 eq), acetic acid (33 µL, 0.5 mmol, 1 
eq) and N-hydroxysuccinimide (0.2 g; 2.0 mmol; 3.5 eq) were dissolved in DCM (10 
6968
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3.40 (b, (m+n+x)•4H, NCH2CH2N), δ 3.40 (b, x•2H, O=CNHCH2CH2OC=O), 3.35-3.28 
(b, n•2H, NHCH2CH2OCH3), 3.08-2.99 (b, x•2H, O=CCH2CH2COON), 3.01-2.90 (b, 
x•4H, ONO=CCH2CH2C=ONO), 2.88-2.80 (b, x•2H, O=CCH2CH2COON), 2.76-2.48 
(b, (n+x)•4H, O=CCH2CH2C=ONH + x•4H, O=CCH2CH2C=O), 2.43-2.20 (b, m•2H, 
CH2CH2CH3), 1.65-1.50 (b, m•2H, CH2CH2CH3), 0.98-0.85 (b, m•3H, CH2CH2CH3). 
Experimentally determined monomer ratio (m/n): 69/17/14. SEC (PMMA) Mn 21.1 kg/
mol, Đ 1.35
 P28a  P(nPropOx-c-N(Me)2-c-OH) 70-15-15  - P28a was synthesized similar 
to P26a starting from P25 (7 g, 0.54 mmol polymer,  17 mmol ester, 1 eq.) using a 
mixture of 2-amino-ethanol (3.5 mL, 3.5 g, 59 mmol, 3.5 eq.) and N1,N1-dimethyl 
ethylene-1,2-diamine  (18.9 mL, 12.9 g, 179 mmol, 10.5 eq.). P28a was obtained 
as a white foam (7.4 g, 96% yield). 1H NMR (500 MHz, D2O + 1v% HCl): δ 3.60 (b, 
x•2H, NHCH2CH2OH), δ 3.70-3.40 (b, (m+n+x)•4H, NCH2CH2N),  3.35-3.28 (b, x•2H, 
NHCH2CH2OH + n•2H, NHCH2CH2 N(CH3)2 ), 2,85 (b, n•6H, NHCH2CH2N(CH3)2), 2.76-
2.48 (b, n•4H, O=CCH2CH2C=ONH), 2.43-2.20 (b, m•2H, CH2CH2CH3), 1.65-1.50 (b, 
m•2H, CH2CH2CH3), 0.98-0.85 (b, m•3H, CH2CH2CH3) Experimentally determined 
monomer ratio (m/n/x): 69/17/14 . SEC (PMMA) Mn 11.0 kg/mol, Đ 1.15
 P28b  P(nPropOx-c-N(Me)2-c-COOH) 70-15-15  - P28b was synthesized similar 
to P26b starting from P28a (5.9 g, 0.42 mmol polymer,  6.3 mmol OH, 1 eq.). P28b 
was obtained as a white solid (4.2 g, 68% yield). 1H NMR (400 MHz, D2O): δ 4.23-
4.14 (b, x•2H, O=CNHCH2CH2OC=O), δ 3.60-3.40 (b, (m+n+x)•4H, NCH2CH2N), 3.45 
(b, n•3H, NHCH2CH2OCH3), δ 3.40 (b, x•2H, O=CNHCH2CH2OC=O), 3.35-3.28 (b, 
n•2H, NHCH2CH2N(CH3)2), 2.85 (b, n•6H, NHCH2CH2N(CH3)2), 2.76-2.48 (b, (n+x)•4H, 
O=CCH2CH2C=ONH + x•4H, O=CCH2CH2C=O), 2.43-2.20 (b, m•2H, CH2CH2CH3), 
1.65-1.50 (b, m•2H, CH2CH2CH3), 0.98-0.85 (b, m•3H, CH2CH2CH3). Experimentally 
determined monomer ratio (m/n/x): 69/15/16. SEC (PMMA) no signal could be 
obtained.
 P28  P(nPropOx-c-OMe-c-NHS) 70-15-15  - P28 was synthesized similar to P26 
starting from P28b  (4.2 g, 0.27 mmol polymer,  4.2 mmol COOH, 1 eq.). P28 was 
obtained as a white foam (4.2 g, 68% yield). ). 1H NMR (400 MHz, D2O): δ 4.23-
4.14 (b, x•2H, O=CNHCH2CH2OC=O), δ 3.60 (b, n•2H, NHCH2CH2N(CH3)2), δ 3.60-
3.40 (b, (m+n+x)•4H, NCH2CH2N), δ 3.40 (b, x•2H, O=CNHCH2CH2OC=O), 3.35-
3.28 (b, n•2H, NHCH2CH2OCH3), 3.08-2.99 (b, x•2H, O=CCH2CH2COON), 3.01-2.90 
(b, x•4H, ONO=CCH2CH2C=ONO), 2.88-2.80 (b, x•2H, O=CCH2CH2COON), 2.85 
(b, n•6H, NHCH2CH2N(CH3)2), 2.76-2.48 (b, (n+x)•4H, O=CCH2CH2C=ONH + x•4H, 
O=CCH2CH2C=O), 2.43-2.20 (b, m•2H, CH2CH2CH3), 1.65-1.50 (b, m•2H, CH2CH2CH3), 
0.98-0.85 (b, m•3H, CH2CH2CH3). Experimentally determined monomer ratio (m/n/x): 
69/15/16. SEC (PMMA) Mn 22.1 kg/mol, Đ 1.33
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3Chapter 3:
Synthesis of pH- and thermoresponsive 
poly(2-n-propyl-2-oxazoline) based 
copolymers
Abstract
Polymers which possess lower critical solution temperature (LCST) behavior such as poly(2-alkyl-2-
oxazoline)s (POx) are interesting for their application as stimulus-responsive materials, for example 
in the biomedical field. In this chapter, we discuss the scalable and controlled synthesis of a library 
of pH- and temperature-sensitive 2-n-propyl-2-oxazoline P(nPropOx) based copolymers containing 
amine and carboxylic acid functionalized side chains by cationic ring opening polymerization and 
post-polymerization functionalization strategies. Using turbidimetry, we found that the cloud 
point temperature (CP) is strongly dependent on both the polymer concentration and the polymer 
charge (as a function of pH). Furthermore, we observed that the CP decreased with increasing salt 
concentration, whereas the CP increased linearly with increasing amount of carboxylic acid groups. 
Finally, turbidimetry studies in PBS-buffer indicate that CPs of these polymers are close to body 
temperature at biologically relevant polymer concentrations, which demonstrates the potential of 
P(nPropOx) as stimulus-responsive polymeric systems in e.g. drug delivery applications.  
Part of this chapter has been published
M. A. Boerman, H. L. Van der Laan, J. C. M. E. Bender, R. Hoogenboom, J. A. Jansen, S. C. 
Leeuwenburgh and J.C.M. Van Hest, J. Polym. Sci. Part A-1: Polym. Chem., 2016, 54, 1573-1582
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To date however, no polymeric systems have been designed that combine both the 
beneficial properties of nPropOx and the structural versatility of POx in forming 
both pH and thermoresponsive polymers. Moreover, the solution properties of both 
pH and temperature responsive polymeric systems consisting entirely of POx are 
only scarcely reported and have not systematically been investigated in the field30.
 Since the direct incorporation of both amine and carboxylic acid moieties would 
interfere with the cationic ring opening polymerization of 2-oxazolines, both 
functionalities have to be introduced in a protected manner. To this end, the methyl 
ester-functionalized MestOx 3 is highly suitable18. After polymerization, it allows 
the introduction of both functional groups via a one-step modification reaction. 
The polymerization kinetics of this monomer with various 2-alkyl-2-oxazoline 
comonomers has been reported by Bouten et al.31 and this monomer has also been 
copolymerized with P(NIPAm) and postmodified forming temperature- and pH-
responsive polymers30, 32. In this respect, MestOx seems to be an ideal monomer for 
the synthesis of more polar and stimuli-responsive nPropOx-based copolymers. 
 Herein, we present the preparation and stimulus-responsive properties of 
P(nPropOx)-based copolymers containing carboxylic acid and amine functional side 
chains. We demonstrate a versatile scalable synthesis strategy of these polymers 
based on the copolymerization of nPropOx and MestOx followed by a modification 
reaction, yielding both pH- and thermoresponsive copolymers. Finally, using 
turbidimetry, a detailed study in various aqueous solutions is performed to determine 
the behavior of these polymers at various biologically relevant conditions.
2. Results and discussion
2.1 Polymer synthesis
The polymers were synthesized by cationic ring opening polymerization (CROP), using 
microwave reaction conditions35 (Scheme 1). For the copolymerization of MestOx 
and nPropOx, the monomers were mixed in the desired ratios to form statistical 
copolymers with close to random monomer distribution as recently reported36. In these 
experiments, methyl tosylate was used as an initiator and piperidine as a terminating 
agent which prevents saponification of the methyl ester side chains of MestOx.  After 
threefold precipitation in ether, P1-P5 were obtained in multigram scale in overall 
high yields (76%). The polymers containing MestOx-side chains P2-P5 were post-
functionalized after polymerization. This was achieved either by (1) hydrolysis of the 
methyl ester side chains to carboxylic acid moieties using 1M NaOH, (Scheme 1, ii) or 
by (2) an amidation reaction in bulk using ethylene diamine as a solvent, yielding the 
polymer with amine-functionalized side chains (Scheme 1, iii)
1. Introduction
Stimuli-responsive polymeric systems are of great interest due to their potential in a 
wide range of applications (for e.g. drug delivery1-3 and coating applications4). Polymers 
which possess lower critical solution temperature (or LCST) behavior are particularly 
interesting in that respect, since these thermosensitive polymers are water soluble 
below their so-called cloud point (CP), but insoluble above this critical temperature. 
This behavior is driven by an unfavorable entropy of mixing above the CP, which 
causes precipitation of the polymer from aqueous solutions. This CP depends on a 
large number of parameters including monomer composition, polymer concentration, 
overall hydrophobic/hydrophilic nature, polymer length, as well as external factors 
like the type of solvent, pH, salt concentration and other additives5-10
 Poly(N-isopropyl acrylamide) (P(NIPAm)) is one of the most frequently studied 
thermoresponsive polymers (LCST ~ 32°C). Its occasionally challenging synthesis 
procedure, the occurrence of hysteresis between heating and cooling, as well as poor 
tunability of the transition temperature have, however, stimulated the search for 
polymer alternatives11.  New candidates have been identified recently, such as the 
poly(oligo ethylene glycol) methacrylate family12-14. Another very promising type of 
polymers are the poly(2-alkyl-2-oxazoline)s15-18 or POx, which  are a class of pseudo-
polypeptides that have gained increasing research interest because of their ease 
of synthesis, structural versatility and potential for application as biomaterials19-21. 
The wide range of studies on the thermoresponsive properties of POx that have 
been performed to date include the LCST behavior of 2-ethyl-2-oxazoline (EtOx, CP 
~ 65°C), 2-isopropyl-2-oxazoline (iPropOx, CP ~ 37°C) and 2-n-propyl-2-oxazoline 
(nPropOx, CP~ 24°C) homopolymers, as well as a great number of POx based 
copolymers22-26. For application in the human body, a transition temperature around 
body temperature is essential. As a consequence, iPropOx based copolymers have 
been studied most extensively. The lower transition temperature of nPropOx based 
copolymers appears to make them the less obvious choice for biomedical purposes. 
Nevertheless, these more hydrophobic nPropOx based polymers can be of interest 
because of their solubility in a wide range of organic solvents, which renders them 
particularly suitable in e.g. coating applications, but also can make them of interest 
for preparing polymer-drug conjugates. Moreover, in comparison to P(iPropOx), 
P(nPropOx) has the additional advantage to be amorphous and does not show 
irreversible crystallization upon annealing above the CP27-29. Finally, taken into 
account that cationic ring opening polymerization allows for the introduction of a 
wide range of hydrophilic co-monomers, carrying for example carboxylic acid or 
amine moieties, these polymers can be made both temperature and pH responsive 
around body temperature.  
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Table 1 Analytical data of synthesized polymers (P1-P10)
Theor. 1H-NMR Yield Mn (kg/mol)
Polymer mol% 
MestOx
mol% 
MestOx
mol% 
COOH
mol% 
NH2
% g Theor. SECa Đ
P1 P(nPropOx)  -  -  -  - 76 1.9 11.4 20.2 1.20
P2 P(nPropOx-c-MestOx) 10 10  -  - 86 51.3 11.9 16.7 1.23
P3 P(nPropOx-c-MestOx) 30 30  -  - 87 23.4 12.7 20.1 1.17
P4 P(nPropOx-c-MestOx) 50 49  -  - 81 14.2 13.6 20.3 1.12
P5 P(nPropOx-c-MestOx) 70 72  -  - q. 2.7 14.5 24.1 1.32
P6 P(nPropOx-c-COOH) 10  - 8  - 69 6.8 11.5 20.6 1.16
P7 P(nPropOx-c-COOH) 30  - 30  - 25 2.4 12.3 24.8 1.16
P8 P(nPropOx-c-COOH) 50  - 49  - 60 5.7 12.9 21.2 1.11
P9 P(nPropOx-c-COOH) 70  - 65  - 66 1.4 13.5 19.2 1.25
P10 P(nPropOx-c-NH2) 10  -  - 9 30 1.4 12.1 21.4 1.20
a SEC was calibrated against PMMA standards, eluent: 0.1 % LiCl in DMA
Figure 1 Overview of 1H-NMR spectra of selected polymers. (A) P2 recorded in CDCl3, (B) P10 recorded 
in D2O, (C) P1 recorded in CDCl3, (D) P6 recorded in D2O + DMSO-d6 (COOH 12 ppm). The integrals of 
the end groups (Me (3 ppm) and piperidine) were observed only in case of P1 and P2, but these were 
too small for accurate integration.
Scheme 1 Synthesis of polymers P1-P10; conditions: i) MeCN, 140°C, µW, 30 min,  ii) NaOH (1M), rt, 
overnight, iii) ethylene diamine,  rt, overnight. 
The workup of P6-P9 was performed by decreasing the pH of the solution to 4 
in order to protonate the side chains, and subsequent heating, which caused the 
polymers to precipitate. After multiple cycles of dissolving the polymers and 
precipitation by heating, the polymers P6-P9 were obtained as pure white powders 
in multigram quantities. This demonstrates that the thermoresponsive behavior of 
these copolymers can be utilized for the workup of these polymers. 
 For the amidation reaction, we aimed to synthesize polymers containing 
various molar percentages of amine functionalities.  Unfortunately, we observed 
intermolecular crosslinking for polymers with higher degrees (>20%) of MestOx-
functionalization. In future experiments, this could be circumvented by using e.g. 
mono-Boc-protected ethylene diamine, which can be coupled via the free amine 
group and subsequently be deprotected under acidic conditions. However, we chose 
to continue with the polymer that was successfully synthesized (P10). Since the 
work-up of this polymer (evaporation of solvent, followed by threefold precipitation 
in ether) proved insufficient to remove all ethylene diamine, a similar workup 
approach as for P6-P9 was performed. The crude polymer was dissolved in water 
and brine was added, which caused precipitation of the polymer. After drying the 
polymer, P10 was obtained in a pure state (30% yield).   
 The analytical data of the synthesized polymers are displayed in Table 1 and 
the 1H-NMR spectra of P1, P2, P6 and P10 are shown in Figure 1. The amount of 
MestOx that was incorporated into the polymers was well controlled as evidenced 
by 1H-NMR spectroscopy and close to the theoretical value.  This was also the 
case for the post-polymerization modifications (COOH and NH2), indicating near-
quantitative conversions. The deviations between theoretical and experimental 
Mn values as observed for all the synthesized polymers can be attributed to the 
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Figure 2 Turbidimetry study 
(A) Overview of cloud points of 
P1, P6-P8 at various polymer 
concentrations in MQ water, (B) 
Overview of cloud points of P1, 
P6-P9 in MQ-water (polymer 
concentration: 5 mg/mL), (C) 
P6 at various concentrations 
of NaCl,  (D) P10 at various 
concentrations of NaCl. 
Polymer concentration: 5 mg/
mL (C &D)
differences in hydrodynamic volume of the synthesized POx compared to the 
PMMA standards which were used for calibration. Integration of the end groups of 
the synthesized polymers proved to be too inaccurate for proper determination of 
the Mn by 
1H-NMR. The Đ of the polymers ranged from 1.1-1.3, indicating a precise 
control over the distribution of polymer chains.
2.2 Turbidimetry 
2.2.1 Polymer concentration
Since polymer concentration is a key parameter in affecting the CP, this was 
investigated for P1 and P6-P8 (Figure 2A). It was expected that at lower polymer 
concentrations hydrogen bonds are more easily formed with surrounding water 
molecules, while at higher polymer concentrations competition with interchain 
aggregation of hydrophobic regions in the polymer chain would occur, which results 
in CP-induction. At higher polymer concentrations (20 mg/mL up to 5 mg/mL) 
the CPs of P6-P8 were similar to the CPs of P1 (~ 25°C), indicating that at these 
concentrations interchain aggregation causes these polymers to precipitate out of 
solution which results in cloud point formation, despite the hydrophilic side chains. 
At lower polymer concentrations (1 mg/mL) however, the ability of P6-P8 to form 
hydrogen bonds with the surrounding water molecules was more predominant. 
This effect became more pronounced with increasing hydrophilicity of the side 
chains, as can be observed for polymers containing 10, 30 and 50% of carboxylic acid 
groups (from P6 to P8), which showed CPs of 38, 47 and 55 °C, respectively. This is 
in contrast with P1, which was not easily hydrated due to the lack of hydrophilic 
side chains. As a result, the CPs recorded for this polymer were around 25 °C for all 
polymer concentrations. 
2.2.2 Amount of COOH groups
Next, the influence of the molar percentage of carboxylic acid groups on the 
polymer’s transition temperature was investigated (Figure 2B).
 It was expected that incorporation of hydrophilic carboxylic acid groups would 
increase the water solubility, resulting into a higher CP. These studies were performed 
using polymers with 0 to 70 mol% of COOH. It was observed, as depicted in Figure 
2B, that indeed a linear relationship existed between the amount of carboxylic acid 
groups on the polymer chain and the CP of the polymer solution in MQ (5 mg/mL). 
These results are in agreement with the findings of Hoogenboom et al.27 and Park 
et al.37 in which statistical copolymers of nPropOx with non-ionic hydrophilic co-
monomers showed similar trends. Overall, increasing the amount of hydrophilic 
groups results in better polymer hydration and consequently a shift in CP from 24°C 
(0% COOH) to 39°C (70% COOH), as can be observed from P1 to P9. 
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Figure 3 Turbidimetry plots of P1, P6 and P10 in phosphate buffers pH 2 (A) and pH 12 (C). The 
ionization states are given respectively in B (pH 2) and D (pH 12). Polymer concentration: 10 mg/mL.
Figure 4 Overview of cloud points of P1, P6 and P10 at various polymer concentrations in PBS 
buffer (0.1 M)
2.2.3 Influence of NaCl 
To study the Hofmeister-related salting out effect38 on the CP of the synthesized 
polymers, a turbidimetric study was performed for P6 and P10 at various salt 
concentrations, as depicted in Figure 2C and 2D. As expected, at increasing salt 
concentrations, the CPs of the polymers dropped since the increased ionic strength 
of the solution as well as a salting out effect of NaCl facilitated precipitation of 
both polymers. This phenomenon was exploited in the synthesis of P6 and P10, 
as was discussed before. This effect was more pronounced for the carboxylic acid-
functionalized polymer as compared to the amine-functionalized polymer. It should 
be emphasized that P6 (Figure 2C) seems to be at the limit of solubility for the 
measurement in a 100 mg/mL NaCl solution, since 100% transmittance was not 
reached in the consecutive heating and cooling cycles.
2.2.4 Effect of pH
The cloud points of polymers P1, acid-functional P6 and amine-functional P10 were 
also determined using turbidimetry measurements in buffers of different pH. This 
study was performed to investigate the influence of the ionization state/charge of 
the side chains of the polymers on their cloud points. In view of the consecutive pKa 
values of carboxylic acids (~4-5) and amines (~8-9), this experiment was conducted 
at pH 2 and pH 12 to ensure that the majority of the functional groups were in the 
protonated or deprotonated state.  P1 was measured as well to study the effect on 
the CP of a polymer without functional side chains in these solvent systems. 
 At pH 2 only P1 and P6 showed a CP (around 24 °C), while P10 did not in the 
temperature range of 15-50 °C (Figure 3A). A CP was observed for P6 since the 
carboxylic acid groups were protonated (Figure 3B), thereby reducing the charge 
and polarity of the side chains. The resulting polymers were less hydrophilic and as 
a consequence CP formation was observed. Another possible explanation for this 
phenomenon could be related to the formation of intramolecular hydrogen bonds 
with the amide groups present in the backbone of POx resulting from protonation of 
the carboxylic acid groups, thereby reducing the interaction with surrounding water 
molecules. This is in agreement with the findings of Weber et al. on copolymers 
based on P(EtOx) and methacrylic acid.39  In contrast, P10 was positively charged 
and consequently soluble over the entire temperature range.  
 At pH 12, a similar relationship between the charge of the side chains and the 
transition temperature was observed (Figure 3C).  In this case, however, P6 was fully 
deprotonated (Figure 3D) and did not show any transition temperature between 
10 to 50 °C due to the hydrophilic side chains. Both P1 and P10 polymers, on the 
other hand, showed a transition temperature of 19 and 27 °C respectively, which 
can be explained by the absence of charge of the side chains, which plays a role 
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P(nPropOx) based co-polymers as both temperature and pH- responsive systems at 
physiologically relevant conditions. 
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5. Experimental
5.1 Materials
All reagents (synthesis grade) for the synthesis of the monomers were purchased 
at Sigma Aldrich and used without further purification, unless stated otherwise. 
All reagents for the synthesis of the polymers were distilled twice before use in the 
polymerizations. Acetonitrile was dried and dispensed under nitrogen atmosphere 
by using an MBraun MB SPS-800 solvent dispersing system. For turbidimetry 
measurements, ultrapure Milli-Q water (MQ) was obtained from a WaterPro PS 
polisher (Labconco, Kansas City, MO) set to 18.2 MΩ/cm.
5.2 Characterization
1H-NMR and 13C-NMR spectra were recorded on a Bruker Avance III 500MHz 
spectrometer using the solvents D2O, MeOD, CDCl3 or DMSO-d6. FT-IR measurements 
were performed on a Bruker Tensor 27 IR ATR spectrometer.  Microwave-assisted 
polymerizations were performed in a Biotage Initiator+, equipped with an 
autosampler. Size exclusion chromatography (SEC) was performed on an Agilent 
1260 - series HPLC system equipped with a 1260 online degasser, a 1260 ISO-pump, 
a 1260 automatic liquid sampler, a thermostatted column compartment, a 1260 
diode array detector (DAD) and a 1260 refractive index detector (RID). Analyses 
were performed on two Mixed-D and a guard column in series at 50 °C. As an 
eluent, N,N-dimethylacetamide (DMA), containing LiCl (concentration 50 mM), 
was used at a flow rate of 0.593 ml min-1. The SEC traces were analyzed using the 
Agilent Chemstation software with the GPC add on. Number average molecular 
weights (Mn), weight average molecular weights (Mw), and dispersity (Ð) values were 
calculated against poly(methyl methacrylate) (PMMA) standards. Monomers were 
distilled using a KDL-1 Wiped film evaporation setup (UIC GmbH) containing both an 
oil pump and an oil diffusion pump. Details can be found in Chapter 2.
in the hydration of the polymer chains. The lower CP of P1 at pH 12 compared to 
pH 2 might be explained by the partial deprotonation of the piperidine end groups, 
thereby making the polymer less charged (less hydrophilic) which induced a small 
decrease in the CP compared to the measurement at pH 2. In addition, the minor 
change in ionic strength may also have a small influence on the CP.
2.2.5 PBS
To study the solution behavior of these polymers in biologically relevant conditions, 
turbidimetry measurements were performed in PBS buffer using P1, P6 and P10 at 
various polymer concentrations (Figure 4).
 As expected, P1 showed a cloud point at 20 °C, irrespective of the polymer 
concentration because of the lack of hydrophilic side chains; this value was slightly 
lower than in the measurements in MQ because of the salting out effect. By 
introduction of functional groups (P6 and P10), however, the cloud points increased 
and these polymers became soluble around body temperature. P6 showed a similar 
behavior as observed in water, since a CP was not observed by turbidimetry at a 
polymer concentration of 1 mg/mL, presumably because of the more hydrophilic 
nature of the deprotonated carboxylic acid groups. In contrast, P10 did not show 
an effect on the polymer concentration. It seems that the amines are more easily 
hydrated/dehydrated independent of the polymer concentration, resulting in a 
constant CP around 38 °C for these polymers. It is evident that incorporation of 
carboxylic acid or amine groups renders the polymers more hydrophilic and soluble 
around body temperature. 
3. Conclusions
Various P(nPropOx-c-MestOx) copolymers were successfully synthesized and 
functionalized with amine and carboxylic acid groups, thereby allowing for precise 
control over their chemical composition. Turbidimetry studies showed that the CP 
of these polymers was lowered by the addition of sodium chloride due to charge 
screening and/or salting out. The CP increased linearly with increasing amount 
of carboxylic acid groups on the polymer. Moreover, a sharp increase in CP was 
observed at lower polymer concentrations (1 mg/mL) compared to higher polymer 
concentrations. The pH of the solution was a key parameter since the charge of 
the polymer chains dominated the CP. As a consequence, the CP can be tuned by 
changing the pH of the polymer solution. As evidenced by measurements in PBS, 
these copolymers become soluble around body temperature upon incorporation 
of amine and carboxylic acid groups, which demonstrates the potential of these 
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P4- P(nPropOx-c-MestOx) 50-50 - The reaction was performed similar to P2 using 
methyl tosylate (0.131 mL, 0.870 mmol), nPropOx (4.83 mL, 43.5 mmol), MestOx 
(2.99 mL, 21.8 mmol) and acetonitrile (7.60 mL).  P(nPropOx)-c-MestOx) 50-50 (P4) 
was obtained as a white foam  (14.2 g, 81% yield). 1H NMR (500 MHz, CDCl3) δ 3.66 
(b, n·3H, CO-O-CH3), δ 3.48 (b, (m+n)·4H, NCH2CH2N), 3.03 (b, 3H, CH3-NCHCH-), 
2.70-2.60 (b, m·4H, COCH2CH2CO),  2.35-2.20 (b, n·2H, CO-CH2-CH2-CH3),  1.70-1.60 
(b, n·2H, CO-CH2-CH2-CH3), 0.90-1.01 (b, n·3H, CO-CH2-CH2-CH3) SEC (PMMA) Mn 
20.3 kg/mol, Đ 1.12  
 P5- P(nPropOx-c-MestOx) 30-70 - The reaction was performed similar to P1 
using methyl tosylate (0.032 mL, 0.214 mmol), nPropOx (0.713 mL, 6.4 mmol), 
MestOx (2.06 mL, 21.8 mmol) and acetonitrile (2.54 mL). P(nPropOx)-c-MestOx) 30-
70 (P5) was obtained as a white foam  (2.7 g, quant. yield). 1H NMR (500 MHz, CDCl3) 
δ 3.60 (b, m·3H, CO-O-CH3), δ 3.45 (b, (m+n)·4H, NCH2CH2N), 2.70-2.50 (b, m·4H, 
COCH2CH2CO),  2.35-2.15 (b, n·2H, CO-CH2-CH2-CH3),  1.50 (b, n·2H, CO-CH2-CH2-
CH3), 0.91-1.01 (b, n·3H, CO-CH2-CH2-CH3) SEC (PMMA) Mn 20.7 kg/mol, Đ 1.32  
Protocol 1: General procedure ester hydrolysis (P6-P9)
P(nPropOx-c-MestOx) (P2-P5) was dissolved in a 0.1 M-solution of NaOH (100 mL) 
and stirred overnight.  The reaction mixture was acidified to pH 4 by dropwise addition 
of a 0.1M-solution of HCl. The reaction mixture was stirred in a heated water bath 
(45°C) which caused precipitation of the polymer as a sticky white precipitate. The 
precipitate was dissolved in cold water (100 mL) and the reaction mixture was stirred 
again in the heated water bath, which caused the polymer to precipitate again. The 
pH of the solution was 4. The sticky white precipitate was either (1) dissolved again 
in DCM (100 mL) and concentrated under reduced pressure or (2) precipitated from 
DMF (20 mL) into diethyl ether (2000 mL) and subsequently filtered and dried under 
high vacuum, yielding the final polymer as a white fluffy powder.  
 P6- P(nPropOx-c-COOH) 90-10 was synthesized from P2 (10.2 g, 9 mmol 
functional groups) according to protocol 1, yielding P(nPropOx-c-COOH) 90-10 (P6) 
as a white solid (6.8 g, 68% yield). 1H NMR (500 MHz, D2O)  δ 3.71-3.30 (b, (m+n)·4H, 
NCH2CH2N), 2.60-2.50 (b, m·4H, COCH2CH2CO),  2.35-2.20 (b, n·2H, CO-CH2-CH2-
CH3),  1.50-1.40 (b, n·2H, CO-CH2-CH2-CH3), 0.90-1.00 (b, n·3H, CO-CH2-CH2-CH3) 
(500 MHz, DMSO-d6)  δ 12.01 (b, m·1H, COOH) FT-IR: 1639 cm-1 (CO amide), 1729 
cm-1 (CO carboxylic acid), 3503 cm-1 (OH carboxylic acid) SEC (PMMA) Mn 20.6 kg/
mol, Đ 1.16
 P7- P(nPropOx-c-COOH) 70-30 was synthesized from P3 (10.0 g, 24 mmol 
functional groups) according to protocol 1, yielding P(nPropOx-c-COOH) 70-30 (P7) 
as a white solid (2.4 g, 25% yield). 1H NMR (500 MHz, D2O)  δ 3.72-3.32 (b, (m+n)·4H, 
NCH2CH2N), 2.60-2.50 (b, m·4H, COCH2CH2CO),  2.35-2.20 (b, n·2H, CO-CH2-CH2-
5.3 Synthesis
The synthetic procedures of monomers can be found in the experimental section of 
Chapter 2. 
Polymer synthesis
The polymers were prepared analogous to the polymers described in Chapter 2
P1- P(nPropOx) - Methyl tosylate (0.131 mL, 0.870 mmol), nPropOx (4.83 mL, 43.5 mmol) 
and acetonitrile (7.60 mL) were mixed in a dry microwave vial under inert atmosphere 
(Ar). The polymerization was heated for 30 min under microwave irradiation after which 
dry piperidine (0.430 mL, 4.35 mmol) was added to the reaction mixture, which was 
stirred for three hours.  The polymer was dissolved in an appropriate amount of DCM 
and precipitated in diethylether (DCM/Et2O, v/v, 1:20). This procedure was performed 
two times. The resulting suspension was filtered and the residue dissolved in DCM 
(100 mL). The solvent was evaporated under reduced pressure. P(nPropOx) (P1) was 
obtained as a white foam (1.9 g, 76% yield). 1H NMR (500 MHz, CDCl3) δ 3.48 (b, n·4H, 
NCH2CH2N), 3.05 (b, 3H, CH3-NCHCH-), 2.35-2.20 (b, n·2H, CO-CH2-CH2-CH3), 1.60-1.40 
(b, n·2H, CO-CH2-CH2-CH3), 0.92-1.01 (b, n·3H, CO-CH2-CH2-CH3)  FT-IR: 1636 cm
-1 (CO 
amide) SEC (PMMA) Mn 20.2 kg/mol, Đ 1.20
 P2- P(nPropOx-c-MestOx) 90-10 - Methyl tosylate (0.131 mL, 0.870 mmol), nPropOx 
(4.83 mL, 43.5 mmol), MestOx (2.99 mL, 21.8 mmol) and acetonitrile (7.60 mL) were 
mixed in a Schlenk flask under inert atmosphere (Ar). After the addition, the flask was 
put in a preheated oil bath (80 °C) and stirred during 10 hrs. Next, dry piperidine (0.430 
mL, 4.35 mmol) was added to the reaction mixture, which was stirred for three hours. 
The polymer was dissolved in an appropriate amount of DCM and precipitated in diethyl 
ether (DCM/Et2O, v/v, 1:20). This procedure was performed two times. The resulting 
suspension was filtered and the residue dissolved in DCM (100 mL). The solvent was 
evaporated under reduced pressure. P(nPropOx)-c-MestOx) 90-10 (P2) was obtained 
as a white foam (53.1 g, 76% yield). 1H NMR (500 MHz, CDCl3) δ 3.66 (b, m·3H, CO-O-
CH3), δ 3.48 (b, (m+n)·4H, NCH2CH2N), 3.03 (b, 3H, CH3-NCHCH-), 2.70-2.60 (b, m·4H, 
COCH2CH2CO),  2.35-2.20 (b, n·2H, CO-CH2-CH2-CH3),  1.70-1.60 (b, n·2H, CO-CH2-CH2-
CH3), 0.91-1.02 (b, n·3H, CO-CH2-CH2-CH3) SEC (PMMA) Mn 16.7 kg/mol, Đ 1.23 
 P3- P(nPropOx-c-MestOx) 70-30 - The reaction was performed similar to P2 using 
methyl tosylate (0.131 mL, 0.870 mmol), nPropOx (4.83 mL, 43.5 mmol), MestOx (2.99 
mL, 21.8 mmol) and acetonitrile (7.60 mL).  P(nPropOx)-c-MestOx) 90-10 (P3) was 
obtained as a white foam  (23.4 g, 86% yield). 1H NMR (500 MHz, CDCl3) δ 3.66 (b, m·3H, 
CO-O-CH3), δ 3.48 (b, (m+n)·4H, NCH2CH2N), 3.03 (b, 3H, CH3-NCHCH-), 2.70-2.60 (b, 
m·4H, COCH2CH2CO),  2.35-2.20 (b, n·2H, CO-CH2-CH2-CH3),  1.70-1.60 (b, n·2H, CO-
CH2-CH2-CH3), 0.93-1.01 (b, n·3H, CO-CH2-CH2-CH3) SEC (PMMA) Mn 20.1 kg/mol, Đ 1.17 
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concentrations using different aqueous solutions, both specified in the main text. For 
these measurements, two subsequent cycles of heating and cooling were conducted. 
The CPs were recorded as the temperature (°C) at which 50% transmittance was 
observed during the second heating cycle without stirring. The measurements at 
the different pH-values were performed using phosphate buffers of pH 2 and pH 12 
as a solvent.
CH3),  1.50-1.40 (b, n·2H, CO-CH2-CH2-CH3), 0.90-1.00 (b, n·3H, CO-CH2-CH2-CH3) 
SEC (PMMA) Mn 24.8 kg/mol, Đ 1.16 
 P8- P(nPropOx-c-COOH) 50-50 was synthesized from P4 (10.0 g, 40 mmol 
functional groups) according to protocol 1, yielding P(nPropOx-COOH) 50-50 (P8) 
as a white solid (6.8 g, 68% yield). 1H NMR (500 MHz, D2O)  δ 3.70-3.30 (b, (m+n)·4H, 
NCH2CH2N), 2.60-2.50 (b, m·4H, COCH2CH2CO),  2.35-2.20 (b, n·2H, CO-CH2-CH2-
CH3),  1.50-1.40 (b, n·2H, CO-CH2-CH2-CH3), 0.90-1.00 (b, n·3H, CO-CH2-CH2-CH3) 
(500 MHz, DMSO-d6)  δ 11,68 (b, n·1H, COOH) FT-IR: 1619 cm-1 (CO amide), 1721 
cm-1 (CO carboxylic acid), 3413 cm-1 (OH carboxylic acid) SEC (PMMA) Mn 21.2 kg/
mol, Đ 1.11
 P9- P(nPropOx-c-COOH) 30-70 was synthesized from P4 (2.21 g, 10  mmol 
functional groups) according to protocol 1, yielding P(nPropOx-COOH) 30-70 (P9) 
as a white solid (1.4 g, 66% yield). 1H NMR (500 MHz, D2O)  δ 3.71-3.42 (b, (m+n)·4H, 
NCH2CH2N), 2.71-2.51 (b, m·4H, COCH2CH2CO),  2.42-2.12 (b, n·2H, CO-CH2-CH2-
CH3),  1.60-1.41 (b, n·2H, CO-CH2-CH2-CH3), 0.91-0.89 (b, n·3H, CO-CH2-CH2-CH3) FT-
IR: 1627 cm-1 (CO amide), 1714 cm-1 (CO carboxylic acid), 3363 cm-1 (OH carboxylic 
acid) SEC (PMMA) Mn 19.2 kg/mol, Đ 1.25 
Amidation  
P10-P(nPropOx-c-NH2) 90-10 was synthesized following a modified literature 
procedure40 - P2 (4.21 g, 4 mmol functional groups) was dissolved in ethylene 
diamine (25 mL, 22.5 g, 0.37 mol, 10 eq.) . The reaction mixture was allowed to stir 
overnight. Excess ethylene diamine was removed under reduced pressure. The 
polymer was dissolved in methanol (20 mL) and precipitated in diethyl ether (250 
mL). A sticky precipitate was formed. This was repeated twice. In order to remove 
residual ethylene diamine, the polymer was subsequently dissolved in cold water (50 
mL), after which brine (10 mL) was added and the mixture was stirred in a water bath 
(50 °C), causing the polymer to precipitate. After this, the polymer was dissolved 
in methanol (30 mL). After concentration of the solvent under reduced pressure, 
P(nPropOx-c-NH2) (P10) was obtained as a white solid (1,4 g, 30% yield) 
1H NMR 
(500 MHz, D2O)  δ 3.55-3.35 (b, n·4H, NCH2CH2N), 3.35-3.30 (b, m·2H, CONH-CH2CH2-
NH2), 2.95-2.90  (b, m·2H, CONH-CH2CH2-NH2),  2.70-2.55 (b, m·2H, COCH2CH2CO), 
2.55-2.40 (b, m·2H, COCH2CH2CO), 2.35-2.20 (b, n·2H, CO-CH2-CH2-CH3),  1.55-1.40 
(b, n·2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, 3H, n·CO-CH2-CH2-CH3) FT-IR: 1670 cm
-1 
(CO amide), 3470 cm-1 (NH stretch) SEC (PMMA) Mn 21.4 kg/mol, Đ 1.20
5.4 Turbidimetry
UV-VIS spectra were recorded on a Jasco V650 containing a temperature controller 
at a wavelength of 500 nm. Measurements were conducted at various polymer 
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4Chapter 4:
Next generation hemostatic materials 
based on NHS-ester functionalized 
poly(2-oxazoline)s 
Abstract
In order to prevent hemorrhage during surgical procedures on soft tissue, a wide range of hemostatic 
agents have been developed in the field so far. However, their efficacy is variable and the majority 
of these agents are derived from animal or human material and/or use bioactive components to 
accelerate coagulation. In this chapter, we develop a synthetic, non-bioactive hemostatic product 
by coating N-hydroxysuccinimide ester (NHS)-functional poly(2-oxazoline)s (NHS-POx) onto 
gelatin patches, which act by formation of covalent crosslinks between polymer, host blood 
proteins, gelatin and tissue to seal the wound site and prevent hemorrhage during surgery. We 
study different process parameters (including polymer, carrier and coating technique) in direct 
comparison with clinical products (Hemopatch® and Tachosil®) to obtain deeper understanding of 
this class of hemostatic products. In this work, we successfully prove the hemostatic efficacy of 
NHS-POx as polymer powders and coated patches both in vitro and in vivo against Hemopatch® and 
Tachosil®, demonstrating that NHS-POx are excellent candidate polymers for the development of 
next generation hemostatic patches.  
Part of this chapter has been published
M.A. Boerman, E.Roozen, M.J. Sánchez-Fernández, A.R. Keereweer, R.P. Félix Lanao, J.C.M.E. 
Bender, R. Hoogenboom, S.C. Leeuwenburgh, J.A. Jansen, H. Van Goor, J.C.M. Van Hest, 
Biomacromolecules, 2017, 18, 2529-2538
4
9392
Chapter 4 Next generation hemostatic materials based on NHS-ester functionalized poly(2-oxazoline)s
4
and polarity, this has stimulated the search for alternative polymers which can be 
used as hemostatic materials.
 Poly(2-oxazoline)s (or POx23-26) are promising polymers for biomedical 
applications due to their versatile synthesis27-29, favorable cytocompatibility30,31 
and promising excretability32-38. In terms of polymer architecture and function, 
POx possesses important advantages over PEG-based systems when applied in 
hemostatic materials. Firstly, cationic ring opening polymerization (CROP) allows 
for the introduction of both functional side chains and end-groups, which is not 
easily achieved by anionic polymerization of PEG-based systems. Moreover, 
this polymerization technique allows for the synthesis of a range of copolymers, 
which makes it possible to accurately control the polarity and degree of side-chain 
functionalization of the resulting polymer. 
 In order to achieve optimal hemostatic performance, three main aspects of 
the hemostatic device should be optimized, namely (1) the carrier, (2) the polymer 
coating and (3) the coating application method onto the carrier material. As a 
carrier, we selected a porous gelatin sponge. Although this carrier is animal derived, 
it has advantages over other synthetic materials, since it is fully biodegradable (4-8 
weeks), shows effective uptake of blood and is already CE-registered as a hemostatic 
product13. Moreover, primary amines are available in gelatin to allow for the formation 
of covalent crosslinks between the carrier, blood proteins and tissue in order to create 
a gel which seals the wound surface and stops the bleeding (Figure 1).
 Regarding polymer design, for optimal hemostatic performance, the polymer 
should have sufficient reactive moieties (NHS-esters) for covalent crosslinking 
(e.g. with blood proteins). The polymer composition should furthermore be chosen 
in such a way that the polymers are soluble in water (beneficial for their biological 
activity) and in organic solvents (beneficial for polymer processing). Moreover, the 
reactive moieties should be available for crosslinking, which requires reactive side 
chains of sufficient flexibility and length as well as an overall polymer composition 
which is polar enough to allow effective wetting under physiological conditions. The 
crosslinking capacity should be optimized to ensure that the polymer has sufficient 
time to crosslink with the various components (blood, carrier and tissue).
 Regarding the coating of the hemostatic patch, we hypothesized that various 
parameters are important to achieve the desired hemostatic properties. First, the 
reactive polymer should be equally distributed over the carrier in order to obtain 
homogeneous hemostatic properties over the whole area of the coated patch. 
Secondly, the polymer and carrier should be combined in such a way that undesired 
crosslinking during the coating process is prevented. Moreover, after coating, 
porosity should be partially conserved in order to obtain a hemostatic patch with 
a dual mechanism of action of both gelatin (natural coagulation cascade) and the 
1. Introduction
One of the main challenges during surgical procedures on parenchymatous tissue 
is to attain control over bleeding1. Suture control, electrocautery2 and ultrasonic 
sealing3 often do not suffice during operations on for example liver or kidneys. As 
a result, procedures like hepatic resections4 or partial nephrectomy5 require an 
alternative approach to control bleeding. For this purpose, a wide range of topical 
hemostatic products has been developed and are clinically available6-8. 
 Nevertheless, as has been described in detail in Chapter 1, currently available 
products (both natural and synthetic) suffer from drawbacks which limits their use 
for treatment of profuse bleedings during surgery on soft tissue. Naturally derived 
hemostatic products 9-15 (e.g. gelatin sponges), which act by means of the natural blood 
coagulation cascade, have a limited capability to seal large wound areas. In addition, 
these products are only effective to a limited extent in patients receiving anticoagulants 
during surgery, while they also are associated with potential transmission of animal 
borne diseases. Synthetic hemostatic products16,17 act independently of the natural 
coagulation cascade by sealing the bleeding surface of the wound. Although for this 
class superior hemostatic efficacy has been reported over their natural counterparts, 
these products have not found widespread acknowledgement in the field yet, since for 
some of these polymers toxicity has been reported during application17.  In addition, 
some of these polymers have been considered biocompatible (e.g. non-toxic and 
cytocompatible) (such as poly(ethyleneglycol) (PEG)), where for other polymer classes 
this has yet to be eludicated.   
 A promising recent approach entails the development of hybrid products, which 
combine the beneficial properties of both synthetic and natural polymers, such 
as Veriset18 (an oxidized regenerated cellulose sheet impregnated with tri-lysine 
and N-hydroxysuccinimide ester functional 4-arm poly(ethylene glycol) (NHS-
PEG)) and Hemopatch19-21 (a porous collagen carrier coated with NHS-PEG). These 
products have been demonstrated improved hemostatic efficacy compared to 
carriers without this coating20, 22 and other commercially available products18-20. 
Nevertheless, the limited efficacy in sealing profuse bleedings might be related to 
the use of NHS-PEG in these devices, as the intrinsic fast crosslinking of NHS-PEG 
(in case of Hemopatch) might lead to poor fixation to tissue (by limited crosslinking 
with the collagen carrier) or irregular sealing of the wound site (by inhomogeneous 
crosslinking with tissue). Moreover, swelling of PEG based materials is a problematic 
issue which might lead to weakening of the seal or compression of blood vessels or 
nerves after application. These potential drawbacks might be solved by modifying 
and fine-tuning the polymer architecture and properties. However, since PEG has 
limited options for tailoring the degree of functionalization (only via the end groups) 
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2. Results and discussion  
2.1. Synthesis
In order to create poly(2-oxazolines) with the desired characteristics for application 
as reactive coating in a hemostatic patch, both polarity and reactivity had to be 
optimized. We selected NHS-esters as the reactive moieties in view of their reactivity 
towards primary amines and their routine application in related medical devices7. 
Since direct incorporation of NHS-esters as functional group is not compatible with 
cationic ring opening polymerization (CROP), we used methyl ester functionalized 
2-methoxycarbonylethyl-2-oxazoline (MestOx) instead. This group can be easily 
modified after the polymerization by direct amidation39 or hydrolysis40-42, as has been 
described in literature, and in Chapters 2 and 3. Furthermore, it has been efficiently 
copolymerized before with various co-monomers (including 2-ethyl-2-oxazoline 
(EtOx)43 and 2-n-propyl-2-oxazoline (nPropOx)44).  For the synthesis of the various 
NHS-POx (P1-P7) we used two different synthetic routes, as depicted in Scheme 1, 
and which were described in more detail in Chapter 2. In all cases, polymers were 
synthesized by CROP of different ratios of EtOx, nPropOx and MestOx under inert 
atmosphere using microwave conditions45, yielding both nPropOx-MestOx and 
nPropOx-EtOx-MestOx-copolymers. In the first route, the MestOx groups were 
hydrolyzed (0.1M NaOH) resulting in a copolymer containing carboxylic acid moieties, 
which were subsequently activated with N-hydroxysuccinimide yielding P1-P6. In 
the second route, MestOx was post-modified by an amidation reaction with ethanol 
amine, yielding copolymers equipped with a hydroxyl moiety in the side chain. 
Subsequently, these hydroxyl groups were partially converted to carboxylic acid 
moieties using succinic anhydride, which were subsequently modified into reactive 
esters by coupling with N-hydroxysuccinimide (P7). Importantly, this second route 
installs a hydrolytically sensitive group in the side chain, favorable for degradation. 
As listed in Table 1, polymers P1-P7 were synthesized with good control over the 
ratio of functional groups, number average molar mass and dispersity values. The 
various synthesized polymers (P1-P7) were analyzed with regard to the amount of 
NHS groups present using both 1H NMR and UV-Vis spectroscopy, confirming a good 
agreement between the theoretical and experimental compositions.
reactive polymer (sealing the wound site by covalent crosslinking). Moreover, the 
blood uptake of the coated patches should be satisfactory to allow for crosslinking 
with all patch components (gelatin, reaction polymer, blood and tissue), but also 
resistant enough to prevent excessive blood flow through the patch.
 In this chapter, we demonstrate a versatile strategy for the preparation of a poly(2-
oxazoline) based hemostatic device. First, a series of NHS-ester functionalized POx 
(NHS-POx) with different ratios of NHS esters and polar groups was synthesized. We 
studied the capacity for covalent crosslinking between these polymers and whole 
blood (hemostatic performance) in order to correlate the hemostatic performance 
with the polarity of the polymers (measured by contact angle measurements). With 
the preselected polymers, we utilized a spraying procedure to create a series of 
homogeneously coated patches. The coated patches were tested in vitro, for e.g. 
blood uptake and crosslinking ability. The best-performing patches in these tests 
were selected to demonstrate in vivo efficacy in a compromised liver and spleen 
injury model of profuse bleedings in heparinized pigs.
Figure 1 Schematic overview of application method and mechanism of action of poly(2-oxazoline) 
coated hemostatic patches. A) Preparation of a hemostatic patch by spray-coating NHS-POx onto a 
gelatin sponge, B) Application of the patch onto the wound site,  C) Hemostasis is obtained by covalent 
crosslinking between the gelatin sponge, NHS-POx, blood proteins and tissue in order to create a gel 
which seals the wound surface and stops the bleeding.
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polymer (NHS-PEG used in Hemopatch) was included as a positive control to compare 
functional group density (mmol NHS/g polymer) in relation to the usage of different 
polymers.  The results of these tests are listed in Table 2. As expected, polymers with 
NHS-esters (P1-P7) gelated with blood due to the presence of the amine-reactive NHS-
esters, unlike the negative controls (P8-P12), which did not. Gelation times of the NHS-
POx series (P1-P7) varied between 1 minute (P7) to 6 minutes (P1-P2), which was slower 
than the NHS-PEG benchmark polymer, which formed a gel with blood instantaneously. 
 As polarity was anticipated to be an important feature of the hemostatic capacity of 
the polymers, POx films were spincoated on glass slides after which static contact angle 
measurements were performed46. Based on these contact angle measurements, it can 
be concluded that polymers functionalized with hydrophilic groups (PEG, OH or EtOX) 
(P3-P8 + P10-P11) exhibit contact angles in a similar hydrophilic range (21°-26°), while 
polymers without hydrophilic groups (P1-P2+P9) have higher contact angles, thereby 
making a clear difference between hydrophilic and somewhat more hydrophobic 
copolymers. It was further calculated that the PEG-based control (P11) shows a much 
lower density of NHS-functional groups (0.36 mmol/g polymer) compared to P1-P7 with 
values ranging from 0.76 mmol/g polymer for P1 to  2.19 mmol/g polymer for P2, which 
is a direct result of the limited functionalization possibilities of PEG via the end-groups.
Table 2 Overview of hemostatic performance (P1-P7)
# Polymer %NHS Functional group content Contact angle Gelation time 
(mmol NHS/g polymer)a) (°)b) (min)c)
P1 P(nPropOx-c-NHS) 10 0.76 36 6
P2 P(nPropOx-c-NHS) 29 2.19 57 6
P3 P(nPropOx-c-EtOx-NHS) 11 0.89 26 3
P4 P(nPropOx-c-EtOx-NHS) 24 1.59 24 3
P5 P(nPropOx-c-EtOx-NHS) 11 0.88 23 3
P6 P(nPropOx-c-EtOx-NHS) 24 1.57 21 3
P7 P(nPropOx-c-OH-NHS) 15 0.91 23 1 
Controls
P8 P(EtOx) -  - 26 no gel
P9 P(nPropOx) -  - 57 no gel
P10 mPEG-OH -  - 24 no gel
P11 NHS-PEGd) - 0.36 21 instantaneous
a) Calculated using NHS-content which was determined by 1H-NMR spectroscopy
b) The measurements were conducted in triplo, blank measurement glass slide (66°)
c) The gelation was determined by the inverted vial method
d) Obtained from commercial source
From both tests, it can be concluded that NHS-esters are essential for the formation 
Scheme 1 Synthesis of NHS-ester functionalized polymers (NHS-POx) (P1-P7).  i) methyl tosylate, 
140°C, CH3CN, ii) 0.1 M NaOH, rt,  iii) NHS-OH, DIC, DCM, rt , iv) 2-amino-ethanol, 60°C, 300 mbar, v) 
succinic anhydride, DMAP, DMF/DCM (v/v, 1:9, rt) 
Table 1 Analytical data of synthesized polymers (P1-P7)
% funct. (1H-NMR)
# Polymer m n y x UV Mn (kg/mol)
m/n/x nPropOx EtOx OH NHS NHS SECa) Ða)
P1 P(nPropOx-c-NHS) 90-0-10 90 - - 10 11 12.6 1.15
P2 P(nPropOx-c-NHS) 75-0-25 71 - - 29 26 13.9 1.11
P3 P(nPropOx-c-EtOx-NHS) 40-50-10 40 49 - 11 9 12.4 1.18
P4 P(nPropOx-c-EtOx-NHS) 40-35-25 40 36 - 24 22 12.4 1.26
P5 P(nPropOx-c-EtOx-NHS) 50-40-10 49 40 - 11 11 12.3 1.16
P6 P(nPropOx-c-EtOx-NHS) 50-25-25 50 26 - 24 23 14.6 1.18
P7 P(nPropOx-c-OH-NHS) 70-10-20 70 - 15 15 15 18.8 1.25
a) SEC was calibrated against PMMA standards, eluent: 0.1 % LiCl in DMA
2.2 Hemostatic performance 
As a first screening for hemostatic activity, the NHS-POx polymers were brought in 
contact with human whole blood and the formation of gels by mixing polymers with 
blood was analyzed using the inverted vial test. Besides the NHS-POx series, negative 
controls (polymers without NHS ester) were tested as well. In addition, a benchmark 
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group density as Hemopatch (~5.2 µmol NHS/cm2), which is beneficial if an open, 
porous structure is required for the carrier material.
Table 3 Coating and functional group densities of patches prepared with P7 (G1-G4)
Samples Coating density (mg/cm2) Functional group density
# Theoretical Measured
mean st dev n (µmol NHS/cm2)a)
G1 0 - - - -
G2 3 3.06a) 0.01 3 2.80
G3 6 5.71a) 0.13 9 5.18
G4 9 9.22a) 0.01 3 8.36
Hemopatch (PEG) - 16.8b) 2.2 5 5.38
a) Mass difference before (gelatin) and after coating (gelatin + NHS-POx)
b) Determined by extraction of the polymer with DCM 
Figure 2 SEM images of NHS-POx coated patches (G1-G4) and Hemopatch (PEG). Scale bars 
correspond to 1 mm or 100 μm (bottom right picture).
of chemical cross links with blood proteins. However, having a surplus of NHS-esters 
does not result in faster gelation. POx-prototypes which contain both NHS-esters 
and hydrophilic groups show faster gelation (P3-P7) compared to polymers without 
hydrophilic groups (P1-P2), but slower than NHS-PEG (P11), which crosslinked 
instantaneously. It was observed that the fast-gelating polymers also exhibited low 
contact angles. The difference in gelation speed between NHS-PEG and NHS-POx 
prototypes could, however, not be explained from the contact angle measurements. 
We assume that polarity and mobility of the polymer chains (limited by the spacer 
length between the polymer backbone and NHS-ester groups) are important 
parameters. NHS-PEG shows the fastest gelation, since the NHS-ester groups are 
highly mobile because of their attachment to the hydrophilic chain ends of the PEG-
polymer. Within the NHS-POx series, P7 shows the fastest gelation (1 min) because 
it has a longer spacer compared to P1-P6. Finally, the differences between P1-P6, 
with the same spacer length, can be explained because of polarity of the polymers; 
polymers containing hydrophilic EtOx groups (P3-P6) show gelation within 3 
minutes, while polymers without these groups (P1-P2) show gelation times around 
6 minutes. Due to its fast gelation, we selected P(nPropOx-OH-NHS) (P7) as the 
main candidate for further development of hemostatic patches.
2.3 Spray coating deposition
To cover the gelatin carrier with a polymer (P7) coating, a procedure was required 
that would result in a homogeneous polymer layer without compromising the 
beneficial properties of the gelatin carrier in terms of e.g. blood uptake capacity. 
Therefore, we used an ultrasonic spraying technique to deposit the polymer from 
volatile organic solvents of low toxicity onto the gelatin sponge and tune the amount 
of polymer by coating multiple layers (coating cycles) followed by drying the coated 
patches in a vacuum oven. 
 Using this approach, hemostatic patches (G1-G4) were prepared at various 
coating densities (0-9 mg/cm2) using a polymer solution of P7 (90 mg/mL in 
2-propanol/2-butanone (v/v, 1:1)). We observed a linear relationship between the 
coating density (mg/cm2) and the amount of coating cycles (Table 3). Additionally, 
the coated patches were analyzed by scanning electron microscopy (SEM) (Figure 2) 
which revealed that the pores of the carrier were not sealed by the polymer coating 
after applying up to six coating cycles. Furthermore, the coating was homogenously 
spread onto the carrier material, unlike Hemopatch (based on NHS-PEG), which 
showed a heterogeneous coverage revealing PEG-coated and uncoated domains. 
The analytical data of G1-G4 are summarized in Table 3. Importantly, as POx is 
functionalized with a higher number of NHS-esters than PEG, a lower amount of 
polymer was required (5.7 mg/cm2 for G3) in order to obtain a similar functional 
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Figure 3A+B In vitro tests A) Blood uptake capacity as a function of coating density.  (** P< 0,001, 
*P<0,01), B) In vitro adhesion test. i) blood was applied between the patches, ii) the patches were 
allowed to crosslink for defined time points (t1, t5, t15 min), iii) The samples were placed in a Zwick 
Roell tensile bench and a vertical force was applied until failure, iv) Results of the adhesion test. (* P 
<0.05, ** P< 0,01, ***P<0,001)  
2.4 In vitro tests
2.4.1 Blood uptake
The blood uptake of the different NHS-POx coated patches (G1-G4) and Hemopatch 
was evaluated by soaking the patches (with the coated side in contact with blood) in 
a mixture of blood/PBS for 30 seconds and determining the blood uptake by weighing 
the carriers before and after the soaking process (Figure 3A). It was observed that 
the uptake capacity of the patches was reduced with increasing coating density. 
Although the polymer coating did not seal the pores of the underlying gelatin carrier 
(Figure 2), the blood uptake was clearly compromised by the deposition of NHS-
POx onto the patches. Hemopatch was included as well in these measurements, and 
showed significantly lower blood uptake values compared to G1-G3. Since blood 
uptake is necessary for satisfactory blood distribution throughout the patch and 
subsequent crosslinking, we conclude that G3 was the best-performing prototype 
in this test, as it allowed for more effective blood uptake compared to G4 and 
Hemopatch, but still prevented bleeding through the patches, which was observed 
for G1 and G2.
2.4.2 Adhesion test    
An in vitro adhesion test was performed (according to ASTM F2258-05 standards) to 
study the attachment between the coated patches upon contact with blood (Figure 
3B). The different patches (G1-G4) were allowed to covalently crosslink onto each 
other for 1, 5 or 15 min, after which the adhesion force (N) was measured until the 
patches were separated. Both a negative control (G1, carrier without polymer) and 
a benchmark (Hemopatch) were included in this study. The data demonstrated that 
the NHS-ester free blank samples (G1) did not adhere to each other as reflected 
by adhesion forces of less than 0.5 N, which confirms that NHS-ester groups are 
necessary for the formation of covalent crosslinks. The coated samples (G2-G4) 
showed an entirely different behavior. At 1 and 5 minutes contacting time, low 
adhesion forces were measured which were comparable to G1, indicating a low 
degree of crosslinking. At 15 minutes, however, a threefold larger force (1.5 N) 
was needed to separate both patches. This indicates that more crosslinks are 
formed during the extended crosslinking time (15 min), resulting in larger adhesion 
forces. However, since these forces were in the same range for all three patches, 
it can be concluded that coating density did not affect the extent of adhesion in 
this experiment. When testing Hemopatch, adhesion forces after 1 and 5 minutes 
crosslinking were similar to the adhesion forces of G2-G4 after 15 minutes. We 
conclude that this product generally crosslinks fast and forms strong gels with 
blood and carrier, which is in agreement with the blood gelation tests. While the 
differences regarding adhesion forces between the NHS-POx samples (G2-G4) 
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Figure 4 In vivo study on pig spleen. A) Images of the different prototypes at selected time points (0, 
1, 5 min) including the success rate of hemostasis, B) Bleeding scores after 5 minutes according to the 
scoring system47
and Hemopatch (15 min) were statistically significant compared to NHS-ester free 
G1 (15 min), adhesion forces after 15 min were not statistically different between 
Hemopatch and the NHS-POx samples (G2-G4).  In summary, it can be concluded 
that Hemopatch crosslinked faster than the NHS-POx samples, whereas the final 
adhesion strength after 15 min was comparable for both samples.
2.5 In vivo efficacy test
NHS-POx functionalized patches were also evaluated in a clinically relevant 
setting by using an established in vivo pig model for profuse bleedings47. In brief, 
standardized bleedings (8 mm diameter, 3mm deep) were created in the liver and 
spleen of heparinized pigs (n = 4, 30 kg, 10 k heparin). The bleedings were imaged at 
selected time points (0, 1 and 5 min after creation of the bleeding) (Figure 4A) and the 
hemostatic efficacy of the different patches was assessed at 0, 1 and 5 min (bleeding/
no bleeding). In addition, the bleeding score after 5 minutes was assessed using a 
visual scoring system ranging from 0 (no bleeding) to 4 (severe bleeding) Figure 4B. 
The efficacy of hemostasis of NHS-POx coatings was tested for G3, which had a 
similar functional group density as the benchmark Hemopatch (~5.2 mmol NHS/cm2) 
(Table 3), but with a different polymer coating coverage. G1 was used as negative 
control (no coating). In addition, Tachosil (a collagen carrier coated with human 
derived fibrinogen and thrombin) was selected because of its common use during 
liver resections15. The results of this study are depicted in Figure 4A+B. G3 was the 
best-performing hemostatic patch in this pig model; in 7 out of 8 events, hemostasis 
was obtained, and bleedings after 5 minutes were scored (0, no bleeding) (Figure 4B). 
In the remaining event (1 out of 8), insufficient pressure during application resulted 
in poor hemostatic action and a bleeding score of 2 (slight bleeding) (Figure 4B). In 
all cases, no significant blood flow through the patch was observed using G3, as was 
expected from the blood uptake experiments. Evidently, G1 was not effective at all 
in this bleeding model and significant blood flow through the patch was observed, in 
line with the in vitro blood uptake experiments (Figure 3A). Moreover, in none of the 
events hemostasis was obtained, which can be related to the absence of chemical 
crosslinkers. As a result, in all events, severe bleedings were scored after 5 minutes 
(Figure 4B). In the experiments using Tachosil, only in 2 out of 8 events hemostasis 
was observed, whereas moderate bleedings were scored for all other cases (Figure 
4). This poor hemostatic efficacy might be due to the use of a high heparin dose 
(10 k units) in this pig model, which inhibits hemostasis solely based on the natural 
coagulation cascade. Using Hemopatch, effective hemostasis was obtained in 5 out 
of 8 events (Figure 4A) and bleeding scores after 5 minutes varied from no bleeding 
(0) to moderate bleedings (3) (Figure 4B). Generally, Hemopatch adhered well 
and quickly to the tissue which made repositioning challenging, a trend which was 
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4.2 Gelation test
This experiment was performed using an inverted vial test adapted from literature.48 
Polymer powders (20 mg) were mixed with freshly obtained heparinized human 
whole blood (1 mL) in a glass vial and vortexed until a visible gel was formed (gelation 
time).
4.3 Contact angle measurements
Microscope cover slips (2 cm2) were soaked in absolute ethanol, sonicated (30 
seconds) and dried under reduced pressure for 15 min. Polymer films were prepared 
by spincoating the polymer solutions (15 mg/mL in DCM, 1 mL) onto the microscope 
cover slips (12000 rpm, 30 seconds) using a Spin 150 spincoater. Subsequently, the 
coated slides were dried overnight under reduced pressure. Static contact angles 
were measured on an OCA-20 goniometer. For each measurement, 1 μL of doubly 
distilled water was placed onto the spincoated films at room temperature. The 
spreading of the droplet was imaged using a high-speed video camera using 1 frame/
second for 30 seconds. The contact angle was determined based upon the Laplace 
Young fitting using the imaging software provided by the supplier (SCA 20, version 
2.1.5 build 16). To determine the contact angle, the first representative frame in 
which a drop shape was observed was selected for analysis. The measurements were 
conducted in triplo per sample (n = 3). 
4.4 Coating deposition
Spray coating was performed using an Exactacoat spraying machine (Sono-Tek) 
equipped with an Accumist ultrasonically agitated nozzle. Coating was performed at 
a dispensing rate of 1 mL/min, a pressure of 40 mbar and a coating speed of 40 mm/s, 
by moving both in the xy-direction over a programmed area. The nozzle height was 
set 30 mm from the top of the substrate. The coating density was adjusted by spraying 
multiple layers of polymer (coating cycles (n)) onto the substrate. Polymer solutions 
were prepared in 2-butanone/2-propanol (v/v, 1:1) with a final polymer concentration 
of 90 mg/mL. After coating, the patches were dried in a vacuum oven (50 mbar, 50°C). 
The coating density (mg/cm2) was determined by weighing the patches (before 
(carrier) and after coating (carrier + polymer) (mg)) divided by the coated area (cm2).    
4.5 Scanning electron microscopy
Samples were attached to an aluminum holder by conducting carbon tape. 
Afterwards, these samples were sputter coated using a gold/palladium coater 
(Cressington 208 HR) for 30 sec (80 mA). At different magnifications, images were 
acquired at an accelerating voltage of 3kV using a JEOL 6330 Field Emission Scanning 
Electron Microscope (SEM). 
observed in the in vitro gelation tests as well. Unlike G3, slight bleeding at the edges 
of the patch was observed in cases where hemostasis was not obtained (Figure 4A), 
which is possibly related to the inhomogeneous deposition of the polymer coating 
compared to the NHS-POx coated patches (Figure 2). From this in vivo study, it 
can be concluded that sealants that rely on chemical crosslinking with surrounding 
soft tissues and blood proteins (G3 and Hemopatch®) hold great promise for the 
treatment of profuse bleeding models, unlike patches which are solely dependent 
on the natural coagulation cascade (non-coated patch (G1) and Tachosil®) which 
were not effective in obtaining hemostasis in these models. Comparing G3 and 
Hemopatch, NHS-POx samples have the additional benefit that they are coated 
more homogeneously than Hemopatch, which results in equal sealing of the wound 
site. In addition, NHS-POx samples are easier to handle due to their slower adhesion 
which allows repositioning of the patch if required. 
3. Conclusions
In this chapter, we have successfully developed a hemostatic device based on NHS-
ester functionalized POx coated on a gelatin patch. We observed that the polymer 
should contain both NHS-esters as well as hydrophilic groups to ensure optimal 
hemostatic performance.  Furthermore, we found that coating homogeneity and 
density are crucial parameters in order achieve the desired hemostatic action in vitro 
(measured by adhesion tests) as well as the desired amount of blood uptake. In vivo 
efficacy tests in a compromised pig model using heparin demonstrated that NHS-POx 
coated patches displayed a similar hemostatic efficacy as compared to Hemopatch. 
NHS-POx coated patches were superior to products relying on activation of the 
natural coagulation cascade. In contrast to PEG, the structural versatility of POx 
allows further fine tuning of the hemostatic performance, thereby rendering NHS-
POx polymers excellent candidates for further development of hemostatic patches. 
4. Experimental Section 
4.1 Synthesis
The experimental procedures for the synthesis of the monomers, intermediate 
products and final polymers (P1-P7) can be found in the experimental section of 
Chapter 2. The analytical details of the synthetic polymers (P1-P7) as well  1H-NMR 
spectra of both P3-P6 and P7 (including intermediate products), can be found in the 
appendix of this chapter.
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by monitoring the bleeding (yes or no). Successful hemostasis was achieved if no 
bleeding was observed after 5 minutes without pressure (yes or no). Additionally, 
after 5 minutes, the bleeding was scored according to the scoring system and the 
adhesion of the patch to the organ was tested. 
4.9 Statistics 
Statistical analyses were conducted using GraphPad Instat software. All results were 
reported as mean ± standard deviation. Differences among groups were analyzed by 
ANOVA using a Tukey-Kramer Multi comparison test and p-values of 0.05 or lower 
were considered as significantly different.  
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4.6 Blood uptake
This experiment was performed using a procedure adapted from literature13. Coated 
gelatin patches with different coating densities (0, 3, 6, 9 mg/cm2) were weighed 
(‘dry weight’ (mg)) and soaked into a mixture of heparinized blood/PBS (v/v, 1:1) 
with the coated side facing the blood mixture. The patches were allowed to absorb 
blood for 30 sec. After this, superficial blood was removed using a filter paper and 
the patches were weighed again (‘weight after’ (mg)) and the amount of absorbed 
blood (‘blood’ (mg)) was determined (weight after (mg) – weight before (mg)).  The 
blood uptake was defined by calculating the amount of absorbed blood per g patch. 
The measurements were performed in sixfold for each sample (n =6). Significant 
differences between samples were analyzed using ANOVA followed by a post hoc 
Tukey-Kramer multi comparison test.
4.7 Adhesion test
This experiment was performed and designed according to modified ASTM F2258-
05 standards49. The samples were attached with double sided tape to 3D-printed grip 
tabs of 2 cm2 and these tabs were placed into a single column tensile tester (Z2.5, 
Zwick/Roell, Ulm, Germany, containing a 20 N load cell). Heparinized blood (200 µL) 
was put between the coated patches which were pressed down using a weight of 20 
g. The patches were allowed to crosslink with blood for defined times (1, 5 and 15 
min). Subsequently, the patches were pulled apart and the load at failure (Fmax, N) 
was measured. The measurements were performed in sixfold for each sample (n = 6). 
Significant differences between samples were analyzed using ANOVA followed by a 
post hoc Tukey-Kramer multicomparison test.
4.8 In vivo efficacy test
Heparinized (10k units) pigs (n = 4, 30 kg) were used in this study. Permission for 
this experiment was granted by the responsible ethical comitees at the Ministry of 
Education of the Czech Republic (project # 56-2015/processing #MSMT-42725/2015-
6). Surgery was performed using standard aseptic techniques. A midline laparotomy 
was performed to access liver and spleen. Using a biopsy punch, standardized lesions 
were created in liver and spleen (8 mm diameter, 3 mm deep). Hemostatic patches of 
2.7 x 2.7 cm were used in this study (n = 8 per prototype randomized per organ using 
a balanced latin square). After the lesion was created, the blood flow was assessed 
according to a visual scoring system (0 = no bleeding, 0.5 = oozing, 1 = very slight, 
2 = slight, 3 = moderate, 4 = severe) described in literature47. Afterwards, superficial 
blood was removed using a dry gauze. Subsequently, the patches were applied with 
the coated side facing the organ and digital pressure was applied for 1 min using 
a dry gauze. The efficacy of the patches was evaluated after 0, 1 and 5 minutes 
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50/26/24. FT-IR (cm-1) 1626 (C=O amide), 1738 + 1785 + 1815 (NHS-ester). UV 
(NH4OH) 22% NHS. SEC (PMMA) Mn 14.6 kg/mol, Đ 1.18
 P7 P(nPropOx-OH-NHS) 70-15-15- 1H NMR (400 MHz, D2O) δ 4.23-4.14 (b, z•2H, 
O=CNHCH2CH2OC=O), 3.70-3.40 (b, (m+y+z)•4H, NCH2CH2N), 3.69-3.60 (b, (y+z)•2H, 
C=ONHCH2CH2OH & C=ONHCH2CH2OC=O),  3.35-3.28 (b, y•2H, C=ONHCH2CH2OH), 
3.08-2.99 (b, z•2H, O=CCH2CH2COON), 3.01-2.90 (b, z•4H, ONO=CCH2CH2C=ONO), 
2.88-2.80 (b, z•2H, O=CCH2CH2COON), 2.76-2.59 (b, (y+z)•2H, O=CCH2CH2C=ONH), 
2.60-2.48 (b, (y+z) •2H, O=CCH2CH2C=ONH), 2.43-2.23 (b, m•2H, CH2CH2CH3), 
1.65-1.50 (b, m•2H, CH2CH2CH3), 0.98-0.85 (b, m•3H, CH2CH2CH3). Experimentally 
determined monomer ratio (m/y/z): 69/16/15. UV (Fe(III)chloride) 15% NHS. SEC 
(PMMA) Mn 18.8, Đ 1.25
S2  1H-NMR spectra of P3-P6 and intermediate products 
Figure S1 Representative 1H-NMR spectra of P(nPropOx-EtOx-NHS) based polymers (P3-P6) and 
intermediate products. A) Structural formulas of I ((P(nPropOx-EtOx-MestOx), II P(nPropOx-EtOx-
COOH), III P(nPropOx-EtOx-NHS)), B) 1H-NMR signals of I, II and III. 
Appendix
S1 Analytical details of the synthesized polymers (P1-P7)
P1 P(nPropOx-NHS) 90-10 - 1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, 
NCH2CH2N), 3.00-2.60 ((b, x•4H, CO-CH2-CH2-CO) + (b, x•4H, CO-CH2-CH2-CO 
(NHS))),  2.40-2.20 (b, m•2H, CO-CH2-CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-
CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3).  Experimentally determined monomer 
ratio (m/x): 90/10. UV (NH4OH) 11% NHS.  SEC (PMMA) Mn 12.6 kg/mol, Đ 1.15
 P2 P(nPropOx-NHS) 75-25 - 1H NMR (500 MHz, D2O) δ 3.70-3.40 (b,(m+x)•4H, 
NCH2CH2N), 3.00-2.60 ((b, x•4H, CO-CH2-CH2-CO + (b, x•4H, CO-CH2-CH2-CO 
(NHS))),  2.40-2.20 (b, m•2H, CO-CH2-CH2-CH3), 1.60-1.40 (b, m•2H, CO-CH2-CH2-
CH3), 0.90-0.80 (b, m•3H, CO-CH2-CH2-CH3).  Experimentally determined monomer 
ratio (m/x): 71/29. UV (NH4OH) 26% NHS. SEC (PMMA) Mn 20.9 kg/mol, Đ 1.20
 P3 P(nPropOx-EtOx-NHS) 40-50-10 - 1H NMR (500 MHz, D2O) δ 3.70-3.40 
(b,(m+n+x)•4H, NCH2CH2N), 3.00-2.60 ((b, x•4H, CO-CH2-CH2-CO + (b, x•4H, CO-
CH2-CH2-CO (NHS))),  2.40-2.20 (b, (m+n)•2H, CO-CH2-CH2-CH3  + CO-CH2-CH3), 
1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, n•3H, CO-CH2-CH3), 0.90-0.80 
(b, m•3H, CO-CH2-CH2-CH3).  Experimentally determined monomer ratio (m/n/x): 
40/49/11. FT-IR (cm-1) 1626 (C=O amide), 1738 + 1785 + 1815 (NHS-ester). UV 
(NH4OH) 11% NHS. SEC (PMMA) Mn 12.5 kg/mol, Đ 1.18  
 P4 P(nPropOx-EtOx-NHS) 40-35-25 - 1H NMR (500 MHz, D2O) δ 3.70-3.40 
(b,(m+n+x)•4H, NCH2CH2N), 3.00-2.60 ((b, x•4H, CO-CH2-CH2-CO + (b, x•4H, CO-
CH2-CH2-CO (NHS))),  2.40-2.20 (b, (m+n)•2H, CO-CH2-CH2-CH3  + CO-CH2-CH3), 
1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, n•3H, CO-CH2-CH3), 0.90-0.80 
(b, m•3H, CO-CH2-CH2-CH3).  Experimentally determined monomer ratio (m/n/x): 
39/33/28. FT-IR (cm-1) 1626 (C=O amide), 1738 + 1785 + 1815 (NHS-ester). UV (NH4OH) 
32% NHS. SEC (PMMA) Mn 16.8 kg/mol, Đ 1.22
 P5 P(nPropOx-EtOx-NHS) 50-40-10 - 1H NMR (500 MHz, D2O) δ 3.70-3.40 
(b,(m+n+x)•4H, NCH2CH2N), 3.00-2.60 ((b, x•4H, CO-CH2-CH2-CO + (b, x•4H, CO-
CH2-CH2-CO (NHS))),  2.40-2.20 (b, (m+n)•2H, CO-CH2-CH2-CH3  + CO-CH2-CH3), 
1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, n•3H, CO-CH2-CH3), 0.90-0.80 
(b, m•3H, CO-CH2-CH2-CH3).  Experimentally determined monomer ratio (m/n/x): 
49/39/12. FT-IR (cm-1) 1626 (C=O amide), 1738 + 1785 + 1815 (NHS-ester). UV 
(NH4OH) 9% NHS. SEC (PMMA) Mn 12.3 kg/mol, Đ 1.16
 P6 P(nPropOx-EtOx-NHS) 50-25-25 - 1H NMR (500 MHz, D2O) δ 3.70-3.40 
(b,(m+n+x)•4H, NCH2CH2N), 3.00-2.60 ((b, x•4H, CO-CH2-CH2-CO + (b, x•4H, CO-
CH2-CH2-CO (NHS))),  2.40-2.20 (b, (m+n)•2H, CO-CH2-CH2-CH3  + CO-CH2-CH3), 
1.60-1.40 (b, m•2H, CO-CH2-CH2-CH3), 0.90-0.80 (b, n•3H, CO-CH2-CH3), 0.90-0.80 
(b, m•3H, CO-CH2-CH2-CH3).  Experimentally determined monomer ratio (m/n/x): 
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S3  1H-NMR spectra of P7 and intermediate products
Figure S2 Representative 1H-NMR spectra of P(nPropOx-OH-NHS) (P7) and intermediate products. 
A) Structural formulas of I (P(nPropOx-MestOx)), II (P(nPropOx-OH)), III (P(nPropOx-OH-COOH)), IV 
(P(nPropOx-OH-NHS)),  B) 1H-NMR signals of I-IV
5Chapter 5:
Understanding hemostatic polymers: 
a rheological study on the gelation 
of NHS-ester functionalized poly(2-
oxazoline)s and poly(ethylene glycol) 
with bovine serum albumin
Abstract 
In this chapter, we performed a systematic rheological study on the reaction of NHS-ester 
functionalized poly(2-oxazoline)s (NHS-POx) or NHS-ester functional 4-arm poly(ethylene glycol) 
(NHS-PEG) with bovine serum albumin (BSA) as a mimic for blood proteins.  The aim of this study 
was to obtain better insight into the network formation of NHS-POx and NHS-PEG as hemostatic 
polymers, as a function of i) the configuration of the crosslinking amine-reactive NHS-ester groups 
on the polymer and ii) the presence of hydrophilic side chains, i.e., hydroxyl (OH) or dimethylamine 
(N(CH3)2) (in case of NHS-POx). In these experiments, we have performed i) oscillatory time sweeps 
for 30 minutes to determine the gelation time, ii) oscillatory frequency sweeps to study the viscoelastic 
behavior of the formed networks over a broad angular frequency range (0.1-100 rad/s), and iii) strain 
sweeps to study the flexibility of the formed networks (0.1-1000% strain) and the yield strain of these 
networks. The oscillatory time sweeps revealed that both NHS-POx and NHS-PEG formed crosslinked 
networks with BSA instantaneously, while NHS-PEG formed more elastic networks with BSA than 
NHS-POx. Both PEG- and POx-based networks showed predominantly elastic behavior over a wide 
frequency range. Interestingly, in contrast to crosslinked NHS-PEG networks, crosslinked NHS-POx 
networks showed strain stiffening behavior as demonstrated by strain sweeps, which can be attributed 
to the presence of the crosslinking groups on the side chains. Furthermore, a pH of 8.5 or higher was 
needed to obtain the most elastic networks between NHS-POx and BSA. No clear effect of the type 
of hydrophilic moieties (OH or N(CH3)2) on network formation was observed. In summary, we conclude 
that NHS-POx and NHS-PEG can be successfully utilized for the development of hemostatic polymers 
as they both form crosslinked networks with BSA instantaneously. It was furthermore demonstrated 
that the configuration and corresponding mobility of the crosslinking NHS-ester groups have a clear 
effect on the network structure which is formed.
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immunogenic, degradable and excretable after application. Moreover, the formed 
network should be sufficiently strong to withstand physiological loading. A wound 
sealant or hemostat should at least mimic the elasticity of a fibrin clot (storage 
modulus (G’) of ~10-100 Pa) in order to withstand blood pressure after wound 
closure22-25. Moreover, the crosslinking strategy should be selected in such way that 
no toxic byproducts or heat are generated during the reaction with tissue. Finally, 
crosslinks should ideally be formed only with the desired tissue (blood or soft tissue), 
while undesired crosslinking with surrounding tissues should be prevented as this 
may cause undesired adhesion (between organs)26.
 For the development of tissue adhesives, poly(ethylene glycol) (abbreviated 
as PEG) is the most commonly investigated synthetic material because of its 
biocompatibility and excellent solubility in both aqueous and organic media27. 
Additionally, since the end groups of this material can be equipped with a wide 
variety of crosslinking groups28, 29, various PEG-based biomedical devices have been 
developed3, 30, 31. An example of a PEG-based hemostatic product is Hemopatch32,33, 
which consists of a porous collagen sponge coated with N-hydroxysuccinimide ester 
functional 4-arm poly(ethylene glycol) (NHS-PEG). Hemopatch acts by means of 
the instantaneous formation of covalent crosslinks between NHS-PEG and amines 
present in tissue, blood proteins and the collagen sponge. The formed crosslinked 
network seals the wound site and allows firm fixation of the patch to the tissue. 
This product is used as a hemostatic agent for non-invasive treatment of bleedings 
of soft tissue. Although clinical efficacy has been reported for PEG-based products, 
the limited crosslinking capacity (using end-groups only) and extensive swelling of 
the crosslinked networks (as reported for certain PEG-based medical devices34) has 
prompted research on alternative polymeric hydrogels.  
 Poly(2-oxazoline)s or POx35-39 are emerging polymers within the biomedical field40, 
41 due to the extensive functionalization possibilities42, 43, limited cytotoxicity44-46 and 
excretability47-49. Since both side chains and end groups of POx can be functionalized, 
these polymers can be crosslinked in multiple ways. Consequently, these polymers 
are increasingly used for the development of crosslinked networks50, 51. Network 
formation has been reported using different chemistries including thiol-ene 
chemistry52, 53, amine-isothiocyanate chemistry54 and Diels-Alder chemistry55. 
 In Chapter 4, we have successfully utilized the crosslinking capacity of 
N-hydroxysuccinimide (NHS) ester functionalized POx (NHS-POx) in hemostatic 
applications. To this end, we designed hemostatic NHS-POx equipped with three 
types of side chain modifications, i.e., i) NHS-ester groups to allow for crosslinking 
with amines, ii) hydrophobic (nPropOx) groups to allow for solubility in organic 
solvents (polymer processability), and iii) hydrophilic side chains to render the 
polymer hydrophilic enough for efficient crosslinking with human-derived whole 
1. Introduction
Insufficient control over bleeding is one of the major threats during surgery on soft 
tissues. As an example, a hepatic resection involves partial removal of the liver, which 
is a complex surgical procedure associated with major blood loss. As a result, the 
success rates of these procedures strongly vary depending on the medical condition 
of the patient and the amount of blood loss1. Inefficient hemostasis2 can severely 
complicate the recovery rate of the patient and even lead to mortality. Since the 
liver is a highly venous organ, traditional methods like suturing and stapling are 
often not sufficient to ensure successful hepatic resection, which has stimulated 
the development of tissue adhesive materials3. These are polymeric materials which 
form a sealing network in the presence of wounded tissue, thereby facilitating 
wound closure. 
 For the development of tissue adhesives, a wide range of polymeric materials 
(both natural and synthetic) is currently available on the market3-5. Natural polymers 
like fibrin glues6,7 are biodegradable and achieve effective tissue adhesion, although 
the risk of the transmission of animal-borne diseases and the lack of mechanical 
properties are drawbacks of this class of materials. Synthetic materials, on the 
other hand, are reported to adhere tightly to soft tissue, although toxicity has been 
reported for materials such as e.g. cyanoacrylates8. 
 Another particular interesting class of tissue adhesives are polymeric hydrogels, 
which are hydrophilic crosslinked three-dimensional polymer networks which are 
used in tissue adhesives and hemostats3, 9, 10, but also in other biomedical fields11 
including drug delivery12, tissue engineering13, 14 and 3D-cell culture15. In these 
polymeric hydrogels, polymeric network structures are formed upon formation of 
crosslinks between polymer chains. These networks can be formed via a wide range 
of physical and chemical interactions such as ionic16, hydrogen17, covalent bonds, 
or combinations thereof18. The formation of covalent bonds is highly advantageous 
if semi-permanent or permanent crosslinked networks are required. This can be 
achieved via various chemistries including condensation reactions19, enzymatic cross 
coupling20 or UV-mediated polymerization21. The formation of crosslinked networks 
prevents direct dissolution of the polymers upon hydration, resulting into absorption 
of large amounts of water by the crosslinked polymer network. The mechanical 
properties of these hydrogels are largely determined by i) the physicochemical 
characteristics of the specific polymer, ii) the type of crosslinks which are formed 
(irreversible or reversible), and iii) the crosslinking density (number of crosslinks 
between polymer chains within a specific volume). 
 In order to develop polymeric hydrogels as tissue adhesive sealants, several 
properties are required9.  For example, the polymer should be non-toxic, non-
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effect of the spatial configuration of the crosslinking groups, we also studied included 
end chain functionalized tetravalent NHS-PEG as a control, a polymer which is 
routinely used in PEG-based biomedical devices32, 33. Using oscillatory time sweeps, 
we monitored the storage modulus (G’) and loss modulus (G’’) for 30 minutes to study 
the change of these viscoelastic properties resulting from network formation between 
the polymer and BSA. Subsequently, after formation of crosslinked networks, angular 
frequency sweeps (0.1-100 rad/s) and strain sweeps (0.1-1000% strain) were performed 
to study the viscoelastic parameters of the BSA-polymer network as a function of 
frequency and measure the yield strain of these networks, respectively. 
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Table 1: Analytical data of the synthesized polymers
# Polymer 1H-NMR (mol%) Mn (kg/mol)
nPropOx OH N(CH3)2 NHS Theor. SEC
a Ða
P1 P(nPropOx-c-OH-c-NHS) (P1) 69 14 - 17 16.5 18.8 1.25
P2 P(nPropOx-c-N(CH3)2-c-NHS) (P2) 69 - 16 15 16.5 22.1 1.33
a SEC was calibrated against PMMA standards, eluent: 0.1 % LiCl in DMA
Figure 1 Schematic overview of the crosslinking reaction between NHS-POx and bovine serum 
albumin (BSA) thereby forming a POx-BSA network.
blood. By coating the polymers on gelatin scaffolds, these so called hemostatic 
patches showed promising hemostatic efficacy in vitro and in vivo in comparison with 
benchmark products based on NHS-PEG based materials. Although both POx and 
PEG-based samples were able to stop bleedings in these experiments, we observed 
strong differences regarding their mode of action (e.g. crosslinking speed), which 
indicates that the kinetics and/or type of network which is formed differs between 
NHS-PEG and NHS-POx. 
 A major structural difference between NHS-PEG and NHS-POx is the way the 
crosslinking moieties are positioned onto the polymer. In NHS-PEG the crosslinking 
groups are located at the polymer chains ends, whereas in NHS-POx these groups 
are present at the side chains of the polymer. Another structural difference between 
these types of polymers involves the hydrophilicity/polarity of the polymers. NHS-
PEG are hydrophilic due to the abundance of ethylene glycol units in the polymer 
backbone, whereas in NHS-POx hydrophilic (hydroxyl) functional side chains render 
the polymer hydrophilic to allow for efficient crosslinking. In addition, the type and 
amount of hydrophilic side chains will have an effect on the polarity of the polymer 
and as a result on the network formation as well. Both factors will have an influence 
on the hemostatic action of NHS-POx.
 In this chapter, we perform a systematic rheological study on the crosslinking 
behavior of two different hydrophilic side chain activated NHS-POx polymers 
(containing either OH and N(CH3)2) with bovine serum albumin (BSA) as a model 
protein (Figure 1). For reasons of comparison, we also studied chain-end functional 
tetravalent NHS-PEG because of its routine use in hemostatic devices. In order to gain 
a deeper insight and a better understanding into the mechanism of action of both 
NHS-PEG and NHS-POx as hemostatic polymers, we aimed to study the effect of i) 
the positioning of the crosslinking groups on the polymer (side chains vs. chain ends) 
and ii) the type of the hydrophilic co-substituents (OH and N(CH3)2) on the network 
formation. Furthermore, we investigated the effect of pH on the network formation. 
2. Results and discussion
2.1 Synthesis
The synthesis of P1 and P2 has been described in detail in Chapter 2. The analytical 
data of the polymers which are used in this chapter are listed in Table 1. 
2.2 Rheometry
In order to investigate the crosslinking behavior of the different side chain functional 
POx polymers (P1 and P2) with BSA, oscillatory rheometry was used. To study the 
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Table 2 Experimental results oscillatory time sweep
polymera ratio NHS/NH2
b Tan delta (t=30 min) (n=6) G’ (Pa)c after 30 min
# μmol NHS Mean SD Mean SD P-value
P1 45.5 2.4 1.1·10-2 2.1 *10-3 351 101 ns
P2 44.4 2.4 3.7 *10-3 6.5 *10-4 400 139 ns
NHS-PEG 16.7 0.9 3.2 *10-3 4.1 *10-3 7667 1973 <0.001d
a Calculated from the NHS-content which was determined by 1H-NMR spectroscopy. The end group 
NHS content of NHS-PEG was determined to be 96% (1H-NMR)
b Number of primary amines in BSA calculated from the information supplied by the manufacturer: Mw 
66 kDa and 30-35 available lysines per protein, 18.6 μmol of amines in each measurement 
c Measurements were performed in sixfold (n=6)
d Against both P1 and P2 (ns = not significant)
2.2.2 Frequency sweeps
After the oscillatory time sweeps, frequency sweeps were performed between an 
angular frequency range of 0.1-100 rad/s (Figure 3). Herein, we observed that P1 and P2 
as well as NHS-PEG displayed a frequency-independent elastic behavior characterized 
by considerably higher storage moduli as compared to corresponding loss moduli; 
this highly elastic behavior was previously reported for tetravalent PEG-systems by 
multiple groups56, 57. In our experiments, a slight increase of the loss modulus at higher 
frequencies was observed in case of P1 and P2, but not for NHS-PEG. 
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Figure 2 Oscillatory time sweep of mixtures of  P1, P2 (A) and NHS-PEG (B) with BSA (35 mg/mL). 
2.2.1 Time sweep experiments
In this experiment, polymer solutions (P1, P2 and NHS-PEG) (100 mg/mL) and 
BSA solutions (70 mg/mL) were mixed together and pipetted onto the rheometer 
plate (t=0). All experiments were performed at a fixed BSA (35 mg/mL) and polymer 
concentration (50 mg/mL). Since the crosslinking of NHS-esters with amines is 
strongly influenced by pH, we performed this experiment at an elevated pH (~8.3) to 
ensure crosslinking. The results of these tests are displayed in Figure 2 and Table 2.
 In all these measurements, we observed that the crosslinking mixture reached 
the gelation point (G’ = G’’) before the measurement was started.  Furthermore, we 
observed that the loss modulus (G”) was significantly lower than the storage modulus 
(G’). These data indicate that elastic gel networks were formed resulting from a 
crosslinking reaction between the synthetic polymers and BSA. We observed that 
both P1 and P2 formed a hydrogel network instantaneously (G’>G’’) with a tan delta 
value <1 from the first data point and a comparable storage modulus (G’) after 30 min 
of gelation of 351 ± 101 Pa (P1) and 400 ± 139 Pa (P2). These values were lower than 
previously reported values (G’ 1100 Pa) for a comparable side chain functionalized 
POx crosslinked system, as reported by Dargaville and coworkers50. This difference 
can be explained by the fact that crosslinkers of low molecular weight were used, 
whereas in our case a macromolecular crosslinker (BSA) was used, which strongly 
affects e.g. the mobility of the crosslinker.  In the present experiment, differences in 
the final storage modulus between P1 and P2 were statisticaly insignificant. It was, 
however, observed that these final values were reached faster for P1 than P2, which 
indicates that the dimethylamine groups influence protonation of the ammonium 
groups of the lysine residues, but not the amount of crosslinks which are eventually 
formed. When mixing BSA with NHS-PEG, a crosslinked network was also formed 
instantaneously with a storage modulus of 7667 ± 1973 Pa, consistent with literature 
values, which indicates that a stiffer network was formed using NHS-PEG 56,57. The 
final storage modulus of the PEG-based network also was significantly higher than 
the gels prepared from P1 and P2. 
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2.2.3 Strain sweeps
Subsequently, we performed strain sweeps between 0.1 -1000% strain on the formed 
networks to quantify the yield strain (Figure 4 and Table 3). Polymers P1 and P2 
stiffened at increasing strain values (between 30% and 210%), which is indicative 
of strain stiffening behavior. This phenomenon was not observed for NHS-PEG 
(Table 3). At strain values higher than 200%, the storage modulus dropped to values 
below the loss modulus was seen, which corresponds to disruption of the network 
structure. The yield strains – defined as the strain at which the storage modulus was 
equal to the loss modulus (G’=G’’) - were 542 ± 118 % and 649 ± 94 %  for P1 and P2 
respectively.  In case of NHS-PEG, the network was destroyed at a yield strain of 473 
± 54 %.  The differences in yield strain were only statistically significant between P2 
and NHS-PEG.
2.3 Structural differences between POx-BSA and PEG-BSA networks
By comparing the results of the time sweep, frequency sweep and strain sweep 
experiments respectively, both NHS-POx and NHS-PEG exhibit a different 
crosslinking behavior with BSA, which results in a different network structure. In 
the oscillatory time sweep measurements, we found that stiffer PEG-BSA networks 
were formed in comparison with POx-BSA networks. We suspect that the differences 
in stiffness can be explained from the difference in architecture of both polymer 
classes (Figure 5). Using NHS-PEG (Figure 5A), the NHS-ester groups are present 
at the end of the extended hydrophilic chains. As a result, crosslinks are formed 
instantaneously because of the accessibility of the end groups which results in a high 
G’. Regarding network formation, because of the limited amount of crosslinking 
possibilities (max. 4 crosslinks per polymer) and the extended spacer length, it is 
not expected that one PEG-molecule forms multiple covalent bonds with one BSA 
protein at the same time. It is rather expected that only intermolecular covalent 
bonds between polymer and protein (crosslinks) are formed in which one PEG binds 
multiple proteins at the same time, at a maximum of 4. This efficient crosslinking 
mechanism ensures the formation of a homogeneously crosslinked network. 
 In contrast, NHS-POx polymers (P1 and P2) contain multiple reactive NHS-ester 
groups as polymer side chains (Figure 5B). Compared to NHS-PEG, these polymers 
present a larger number of reactive groups (theoretically 2.7 times more, Table 
2) available for reaction with BSA. Additionally, the ratio between amines (BSA) 
and the crosslinking groups on the polymer is higher in case of NHS-POx (molar 
ratio NHS/amines: 2.4) compared to NHS-PEG (molar ratio NHS/amines: 0.9). 
Consequently, it was expected that a stiffer network would be formed. However, the 
lower G’ values which were observed experimentally for NHS-POx polymers indicate 
that less intermolecular crosslinks were formed between BSA and NHS-POx, which 
Figure 3 Oscillatory frequency sweeps (0.1-100 Hz) for P1 + P2 (A) and NHS-PEG (B). Experiments 
were performed (n=6)
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Figure 4 Strain sweep for P1 + P2 (A) and NHS-PEG (B) from 0.1 -1000% strain.
Table 3 Experimental results of the strain sweep
Strain stiffening behavior Yield strain (%)
# % strain Ratio G’ (max strain)/G’ (0.05 % strain)b Mean SD P-value
P1 between 30-210 2.6 542 118 ns
P2 between 30-210 3.1 649 94 <0.05c
NHS-PEG - 1.05 473 54 ns
a The experiments were performed (n=6)
b G’ (max) = G’ maximum strain values
c Only against NHS-PEG, not against P1
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These experiments have demonstrated that the configuration of the amine-
reactive NHS ester groups is of great importance for the formation of crosslinked 
networks.  No differences in network structure were observed between P1 and P2, 
which indicates that nature of the hydrophilic moiety which is incorporated into the 
polymer influenced the obtained network structure.  
 In view of therapeutic application, it must be emphasized that both NHS-PEG and 
NHS-POx are suitable as hemostatic polymers since they both crosslink with BSA 
 Figure 5 Differences in network formation with BSA for NHS-PEG (A) and NHS-POx (B).
contribute to the strength of the network. This phenomenon can be attributed to 
the specific architecture of the NHS-POx polymer. Because of the higher amount 
of reactive functional groups and the higher functional group density (at the side 
chains) compared to NHS-PEG, it is expected that NHS-POx forms multiple bonds 
with the same BSA molecule in addition to intermolecular crosslinks. However, 
these covalent bonds do not contribute to the stiffness/strength of the network, 
since no additional crosslinks between polymer chains are generated in this case. 
Overall, this results in a more heterogeneously crosslinked network as compared to 
NHS-PEG (Figure 5B).    
 An additional explanation for the lower storage modulus of gels containing NHS-
POx could be related to the fact that this heterogeneous crosslinking prevents 
complete crosslinking. In order to test whether stiffer gels were formed upon 
prolonged crosslinking time, we performed an oscillatory time sweep experiment of 
9 hrs (instead of 30 min) for P1, P2 and NHS-PEG. It was found that for P1 and P2, a 
continuous increase in G’ and G’’ was seen even after 9 hrs (G’ of 800 Pa (P1) and 671 Pa 
(P2)), while the G’ of NHS-PEG reached a plateau (G’ 8500 after 2 hrs). This suggests 
that further crosslinking is not hampered by the structure of the network for P1 and 
P2, but more research is needed to prove statistically significant differences. 
 In the oscillatory strain sweeps, strain stiffening was observed for NHS-POx, but 
not for NHS-PEG.  This strain stiffening behavior is reported for natural polymers such 
as collagen58 and actin59 as well as for physically crosslinked synthetic hydrogels60, 61, 
but not yet for POx-based networks. Several important  parameters61,62 have been 
reported to play a role in strain stiffening, such as the network microstructure59 
and the identity of the crosslinker62. Because of the apparent structural differences 
between NHS-POx and NHS-PEG but identical crosslinker (BSA),  we suggest that 
the strain stiffening behavior can be explained from the different network structures 
which are formed (PEG-BSA vs. POx-BSA (Figure 5). 
 If strain is continuously increased for crosslinked networks, the polymer chains 
will be stretched until the network structure is disrupted. In case of POx-BSA, the 
network consists of covalent crosslinks between polymer chains and BSA (which 
govern the network structure), but also domains in which one POx chain binds a single 
BSA protein via multiple covalent crosslinks. We hypothesize that if increasing strain 
is applied to these crosslinked POx-networks (P1 and P2), the complete stretching 
and disruption of the network is hampered by these densely crosslinked domains, 
which prevent full stretching of the network. Instead, the networks stiffen upon 
increasing strain until network disruption occurs. In case of PEG-BSA, the network 
predominantly consists of covalent crosslinks between polymer and BSA. Due to 
this more homogeneous network structure, the network can be fully stretched and 
disrupted with increasing strain without demonstrating strain stiffening behavior.  
127126
Chapter 5 Understanding hemostatic polymers
5
30 minutes, 60% of the NHS-ester groups were hydrolyzed at pH 8 and 90 % at pH 
9, indicating that during 30 minutes the majority of the functional groups either 
reacted with amines or were hydrolyzed. No differences between P1 and P2 were 
observed in these hydrolysis experiments. 
 This study on the effect on pH on the formation of the network structure is 
particularly relevant from a clinical perspective.  By tuning the pH of the device 
through the addition of a biocompatible basic component (e.g. sodium carbonate), 
Figure 6 Effect of the pH on the network formation for P1 (A) and P2 (B). Experiments were performed 
in triplo (n=3). P(*** P< 0.001, **  P< 0.01, * P<0.05)
instantaneously (tan delta <1). The mechanical properties of both NHS-PEG and 
NHS-POx based networks exceed the minimal stiffness of fibrin clots (~ G’ 10-100 
Pa)22-23 and show highly elastic behavior over a wide frequency, which renders these 
polymer networks theoretically capable to withstand forces within the body (such 
as blood pressure) upon clinical application. A benefit of NHS-POx could be that the 
slower crosslinking via side chains – as opposed to faster crosslinking via flexible end 
groups for NHS-PEG - may allow for more controlled application of the hemostatic 
patch in clinical applications. We observed in Chapter 4 that this was impossible 
for NHS-PEG based hemostatic agent Hemopatch which adhered directly to tissue, 
leading to inhomogeneous coverage of the bleeding site. It must, however, be taken 
into account that these studies were based on the use of BSA as a model protein and 
not on whole blood. Consequently, direct translation of these results towards clinical 
applications is not possible based on the current experimental design.
2.4 Effect of the pH on crosslinking behavior of NHS-POx 
Since the reaction of NHS-esters with amines is highly sensitive to pH, we 
investigated the influence of the pH on both the formation speed and stiffness of the 
crosslinked networks containing P1 and P2. To this end, we performed time sweeps 
at fixed polymer (50 mg/mL) and BSA concentrations (35 mg/mL), but at different 
pH values by adjusting the pH of the BSA solution. By mixing the polymer solution 
(pH ~5) with the basic BSA solution (pH 8-11), the pH of the crosslinking mixture 
can be precisely tuned in order to obtain the desired pH value (7-9.5). At basic 
pH, crosslinking with amines is in competition with hydrolysis of the NHS-esters. 
Consequently, we expected an optimum pH for the crosslinking reaction to be in 
place, resulting into the formation of the stiffest networks.  Therefore, we  studied 
network formation of P1 and P2 over a range of pH-values (7-9.5).  The results of this 
experiment are displayed in Figure 6A (P1) + 6b (P2). 
 It can be observed from Figure 6A that gels were formed by mixing BSA with P1 
at all pH values (tan delta <1). However, the stiffest gels were formed at an optimum 
pH of 8.5. For P2 (Figure 6B), gels were formed after 30 min (tan delta <1). It must 
be noted, however, that the crosslinking reaction should occur at a pH of 8.5 or 
higher to obtain the stiffest gels within this series.  In the experiments which were 
performed at a pH <8, softer gels were formed, which was attributed to the fact 
that the lysine residues in BSA were not sufficiently deprotonated to allow effective 
network formation. Since the stiffness of the gels (G’) decreased again at pH values 
higher than 8.5 (for P1), we hypothesized that the hydrolysis of the NHS-ester 
was predominant at this pH over the network formation by means of amidation. 
In order to test this, a control experiment was performed by 1H-NMR spectroscopy 
to study the hydrolysis rate of NHS-esters at pH 8 and pH 9. It was found that after 
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5. Materials and methods
5.1 Materials
N-hydroxysuccinimide ester functional 4-arm poly(ethylene glycol) (NHS-PEG) was 
obtained from NOF America corporation. BSA (66.3 kDa, >95% pure, protease free) 
was obtained from Sigma-Aldrich.  
5.2 Synthesis
The synthetic procedures of P1 and P2 are described in the experimental section 
of Chapter 2.  1H-NMR spectra of P1 and P2 are shown in the Appendix (Figure S1) 
5.3 Rheology
Rheological measurements were conducted with a TA Instruments AR 2000 
Rheometer equipped with a Peltier plate. For all measurements, a flat geometry 
with a diameter of 20mm was used. All gels were prepared as follows (Figure 7): 
solution A was prepared by dissolving bovine serum albumin (BSA) in a solution of 
sodium borate (0.1-0.4 M) or a solution of sodium carbonate (0.01-0.1 M) to a final 
BSA concentration of 70 mg/mL. Solution B was prepared by dissolving P1, P2 or 
NHS-PEG in demineralized water to a final polymer concentration of 100 mg/mL. P1 
was shortly cooled on crushed ice to allow full solubilization.  The formulations used 
for the rheology experiments were prepared by mixing both solution A and solution 
B (v/v, 1:1) to a final volume of 500 µL. This solution (A+B) was vortexed for 5 seconds 
and 200 µL was transferred to the rheometer plate. (Figure 7). Directlty thereafter, 
three consecutive rheological experiments were performed, starting with a time 
sweep experiment at an oscillation frequency of 10 rad/s and a constant strain of 
5% during 30 minutes. Secondly, frequency sweep experiments were performed at 
an increasing oscillation frequency from 0.1 rad/s to 100 rad/s and a constant strain 
of 5%. Finally, strain sweep experiments were performed at a constant oscillation 
frequency of 10 rad/s and an increasing strain from 0% to 1000%, to measure the 
yield strain of the networks. In these experiments, the yield strain was defined as the 
strain at which the storage modulus was equal to the loss modulus (G’=G’’). Unless 
stated otherwise, the experiments were carried out at 25°C in six-fold (n=6). The 
pH of the different formulations was assesed as follows: after preparation of the 
solution A+B, the pH of the solution was directly measured using a Mettler Toledo 
FE-280-Basic pH meter equipped with an in-Lab micro pH electrode (3 mm). 
the pH of the area around the wound site will be locally elevated to the desired pH 
(~8.5) which speeds up crosslinking. After crosslinking has been achieved, the pH will 
be normalized by the buffering ability of the blood. This approach towards control 
of reaction pH has already been suitably employed in various commercially available 
tissue adhesives and hemostatic products in the biomedical field, such as Duraseal63 
and Coseal31. 
3. Conclusion
We have performed a systematic rheological study on the crosslinking of NHS-POx 
and NHS-PEG with BSA (as a mimic for blood proteins) in order to study the effect of 
i) the positioning of the crosslinking groups and ii) the identity of the hydrophilic side 
chains (OH (P1) and N(CH3)2 (P2)) on the network structure. It was found that both 
NHS-POx (P1 and P2) and NHS-PEG were able to form crosslinked networks with 
BSA, however we observed that NHS-PEG and NHS-POx clearly formed different 
network structures with BSA. During oscillatory time sweeps, we have found that 
NHS-PEG formed stiffer homogeneous networks than NHS-POx, which formed 
inhomogeneous networks of lower stiffness, because of the different distribution of 
functional groups along the polymer chain. Both PEG-BSA and POx-BSA networks 
showed elastic behavior over the entire frequency range which was tested. During 
oscillatory strain sweeps, it was observed that in contrast to PEG-BSA networks, 
POx-BSA networks showed strain stiffening behavior upon increased strain (30-
210% strain), which can be related to the different network structure which is 
formed. For NHS-POx, it was found that by performing the crosslinking reaction 
at a pH of 8.5, the stiffest crosslinked networks were obtained (G’=1200) for P1 and 
(G’=800) for P2. In conclusion, these experiments demonstrate that the positioning 
of the crosslinking groups on the polymer chains and the pH at which the crosslinking 
is performed is of great influence on the characteristics of network structure. In 
contrast, the identity of the hydrophilic moiety (OH or N(CH3)2) is of little influence 
on the network struture which is formed.   
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Figure 7 Overview of the experimental procedure for the rheological experiments
5.4 Hydrolysis experiments
The polymers (P1 and P2) were dissolved in D2O (15 mg/mL) and hydrolysis was 
determined at different pH values (7, 8 and 9) by performing 1H-NMR measurements 
over the time course of 60 minutes. The percentage of hydrolysis was determined 
from the ratio of the integrals corresponding to the polymer-bound NHS (2.8 ppm) 
and free NHS (2.7 ppm) (Figure S2).   
5.5 Statistics
Statistical analyses were conducted using GraphPad Instat software. All results were 
reported as mean ± standard deviation. Differences among groups were analyzed by 
ANOVA using a Tukey-Kramer Multi comparison test and p-values of 0.05 or lower 
were considered as significantly different.
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Appendix
1H-NMR spectra of P1 and P2 
Figure S1 Overview of 1H-NMR spectra of P1-P2. The spectrum of P1 was recorded in CD3CN, the 
spectrum of P2 was recorded in D2O
Figure S2 Representative 1H-NMR spectrum of P1 after incubation in pH 7 for 60 min. Signal at 2.85 
ppm corresponds to polymer bound NHS-ester, while signal at 2.65 ppm represents free NHS in 
solution.    
35. R. Hoogenboom, Angew. Chem. Int. Ed. , 2009, 48, 7978-7994.
36. T. G. Bassiri, A. Levy and M. Litt, J. Polym. Sci. B-1 Polym. Lett., 1967, 5, 871-879.
37. A. Levy and M. Litt, J. Polym. Sci. A-1 Polym.Chem., 1968, 6, 1883-1894.
38. D. A. Tomalia and D. P. Sheetz, J. Polym. Sci. A-1 Polym. Chem., 1966, 4, 2253-2265.
39. W. Seeliger, E. Aufderhaar, W. Diepers, R. Feinauer, R. Nehring, W. Thier and H. Hellmann, Angew. 
Chem. Int. Ed. , 1966, 5, 875-888.
40. N. Adams and U. S. Schubert, Adv. Drug Deliv. Rev., 2007, 59, 1504-1520.
41. V. R. De La Rosa, J. Mater. Sci. Mater. Med., 2014, 25, 1211-1225.
42. E. Rossegger, V. Schenk and F. Wiesbrock, Polymers, 2013, 5, 956-1011.
43. B. Guillerm, S. Monge, V. Lapinte and J. J. Robin, Macromol. Rapid Commun., 2012, 33, 1600-1612.
44. J. Kronek, E. Paulovičová, L. Paulovičová, Z. Kroneková and J. Lustoň, J. Mater. Sci. Mater. Med., 
2012, 23, 1457-1464.
45. J. Kronek, E. Paulovičová, L. Paulovičová, Z. Kroneková and J. Lustoň, Biocompatibility and 
Immunocompatibility Assessment of Poly(2-Oxazolines), 2013, DOI: 10.5772/51501
46. M. Bauer, C. Lautenschlaeger, K. Kempe, L. Tauhardt, U. S. Schubert and D. Fischer, Macromol. 
Biosci., 2012, 12, 986-998.
47. F. C. Gaertner, R. Luxenhofer, B. Blechert, R. Jordan and M. Essler, J. Control. Release, 2007, 119, 
291-300.
48. L. Wyffels, T. Verbrugghen, B. D. Monnery, M. Glassner, S. Stroobants, R. Hoogenboom and S. 
Staelens, J. Control. Release, 2016, 235, 63-71.
49. R. W. Moreadith, T. X. Viegas, M. D. Bentley, J. M. Harris, Z. Fang, K. Yoon, B. Dizman, R. Weimer, 
B. P. Rae, X. Li, C. Rader, D. Standaert and W. Olanow, Eur. Polym. J., 2016, 88, 524-552
50. T. R. Dargaville, R. Forster, B. L. Farrugia, K. Kempe, L. Voorhaar, U. S. Schubert and R. 
Hoogenboom, Macromol. Rapid Commun., 2012, 33, 1695-1700.
51. M. Hartlieb, K. Kempe and U. S. Schubert, J. Mater. Chem. B, 2015, 3, 526-538.
52. B. L. Farrugia, K. Kempe, U. S. Schubert, R. Hoogenboom and T. R. Dargaville, Biomacromolecules, 
2013, 14, 2724-2732.
53. T. R. Dargaville, B. G. Hollier, A. Shokoohmand and R. Hoogenboom, Cell. Adh. Migr., 2014, 8, 88-93.
54. S. Cesana, J. Auernheimer, R. Jordan, H. Kessler and O. Nuyken, Macromol. Chem. Phys., 2006, 207, 
183-192.
55. Y. Chujo, K. Sada and T. Saegusa, Macromolecules, 1990, 23, 2636-2641.
56. A. M. Jonker, A. Borrmann, E. R. H. van Eck, F. L. van Delft, D. W. P. M. Löwik and J. C. M. van Hest, 
Adv. Mater., 2015, 27, 1235-1240.
57. A. M. Jonker, S. A. Bode, A. H. Kusters, J. C. M. van Hest and D. W. P. M. Löwik, Macromol. Biosci., 
2015, 15, 1338-1347.
58. S. Lin and L. Gu, Materials, 2015, 8, 551-560.
59. K. A. Erk, K. J. Henderson and K. R. Shull, Biomacromolecules, 2010, 11, 1358-1363.
60. P. H. Kouwer, M. Koepf, V. A. Le Sage, M. Jaspers, A. M. van Buul, Z. H. Eksteen-Akeroyd, T. 
Woltinge, E. Schwartz, H. J. Kitto, R. Hoogenboom, S. J. Picken, R. J. Nolte, E. Mendes and A. E. 
Rowan, Nature, 2013, 493, 651-655.
61. M. Jaspers, M. Dennison, M. F. Mabesoone, F. C. MacKintosh, A. E. Rowan and P. H. Kouwer, Nat. 
Commun., 2014, 5, 5808.
62. B. Wagner, R. Tharmann, I. Haase, M. Fischer and A. R. Bausch, Proc. Natl. Acad. Sci. U. S. A., 2006, 
103, 13974-13978.
63. M. C. Preul, W. D. Bichard, T. R. Muench and R. F. Spetzler, Neurosurgery, 2003, 53, 1189-1199.
6Chapter 6:
Degradation and excretion of NHS-
ester functionalized poly(2-oxazoline)s
Abstract
In this chapter, we studied the degradability and excretability of NHS-ester functionalized poly(2-
oxazoline)s (NHS-POx). In order to obtain insight into the degradability of NHS-POx, we first 
performed an in vitro degradation study by incubation of NHS-POx in relevant physiological media 
(PBS and whole blood plasma) for various time points, and identified the main degradation product 
by 1H-NMR spectroscopy. Next, we studied i) the excretion pathway of this degradation product 
and ii) possible accumulation of these degradation products in specific organs. To this end, the 
most relevant degradation product was synthesized and functionalized with a diethylene triamine 
pentaacetic acid (DTPA) label which allowed chelation of radioactive isotopes (e.g. 111Indium). After 
labeling and purification, the radiolabeled polymers were injected in Wistar-rats and the excretion 
was monitored using Single Photon Emission Computed Tomography (SPECT/CT) by imaging the 
rats at different time points (1 hr, 6 hrs, 24 hrs and 7 days). Additionally, after 7 days, the organs 
of the rats were dissected and their radioactivity counted using an automated γ-counter. It was 
observed that the injected polymer did not accumulate in organs and the majority of the polymer 
was cleared within 24 hrs, mainly via renal clearance. Although a steady decline was observed in 
the amount of radiolabeled polymer over time, after 7 days, 3.1 ± 1.1 of the injected dose per gram 
(ID%/g) by SPECT/CT or 9.5 ± 0.6 ID%/g (γ-counter) was still observed in kidneys. Although the 
majority of the injected dose of radiolabeled polymer (%ID/g: 80-90) was renally excreted, more 
research is needed to explain the retention of this polymer in the kidneys in more detail, for example 
by repeating our study using a covalently attached radiolabel. 
6
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dependent on many more parameters than size alone, it is hard to predict a priori 
whether a polymer will be excreted or not.
 Poly(2-oxazoline)s or POx21-23 are particularly attractive for biomedical aplications 
due to their versatile functionalization possibilities. However, only a few studies 
have been reported in literature on the biodistribution and excretion of this class of 
polymers24-28. In a recent study, Wyffels and coworkers reported the synthesis of well-
defined homo-polymers based on 2-ethyl-2-oxazoline (EtOx) (Mn 5-110 kDa, Đ 1.01-
1.11) containing a deferoxamine ligand, and studied the biodistribution in a mouse 
model after intravenous administration using micro-positron emission tomography/
computed tomography (µPET/CT) by chelating a 89Zr-radiolabel25. It was observed 
that polymers below a threshold of 20 kDa were excreted from the body (mainly 
via renal clearance), while larger polymers (Mn>40 kDa) showed prolonged blood 
circulation in this mouse model. These results indicated that the hydrodynamic 
volume of these polymers determined the excretability of these polymers. More 
recently the same authors reported a comparative biodistribution study in a mouse 
model using EtOx homo-polymers equipped with a 18F or a 89Zr radiolabel (Mn of 
5 kDa for both polymers, Đ of 1.01 (89Zr) or 1.08 (18F)). It was observed that the 
excretability of the polymer was influenced by the type of ligand and/or radiolabel26, 
which stresses the importance of proper selection of the labeling strategy. Despite 
these systematic studies, to date, the majority of the excretion studies on POx are 
mainly based on 2-methyl-2-oxazoline (MeOx) or EtOx-containing polymers, while 
other types of POx polymers remain largely unexplored.
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Figure 1 Composition of NHS-POx used for the design of NHS-POx coated gelatin sponges for 
hemostatic purposes (see Chapter 4 for more details). The hydrolytically cleavable ester bond is 
highlighted in blue.
1. Introduction 
Insufficient control over bleeding remains one of the biggest challenges in trauma 
surgery of soft tissues such as liver or kidney1. This cannot be treated using traditional 
invasive wound closing methods such as sutures or staples, since this would create an 
additional bleeding. As a result, a variety of hemostatic agents has been developed 
for the non-invasive treatment of bleedings on these organs2, 3. 
 Previously, we developed a polymeric hemostatic agent comprised of a porous 
gelatin sponge coated with NHS-ester functionalized poly(2-oxazoline)s (NHS-POx) 
(Chapter 4). Polymers containing NHS-esters are intrinsically reactive to primary 
amines, which are abundantly present in tissue and blood proteins. When this coated 
sponge is applied to a wound site, NHS-POx is capable of forming covalent crosslinks 
between polymer, host blood proteins, a gelatin sponge and tissue to seal the wound 
site and prevent hemorrhage during surgery. Hemostatic activity was demonstrated 
on soft organs (spleen and liver) in a pig model.  However, the long-term fate of this 
biomedical device remains to be elucidated4. Two important research parameters in 
this respect are: i) degradation of the polymer and ii) elimination of the polymer and 
associated degradation products from the body (excretion).
 Degradation is strongly determined by the presence of hydrolytically or 
proteolytically cleavable moieties in the polymer structure such as ester or amide 
groups5, 6.  Since our system consists of two different components, a gelatin 
sponge and a NHS-POx coating, the degradability of both components should be 
considered. As gelatin is susceptible to proteolytic degradation in vivo, it will quickly 
degrade to smaller peptide and amino acid fragments and resorb fully within weeks, 
as confirmed previously 7-10. Regarding the polymer, the backbone structure of POx 
(which consists of tertiary amide groups) is generally stable under physiological 
conditions11, but the presence of the ester moiety renders the side chains intrinsically 
biodegradable (Figure 1). Consequently, this ester linkage will strongly influence the 
degradability of the NHS-POx coating.
 In general, excretion of polymeric materials mainly occurs via the kidneys12 or via 
the mononuclear phagocytic system (MPS)13, where the excretion rate is determined 
by many factors including the hydrodynamic volume (molecular weight)14, surface 
charge15, polymer dispersity16 and architecture17, 18. An important measure for 
the excretability of polymeric materials is the renal clearance threshold, which is 
the hydrodynamic volume below which particles are excreted via the kidneys19. 
Particles above this critical threshold will display a prolonged residence time or 
accumulation in the body12. For instance, this threshold was reported around 30 kDa 
for poly(ethylene glycol) (PEG), which is a common polymeric material for e.g. drug 
delivery purposes16,20. However, considering the fact that the renal excretion rate is 
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2. Results
2.1 In vitro degradation of NHS-POx
We performed several degradation studies by incubation of NHS-POx in phosphate 
buffered saline (PBS) and human derived blood plasma in order to study the chemical 
nature of the degradation products and the stability of the side chains in vitro using 
1H-NMR spectroscopy as analytical method.   
2.1.1 Incubation in PBS
In the first incubation study, we dissolved NHS-POx (Mn 18.8 kDa (SEC), sidechains: 
69 mol% nPropOx  14 mol% OH, 17 mol% NHS (1H-NMR)) (synthesized in Chapter 
2) in PBS (1x, pH 7.4) at a polymer concentration of 15 mg/mL and incubated the 
polymer at 37 °C for time periods of 24 and 48 hrs. 1H-NMR spectra of the polymers 
at these time points are shown in Figure 2. After 24 hours of incubation in PBS, the 
NHS-ester was fully hydrolyzed, as indicated by the shift of polymer-bound NHS (2.8 
Figure 3 1H-NMR signals of hydrolyzed NHS-POx by incubation in whole blood plasma at 37°C during 
various time points (t=0, 2 days, 6 days)
In this chapter, we have studied the processes of NHS-POx degradation and 
excretion. To this end, we first performed an in vitro degradation study by incubating 
the polymer NHS-POx in phosphate buffered saline (PBS) and human derived 
blood plasma to identify the degradation products using 1H-NMR spectroscopy. 
Next, the main degradation product was synthesized containing an S-2-(4-
isothiocyanatobenzyl)-diethylenetriamine penta-acetic acid (or DTPA) ligand. 
Finally, the polymer was labeled with radioactive 111Indium and the excretability of 
the radiolabeled polymer (using SPECT/CT and an automated γ counter) was studied 
in time after intravenous injection in Wistar rats to investigate i) the excretion 
pathway of the synthesized polymer and ii) potential accumulation of the polymer 
in specific organs.     
Figure 2  1H-NMR signals of NHS-POx by incubation in PBS at 37°C for 0, 24 and 48 hrs.
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the presence of the DTPA group on the polymer (P3). Subsequently, the methyl ester 
groups at the side chains were modified quantitatively by amidation using 2-amino-
ethanol, yielding the hydroxyl side chain functionalized POx (P4). In a final step, 
the carboxylic acid groups were introduced using a sub-stoichiometric amount of 
succinic anhydride (compared to the hydroxyl groups) and dimethylaminopyridine 
(DMAP) as a catalyst (P5). The analytical data of the synthesized polymers P1-P5 are 
listed in Table 1. The polymers were synthesized with good control over the ratio of 
functional groups (1H-NMR) and dispersity values (SEC). Unfortunately, no SEC signal 
could be obtained for P5, but based on the results of the other polymers (P1-P4) no 
change in dispersity is expected throughout the postmodification functionalization 
steps. Moreover, the 1H-NMR spectrum of P5 (Figure 4) demonstrated that P5 is 
functionalized with both a desired ratio of functional side chains and a DTPA ligand 
for radiolabeling, which allows the polymer to be used in biodistribution experiments. 
Scheme 1 Synthesis route towards P(nPropOx-c-OH-c-COOH)-N-pip-DTPA (P5). Reactions conditions: 
i) methyl tosylate, MeCN, 140°C, µW, 30 min, ii) N-Boc-piperazine, rt, 3 days, iii) TFA/DCM (v/v, 1:3), rt, 
30 min, iv) p-SCN-Bn-DTPA, Et3N, DMF, rt, overnight, v) 2-amino-ethanol, 60°C, 300 mbar, overnight, 
vi) succinic anhydride, DMAP, DMF, rt, overnight
ppm, 6) to free N-hydroxysuccinimide (2.7 ppm, 6’). No further degradation of the 
polymer was observed, since no change in other integrals was seen, which indicates 
that the ester linker in the side chain is stable upon incubation in PBS.     
2.1.2 Incubation in blood plasma
To further assess the stability of the ester bond, POx-COOH, obtained via hydrolysis 
of the succinimide esters of NHS-POx, was incubated in human-derived blood 
plasma (polymer concentration 15 mg/mL) for two and six days. The results of this 
study are shown in Figure 3. Also in this experiment, we observed that the ester 
moiety in the side chain did not degrade over a period of six days, demonstrating the 
stability of the ester bond.
 Both in vitro degradation experiments indicate that the ester bond in the side 
chain is stable, whereas the NHS ester is hydrolyzed to carboxylic acid-functionalized 
POx (POx-COOH) under physiological conditions. Although further degradation in 
vivo (e.g. by proteolytic enzymes) cannot be excluded, POx-COOH was selected for 
further in vivo excretion studies. 
2.2 Synthesis of carboxylic acid-functionalized POx 
Carboxylic acid functional POx was synthesized according to procedures described 
in Chapter 2 (P(nPropOx-c-OH-c-COOH) 70-15-15). In order to be able to study the 
polymer in vivo by means of SPECT/CT imaging, we functionalized the end group 
of the polymer using a DTPA ligand. This ligand is capable of chelating radioactive 
ions which can be used to trace the polymer after injection. We used end-group 
functionalization since it allowed us to introduce only a single ligand per polymer 
chain. Moreover, by choosing end group functionalization we circumvented the 
potential risk of degradation of the ligand in case of degradation of the side chains in 
vivo. For the introduction of the ligand, we used a literature procedure by Gaertner 
and coworkers27. The synthetic route towards these polymers is shown in Scheme 1.
 First, we synthesized the P(nPropOx-c-MestOx) copolymer, where we terminated 
the reaction with N-1-(tert-butoxycarbonyl)-(Boc)-piperazine yielding POx which was 
end-capped with a Boc-protected amine moiety (P1). It was determined by 1H-NMR 
spectroscopy that 46% of the polymer chains was terminated with the N-Boc-
piperazine.  Hereafter, we deprotected this Boc group using a mixture of TFA in DCM 
(v/v, 1:3). This deprotection proved quantitative as was determined by 1H-NMR, since 
the characteristic signal of the Boc group (1.3 ppm) disappeared completely (P2). 
Subsequently, the DTPA ligand was introduced by amine-isothiocyanate coupling 
using triethylamine (Et3N) as a base to facilitate an efficient reaction. Although the 
quantification of the end-groups was difficult using 1H-NMR spectroscopy, a clear 
aromatic signal attributed to the DTPA-ligand was observed which was indicative of 
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Figure 5 SPECT/CT images of Wistar rats at various time points after intravenous injection of 
radiolabeled P5
Table 3 Quantification of the radioactivity at different time points (%ID/g)
1 hrs 6 hrs 24 hrs 7 days
mean sd mean sd mean sd mean sd
Kidneya) 12.5 2.1 11.2 1.9 8.9 1.3 3.1 1.1
a) measured values are expressed in value per kidney (n=6)
Figure 6 Biodistribution study of the 
dissected organs using an automated 
γ-counter after 7 days. Experiments 
were performed (n=3), except for 
measurements on kidneys (n=6). 
Statistics: * P<0.001
10.5
8.5
10.0
9.5
9.0
0.4
0.3
0.2
0.1
0
%
 ID
/g
*
Table 1 Analytical data of synthesized polymers P1-P5
# Name Yield 1H-NMR Mn
a
g % % MestOx %OH %COOH Theor. SEC Đ
P1 P(nPropOx-c-MestOx)-N-pip-NBoc 8.1 75 31 - - 12.8 12.2 1.19
P2 P(nPropOx-c-MestOx)-N-pip-NH 1.8 q. 31 - - 12.7 12.1 1.18
P3 P(nPropOx-c-MestOx)-N-pip-N-DTPA 335 mg 61 31 - - 13.4 14.4 1.13
P4 P(nPropOx-c-OH)-N-pip-N-DTPA 53 mg 49 - 31 - 14.1 21.4 1.11
P5 P(nPropOx-c-COOH-c-OH)-N-pip-N-DTPA 9 mg 23 - 14 17 16.3 b b
a SEC was calibrated against PMMA standards, eluent: 0.1 % LiCl in DMA.
b No signal could be obtained
Figure 4 1H-NMR signals of P(nPropOx-c-OH-c-COOH)-N-pip-DTPA (P5) 
2.3 Radiolabeling
In order to obtain sufficient signal intensity using SPECT/CT scanning it is crucial 
to select the proper radioisotope in terms of half-life. In this work, we selected 
Indium-111 (111In) in view of its half-life of 2.8 days29 and widespread usage in the 
radiolabeling of macromolecules27, 30.
 As a result, radiolabeling of P5 with 111In was performed by incubation of the 
polymer with 111InCl3. After purification using a PD10 column, the radiolabeled 
polymers were obtained at a radiochemical purity of >95% and a radioactivity of 27-
53 MBq, which proved sufficient to perform the in vivo experiments.
 Directly after radiolabeling, the labeled polymers were injected via intravenous 
injection in the tail of Wistar rats. The rats were monitored and imaged by SPECT/CT 
at relevant time points (1 hrs, 6 hrs, 24 hrs and 7 days). After the measurements, the 
SPECT/CT images were quantified by comparison with a series of injected standards. 
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molecular weight P(EtOx) (Mn 4.5 kDa, Đ 1.15), which was well below the glomular 
filtration cut off for P(EtOx) (40 kDa)27. Nevertheless, they observed the presence 
of labeled polymer in the kidneys 24 hrs p.i., which suggests that this retention was 
related to the type of radiolabel which was used. It would therefore be interesting to 
repeat our study using a different radiolabel. 
 Another factor which can inhibit successful excretion is the hydrodynamic volume. 
Although the hydrodynamic volume of polymer P5 is below the globular filtration 
threshold of P(EtOx) (40 kDa), it cannot be excluded that the higher molecular 
weight fraction of the polymer causes the retention or slower excretion from the 
kidneys. A final parameter that should be taken into account is the polarity of the 
polymer, as it is known that surface charge and polarity strongly influence polymer 
excretion15. So far there is no relevant literature available on excretion of related 
POx polymers containing both hydrophobic nPropOx-residues and polar residues 
such as hydroxyl groups and carboxylic acid groups. In conclusion, although several 
factors have been reported to influence retention of polymers in kidneys, why the 
retention of polymers was observed in our case remains to be elucidated through 
more systematic studies.  
 Regarding clinical translation, it should be emphasized that the injected dose (1.2 
mg polymer/kg body weight based on a rat of 250 g) is likely to be high compared to 
future clinical scenarios. A healthy male (70 kg) receiving one hemostatic NHS-POx 
coated sponge (containing ~40 mg NHS-POx) is administrated half of the polymer 
dose (0.6 mg/kg), as used in the current experiment. As a result, this experiment 
represents a polymer dose corresponding to the administration of two NHS-POx 
coated sponges.  Additionally, it must also be noted that the release profile of the 
polymer into the blood stream will be more complex than the single dose injection 
as performed in the current work. Despite the apparent stability of the side chains 
which was demonstrated in the hydrolysis experiments in vitro, degradation in 
vivo cannot be excluded, since  bio-degradation and bio-erosion are complex 
phenomena32, 33 which strongly determine the release profile of the polymer into the 
blood stream upon clinical application.  
 Nevertheless, it can be concluded that the majority of the injected dose of 
radiolabeled polymer (80-90 %ID/g) can be excreted within a day without showing 
accumulation in organs other than kidneys. The excretion of this polymer proceeded 
mainly via the renal pathway. Whether the presence of the labeled polymer after 7 
days is caused by retention or slow excretion remains to be eludicated.
In addition, after the last SPECT/CT measurement, the rats were euthanized and 
the organs of the rat were dissected followed by measurement of their radioactivity 
using an automated γ counter. The results of these experiments are displayed in 
Figure 5+6 and Table 3.
 It was observed that the majority of the radiolabeled polymer (%ID/g) was cleared 
within an hour, as  the radiolabeled polymer was only present in kidneys (%ID/g 12.5 
± 2.1) and bladder (not quantified) based on SPECT/CT imaging (Figure 5 and Table 
3). The clearance from the kidneys appeared to occur slowly overtime, as indicated 
from the measured doses at 6 hrs (%ID/g 12.5 ± 2.1) and 24 hrs (%ID/g 8.9 ± 1.3). 
Ultimately, after 7 days 3.1 ± 1.1 %ID/g was found in the kidneys. No accumulation of 
radiolabeled polymer was found in other organs than kidneys over the time course 
of the experiment. The measurements on the dissected organs using the γ-counter 
confirmed this observation (Figure 6). However, in comparison with the SPECT/CT 
measurements, a higher percentage of radiolabeled polymer was found in kidneys 
(%ID/g 9.5 ± 0.6).  
3. Comparison with related excretion studies 
Both the SPECT/CT and the γ-counter measurements confirmed that the majority of 
the ~80-90 %ID/g of labeled polymers was renally excreted from the rats after 7 days, 
without notable accumulation of the polymer in other organs. The renal excretion of 
the polymers is not complete after 7 days post injection (p.i.), since a low amount 
of the radiolabeled polymer (%ID/g: 3.1 ± 1.1 as determined using SPECT/CT and 
9.5 ± 0.6 as measured using γ counting) was still detected in kidneys. Although, the 
exact reason for this presence in this case is yet unknown, certain aspects of this 
retention can be explained from related excretion studies. The slow clearance of the 
final traces of radiolabeled POx as observed herein was also observed in the work 
of Moreadith et al. which showed -despite a steady decline in the signal- presence 
of radiolabeled polymers in bile, liver and spleen of a rat model after 14 days24 (p.i.). 
Since in our case a steady decline is observed as well, it would be interesting to 
repeat the experiments using time points exceeding 7 days to see whether these 
extended time points are sufficient for effective excretion from the kidneys. 
 Another explanation for the presence of radiolabeled polymers in the kidneys, is 
that the type of radiolabel/labeling strategy which is used in the experiment causes 
undesired retention of the polymer. This observation was previously reported by 
Glassner and coworkers26 and was also reported for radiolabeled peptides by Vegt 
and coworkers31. In addition, Gaertner and co-workers used the same radiolabel 
as employed in the current study (111Indium) to investigate the clearance of low 
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The Netherlands). Human blood plasma was obtained by centrifugation of freshly 
obtained human whole blood from Sanquin (Nijmegen, The Netherlands)  
6.2 Instrumentation
1H-NMR and 13C-NMR spectra were recorded on a Bruker Avance III 500MHz 
spectrometer using the solvent D2O. Microwave-assisted polymerizations were 
performed in a Biotage Initiator+, equipped with an autosampler. Size exclusion 
chromatography (SEC) was performed on an Agilent 1260 - series HPLC system 
equipped with a 1260 online degasser, a 1260 ISO-pump, a 1260 automatic liquid 
sampler, a thermostatted column compartment, a 1260 diode array detector (DAD) 
and a 1260 refractive index detector (RID). Analyses were performed on two Mixed-D 
and a guard column in series at 50 °C. As an eluent, N,N-dimethylacetamide (DMA), 
containing LiCl (concentration 50 mM), was used at a flow rate of 0.593 ml min-1. 
The SEC traces were analyzed using the Agilent Chemstation software with the GPC 
add on. Number average molecular weights (Mn), weight average molecular weights 
(Mw), and dispersity (Ð) values were calculated against poly(methyl methacrylate) 
(PMMA) standards.  SPECT/CT was acquired on a small animal SPECT/CT scanner 
(U-SPECT-II, MIlabs, Utrecht, Netherlands) with a 1.0 mm multipurpose rat 
collimator, using 108 bed positions and an acquisition time of maximal 120 minutes. 
CT was acquired after SPECT acquisition for anatomical reference (65 kV, 615 µA, 
3 bed positions, spatial resolution 160 µm). Scans were reconstructed with MILabs 
reconstruction software (which uses an ordered-subset expectation maximization 
algorithm), a voxel size of 0.75mm, 16 subsets, and 1 iteration. Radioactivity was 
measured in a shielded well-type γ-counter (Perkin–Elmer).
6.3 In vitro degradation experiments
In Eppendorf tubes, polymers were dissolved in aqueous media (PBS or human derived 
whole blood plasma) to provide a polymer concentration of 15 mg/mL. The tubes 
were continuously shaken at 37°C for defined times (1, 2 or 6 days). Subsequently, 
the Eppendorf tubes were lyophilized yielding the polymer as white powders. These 
powders were dissolved in methanol (1 mL) and filtered over Sephadex (G-25, Sigma 
Aldrich) to remove residual impurities. The organic solvent was removed under an 
argon flow. The powders were dissolved in D2O (10 mg/mL) and the polymers were 
characterized by 1H-NMR spectroscopy (500 MHz, 64 scans).  
6.4 Synthetic procedures for P1-P5
P1 - P(nPropOx-c-MestOx)-N-piperazine-NBoc - Methyl tosylate (0.13 mL, 0.87 
mmol, 1 eq.), nPropOx (6.76 mL, 67.0 mmol, 77 eq.), MestOx (3.60 mL, 28.7 mmol, 
33 eq.) and acetonitrile (7.60 mL) were mixed in a dry microwave vial under inert 
4. Conclusions
In this chapter, we have investigated the degradability and excretability of NHS-
POx in order to gain deeper insight into the fate of the polymer after the therapeutic 
action has been achieved.  We performed an in vitro degradation study by testing 
the stability of the polymer in PBS (2 days) and blood plasma (up to 6 days), and 
characterized the degradation products by 1H-NMR spectroscopy. It was found that 
the hydrolytically sensitive ester group of NHS-POx was predominantly stable in 
these experiments, whereas the NHS ester was effectively hydrolyzed as expected. 
For the in vivo excretion studies, the carboxylic acid functional polymer was therefore 
chosen as the main degradation product. This polymer was successfully synthesized 
containing a DTPA ligand at the polymer chain end and subsequently radiolabeled 
with 111Indium. The polymer was injected in Wistar rats via a tail injection and the 
excretion was followed by SPECT/CT for 1 hr, 6 hrs, 24 hrs and 7 days. After 7 days, 
the organs of the rats were dissected and measured for radioactivity using an 
automated γ-counter. Using these experiments, it was found that the majority of the 
injected radiolabeled polymer (~80-90% %ID/g) was excreted via renal excretion, 
however a minority of polymer was still present in kidneys after 7 days (%ID/g: 3.1 ± 
1.1 (SPECT/CT) and 9.5 ± 0.6 (γ-counter). No accumulation of radiolabeled polymer 
in other organs was observed. More systematic research is needed in order to explain 
the kidney retention of the radiolabeled polymer in this experiment.
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6. Experimental section
6.1 Materials
All reagents for the synthesis of the polymer were distilled twice before use in 
the polymerization reactions. Acetonitrile (obtained from Actu-all Chemicals) was 
dried and dispensed under nitrogen atmosphere by using an MBraun MB SPS-
800 solvent dispersing system. Unless otherwise stated, all other chemicals were 
obtained from Sigma-Aldrich and used as received. p-SCN-Bn-DTPA was obtained 
from Macrocyclics (USA). 111InCl3 was obtained from Mallinckrodt Medical (Petten, 
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 1H NMR (500 MHz, D2O) δ 7.30 (d, J= 10 Hz, 2H, -SCNH-CH-CH-), δ 7.18 (d, J= 5 
Hz, 2H, -SCNH-CH-CH-), δ 3.77 (s, 10H, N-CH2-COOH), δ 3.66 (b, m·3H, CO-O-CH3), 
δ 3.48 (b, (m+n)·4H, NCH2CH2N), 3.01 (b, 7H, N-CH2CH2-N), 2.70-2.60 (b, m·4H, 
COCH2CH2CO),  2.35-2.20 (b, n·2H, CO-CH2-CH2-CH3),  1.70-1.60 (b, n·2H, CO-CH2-
CH2-CH3), 0.91-1.02 (b, n·3H, CO-CH2-CH2-CH3) SEC (PMMA) Mn 14.4kg/mol, Đ 1.13. 
Experimentally determined monomer ratio (m/n): 69/31 
 P4 - P(nPropOx-c-OH)-N-piperazine-NH-DTPA - P3 (102 mg, 8 µmol polymer, 
236 µmol functional groups, 1 eq.) was dissolved in 2-amino-ethanol (2 mL, 2.0 g, 
33 mmol, 142 eq.) and the reaction mixture was allowed to reflux overnight at 60°C 
under reduced pressure (300 mbar). After this, 2-amino-ethanol was removed under 
reduced pressure and the polymer was dissolved in methanol (5 mL) and precipitated 
into Et2O/acetone (v/v, 4:1, 100 mL). This procedure was repeated three times. 
Subsequently, the precipitate was dissolved in MQ water (5 mL) and lyophilized. P4 
was obtained as a white powder (53 mg, 49% yield).
 1H NMR (500 MHz, D2O) δ 7.23 (b, 2H, -SCNH-CH-CH-),  7.16 (b, 2H, -SCNH-
CH-CH-), 3.66 (s, 10H, N-CH2-COOH), 3.57 (b, n·2H, CONH-CH2-CH2-OH), 3.48 (b, 
(m+n)·4H, NCH2CH2N), 3.24 (b, n·2H, CONH-CH2-CH2-OH, 3.01 (b, 7H, N-CH2CH2-N), 
2.70-2.60 (b, n·4H, COCH2CH2CO),  2.35-2.20 (b, m·2H, CO-CH2-CH2-CH3),  1.70-1.60 
(b, m·2H, CO-CH2-CH2-CH3), 0.91-1.02 (b, m·3H, CO-CH2-CH2-CH3) SEC (PMMA) Mn 
21.4 kg/mol, Đ 1.11. Experimentally determined monomer ratio (m/n): 69/31 
 P5 - P(nPropOx-c-OH-c-COOH)-N-piperazine-NH-DTPA - P4 (33 mg, 2.3 µmol 
polymer, 71 µmol functional groups, 1 eq.), DMAP (4.6 mg, 38 µmol, 0.5 eq.) and 
succinic anhydride (4.6 mg, 46 µmol, 0.6 eq.) were dissolved in DMF (1 mL) and the 
reaction mixture was allowed to stir overnight. After this, DMF was removed under 
reduced pressure and the polymer was dissolved in methanol (5 mL) and precipitated 
into Et2O (100 mL). Subsequently, the polymer was dissolved in methanol (5 mL) 
and filtered over SCX-2 (20 mg SCX-2, 3.4 eq. towards DMAP) and flushed with 
methanol (4 x 1 mL). Afterwards, the fractions were combined and concentrated 
under reduced pressure. Subsequently, the polymer was dissolved in MQ water (5 
mL) and lyophilized. P5 was obtained as a white powder (9 mg, 23% yield).
 1H NMR (500 MHz, D2O) δ 7.29 (b, 2H, -SCNH-CH-CH-), 7.21 (b, 2H, -SCNH-CH-
CH-), 4.10 (b, x·2H, CONH-CH2-CH2-OCO), 3.76 (b, 10H, N-CH2-COOH), 3.56 (b, n·2H, 
CONH-CH2-CH2-OH), 3.48 (b, (m+n+x)·4H, NCH2CH2N), 3.38 (b, x·2H, CONH-CH2-
CH2-OCO), 3.24 (b, n·2H, CONH-CH2-CH2-OH), 2.92 (b, 7H, N-CH2CH2-N), 2.70-2.40 
(b, (n+x)·4H, COCH2CH2CO), 2.56 (b, x·4H, COCH2CH2COOH),  2.35-2.20 (b, m·2H, 
CO-CH2-CH2-CH3),  1.70-1.60 (b, m·2H, CO-CH2-CH2-CH3), 0.91-1.02 (b, m·3H, CO-
CH2-CH2-CH3) SEC (PMMA) No signal could be obtained. Experimentally determined 
monomer ratio (m/n/x): 69/14/17 
atmosphere (Ar). The reaction mixture was heated for 30 minutes at 140°C under 
microwave irradiation after which a solution of N-Boc-piperazine in MeCN (480 mg, 
4.35 mmol, 3 eq.) was added to the reaction mixture, which was stirred for three days 
at room temperature. The polymer was dissolved in DCM (25 mL) and precipitated 
in diethylether (DCM/Et2O, v/v, 1:20) (500 mL). This procedure was performed twice. 
The resulting suspension was filtered and the residue dissolved in DCM (100 mL). 
The solvent was evaporated under reduced pressure, yielding the final polymer as 
a white foam (8.1 g, 75% crude yield). 1H-NMR confirmed that product was formed 
but that traces of unbound N-Boc-piperazine were present. Hereafter, the polymer 
was purified in smaller batches of 1 g. As an example, 997 mg of the crude material 
was dissolved in water, heated to 60°C, which caused precipitation of the polymer, 
and centrifugated (4000 rpm, 15 min., 40°C). The water layer was decanted and the 
resulting pellet was dissolved in MQ-water and lyophilized. P1 was obtained as a 
white powder (0.7 g, 72 % yield)
 1H NMR (500 MHz, D2O) δ 3.66 (b, n·3H, CO-O-CH3), 3.48 (b, (m+n)·4H, 
NCH2CH2N), 3.03 (b, 3H, CH3-NCHCH-), 2.70-2.60 (b, n·4H, COCH2CH2CO),  2.35-
2.20 (b, m·2H, CO-CH2-CH2-CH3),  1.70-1.60 (b, m·2H, CO-CH2-CH2-CH3), 1.46 (s, 9H, 
NCOOC(CH3)3), 0.91-1.02 (b, m·3H, CO-CH2-CH2-CH3) SEC (PMMA) Mn 12.2 kg/mol, 
Đ 1.19. Experimentally determined monomer ratio (m/n): 69/31. 
 P2 - P(nPropOx-c-MestOx)-N-piperazine-NH - P1 (1.8 g, 0.14 mmol, 1 eq) was 
dissolved in TFA/DCM (v/v, 1:3, 229 eq.) (10 mL) and stirred for 60 min, whereafter 
the reaction mixture was concentrated under reduced pressure. The polymer was 
dissolved in DCM (10 mL) and precipitated in Et2O (250 mL). The precipitate was 
dissolved in MQ-water and lyophilized. P2 was obtained as a white powder (1.8 g, 
quant. yield)
 1H NMR (500 MHz, D2O) δ 3.66 (b, n·3H, CO-O-CH3), 3.48 (b, (m+n)·4H, NCH2CH2N), 
3.03 (b, 3H, CH3-NCHCH-), 2.70-2.60 (b, n·4H, COCH2CH2CO),  2.35-2.20 (b, m·2H, 
CO-CH2-CH2-CH3),  1.70-1.60 (b, m·2H, CO-CH2-CH2-CH3), 0.91-1.02 (b, m·3H, CO-
CH2-CH2-CH3) SEC (PMMA) Mn 12.2 kg/mol, Đ 1.18. Experimentally determined 
monomer ratio (m/n): 69/31
 P3 - P(nPropOx-c-MestOx)-N-piperazine-NH-DTPA - P2 (522 mg, 41 µmol, 1 
eq.), p-SCN-Bn-DTPA (34.6 mg, 58 µmol, 1.4 eq.) and Et3N (50 µL, 36.5 mg, 361 µmol, 
8.8 eq.) were dissolved in DMF (2 mL) and stirred overnight, whereafter the reaction 
mixture was concentrated under reduced pressure. The polymer was dissolved 
in DCM (5 mL) and precipitated in Et2O (100 mL). The precipitate was dissolved 
in cold MQ-water (5 mL, 5°C), heated to 40°C, which caused precipitation of the 
polymer. The resulting suspension was centrifugated (4000 rpm, 15 min., 40°C), 
the supernatant was decanted, the pellet was dissolved in MQ-water (5 mL) and 
subsequently lyophilized. P3 was obtained as a white powder (335 mg, 61% yield).
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6.5 Labeling with 111In and purification 
The polymer (P5) was dissolved in 0.5 M MES (2-(N-morpholino)ethanesulphonic 
acid) buffer, pH 5.5 (5mg/mL), whereafter 0.5 M MES-buffer (125 µL) and a 
solution of 111InCl (in 0.05 M HCl) (118 MBq) (125 µL) were added. The solution was 
incubated for 30 min at room temperature whereafter the radiochemical efficiency 
was determined by instant thin layer chromatography on ITLC-SG strips (Agilent 
Technologies) with 0.1 M citrate (pH 6.0) as a mobile phase, resulting in a labeling 
efficiency of 49%. The labeled product was purified by gel filtration chromatography 
on a PD-10 column (GE Healthcare) using PBS/BSA as a mobile phase to provide a 
labeled polymer sample of 32.5 MBq with radiochemical purity of 99%  (ITLC, 0.1 M 
citrate buffer, Rf value: 0.1).    
6.6 Biodistribution study using SPECT/CT
For this experiment, Wistar rats (n=4, 230-280 g, Harlan, Horst, The Netherlands) 
were used. The animals were allowed to acclimatize for at least five days prior to the 
experiment. They were housed in individually ventilated cages. Permission for this 
experiment was granted by de Centrale Commissie Dierproeven (CCD) (projectnumber 
2015-0012). The labeled polymers (300 µL, 27-52 MBq, 273 µg polymer) were injected 
intravenously in the tail of Wistar rats. The animals were imaged by SPECT/CT after 1 hr 
(20 min), 6 hrs (40 min) and 24 hrs (60 min). During imaging the rats were anesthetized 
using isoflurane in a 1:1 mixture of oxygen and pressurized air (5% induction, 2.5-
3.5% maintenance. After 7 days, the rats were euthanized (using CO2) and afterwards 
imaged using SPECT/CT (120 min). The images were quantified via a series of calibration 
standards and expressed as injected dose per gram tissue ± standard deviation (%ID/g ± 
SD) per organ. The experiments were performed in triplo (n=3). 
6.7 Biodistribution using an automated γ-counter
Biodistribution studies were performed on the euthanized rats. From these rats, 
the organs of interest (heart, lung, blood, kidney (left/right), spleen, liver, bladder, 
pancreas, muscle) were dissected, weighed and analyzed using a γ-counter along 
with a standard containing the injected activity to allow calculation of the injected 
dose per gram tissue ± standard deviation (%ID/g ± SD). The experiments were 
performed in triplo (n=3), except for the kidneys (n=6).
6.8 Statistics
Statistical analyses were conducted using GraphPad Instat software. All results were 
reported as mean ± standard deviation. Differences among groups were analyzed by 
ANOVA using a Tukey-Kramer Multi comparison test and p-values of 0.05 or lower 
were considered as significantly different.
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these synthetic routes were further employed for the preparation of the POx 
polymers in the remaining chapters of this thesis.  
 In Chapter 3, we performed a systematic study on the pH- and temperature-
responsive behavior of nPropOx copolymers containing carboxylic acid groups 
(P(nPropOx-c-COOH) and nPropOx copolymers containing amine groups 
P(nPropOx-c-NH2). This lower critical solution temperature (LCST) behavior was 
studied by turbidimetry by studying the effect of various parameters on the cloud 
point (CP). It was found that the polymer concentration had a strong influence on the 
CP. Furthermore, the CP was linearly related to the amount of hydrophilic carboxylic 
acid groups as present on the polymer. The addition of increasing amounts of salt 
(NaCl) led to a Hofmeister-related salting out effect of the polymers. Additionally, 
it was found that the pH had a strong effect on the polymer charge and thus the 
CP of the polymer. Finally, turbidimetric studies in PBS showed that the polymers 
were soluble around body temperature. Overall, this tunable behavior was found 
very useful as purification method for intermediate polymers in route B (Chapter 2), 
but also offers possibilities for the development of thermoresponsive systems based 
on these polymers, which can be utilized for e.g. drug delivery applications.
 In Chapter 4, the hemostatic efficacy of various NHS-POx polymers (described 
in Chapter 2) was tested in vitro as well as in vivo against commercial controls.  In a 
first study, we tested the hemostatic potential of a series of NHS-POx polymers by 
crosslinking these polymers with human whole blood. In this experiment, NHS-POx 
with hydrophilic groups demonstrated the fastest gelation compared to NHS-POx 
polymers without these groups but not as fast as NHS-PEG. The best performing 
NHS-POx polymer was coated on gelatin sponges using a spraying method, thereby 
creating homogeneously coated hemostatic sponges with good control over the 
coating density (mg/cm2). The sponges were tested for blood uptake and adhesion. 
It was found that increasing the amount of the polymer coating led to a decrease in 
blood uptake. In the adhesion test, a clear effect of the presence of the coating was 
found, but no effect on the amount of coating was observed.  The best performing 
sponge was tested in vivo in a model for profuse bleeding against commercially 
available products Hemopatch (based on NHS-PEG) and Tachosil. In this experiment, 
the NHS-POx coated sponge proved superior in terms of hemostatic efficacy (7 out of 
8 bleedings) compared to a gelatin sponge without this coating (0 out of 4 bleedings) 
and Tachosil (1 out of 4 bleedings). Moreover, in comparison with Hemopatch (5 out 
of 8 bleedings) the NHS-POx coated sponge proved superior in terms of sealing the 
wound site, indicating that coating homogeneity is an important parameter in the 
design of a hemostatic device.
 In Chapter 5, we performed a systematic rheological study to get a clearer 
insight into the mode of action of NHS-POx and NHS-PEG as hemostatic polymers. 
1. Summary
Surgical procedures on soft tissues such as liver and kidneys often result in severe 
bleedings, as these organs are highly venous. As a result, invasive wound closing 
methods such as sutures and staples cannot be used to treat bleedings of these organs. 
In this thesis, we have focused on the development of a non-invasive hemostatic 
agent based on poly(2-oxazolines) (POx) equipped with N-hydroxy succinimide 
(NHS) esters. The mechanism of action of these NHS-ester functionalized polymers 
is based on the intrinsic capacity of the NHS-esters to react with primary amines 
which are ubiquitously present in blood (e.g. albumin) and other tissues (e.g. liver, 
kidney). This reactivity makes these polymers highly suitable as hemostatic agents 
by formation of an artificial blood clot or by acting as wound sealants by adhering 
to tissue. As has been discussed in Chapter 1, NHS-esters have been utilized in 
poly(ethylene glycol) (PEG)-based biomedical devices, but these materials have a 
limited capacity to seal profuse bleedings. In view of the versatile functionalization 
possibilities and the biocompatibility of this polymer class, we therefore selected 
POx as an alternative material candidate for the development of hemostatic patches. 
 In Chapter 2, various synthetic routes towards NHS-POx were discussed. Since 
direct incorporation of NHS-esters during polymerization is not possible for cationic 
ring opening polymerization (CROP), the most common way of synthesizing POx, 
we used CROP and post polymerization modification strategies to develop a scalable 
route towards NHS-ester functional polymers. We developed three different routes 
(A-C), which all relied on the introduction of methyl esters onto the polymers since 
this moiety allows for effective introduction of NHS-esters into polymers. In the 
first route (A), we made use of partial acidic hydrolysis of commercially available 
poly(2-ethyl-2-oxazoline) (Aquazol®), yielding polymers with a defined number of 
linear polyethyleneimine (l-PEI) units, which were further functionalized towards 
NHS-POx via introduction of methyl esters. In the second route (B), we used CROP 
using methyl ester functionalized monomer (MestOx) in combination with non-
functionalized monomers 2-ethyl-2-oxazoline (EtOx) and 2-n-propyl-2-oxazoline 
(nPropOx) to tune the polarity. Subsequently, we converted the methyl ester groups 
by post polymerization modification (via hydrolysis) in order to design a series of 
NHS-POx with varying polarities. In a third route (C), similar to B, we made use 
of CROP and postmodification strategies (by amidation of the methylester). In this 
route, we introduced both the hydrophilic moieties and the crosslinking NHS-ester 
groups via modification of the methyl ester. After synthesis of the polymers, they 
were tested for their physicochemical properties such as their solubility in water. 
In conclusion, only routes B and route C were viable in terms of robustness of the 
synthetic procedures and physicochemical properties of the polymers. Therefore, 
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7 days, the animals were sacrificed, relevant organs were dissected, weighed and 
analyzed using an automated γ-counter. It was found that the majority of the 
injected polymer was cleared within 24 hrs mainly via renal clearance. Nevertheless, 
after 7 days, despite a steady decline, still 3.1 ± 1.1 of the injected dose per gram 
(ID%/g) by SPECT/CT or 9.5 ± 0.6 ID%/g by the γ-counter was still observed in the 
kidneys.  No accumulation of radiolabeled polymers in other organs was observed. In 
conclusion, although the majority of the radiolabeled polymers seems to be suitably 
excreted from the rat model, a minor percentage remains present in the kidneys. 
More systematic research is needed in order to draw valid conclusions on the full 
excretability and possible kidney retention of the degradation products of NHS-POx 
in the kidneys.
 In conclusion, we have demonstrated that NHS-ester functionalized poly(2-
oxazoline)s are excellent candidates for the development of hemostatic agents.
2. Future perspectives
The development of hemostatic agents has evolved tremendously over the past 
decades1, 2. Previously, products were mainly based on polymers of natural origin 
(such as collagen3 and gelatin4) because of their wide availability, fast degradation 
profile and low cost price. These materials will probably remain to be used for the 
treatment of less severe bleedings in the clinic, but do not offer an adequate solution 
for severe profuse bleedings on venous organs. Therefore, more advanced surgical 
hemostats have been developed which combine the benefits of both synthetic 
and natural polymers (such as Hemopatch, Veriset and Tachosil)5,6. However, 
these products suffer from specific drawbacks (which are described in Chapter 1) 
as well, which has stimulated the search for novel hemostatic agents. NHS-ester 
functionalized poly(2-oxazoline)s (NHS-POx) have been described in this thesis as a 
highly promising alternative to existing systems.
 Although the suitability of NHS-POx for use in as hemostatic devices has been 
illustrated in this work, several improvements can be made to enhance the potential 
of these polymers even further. The successful hemostatic action of these polymers 
is based on the efficient crosslinking reaction of NHS-esters with primary amines 
(e.g. in blood and soft tissue). Since availability of the crosslinking groups seems to 
be an important parameter for the design of hemostatic POx, as shown in Chapter 5, 
it would be interesting to develop POx containing extended sidechains by increasing 
the spacer length between the POX-backbone and the NHS-ester moiety. This 
strategy might render the crosslinking groups more mobile, which could facilitate 
the crosslinking reaction. Another option to enhance the crosslinking capacity of 
Therefore, we studied the network formation of these polymers, by means of 
gelation, with bovine serum albumin (BSA) as a model protein. In this study, we were 
particularly interested in the effect of i) the positioning of the crosslinking NHS-
ester groups (side chains or end groups) and ii) the type of the hydrophilic side chain 
moieties (OH or N(Me)2, in case of NHS-POx), on the network structure. In addition, 
we studied the effect of the pH on the network formation for NHS-POX. The 
network properties were analyzed via i) oscillatory time sweeps thereby studying 
the gelation time, ii) oscillatory frequency sweeps to study the elasticity of the 
formed networks and iii) strain sweeps to study the strength of the formed networks 
upon increased strain values. During oscillatory time sweeps, we observed that both 
NHS-POx and NHS-PEG instantaneously formed crosslinked networks with BSA, 
although NHS-PEG formed stiffer networks with BSA than NHS-POx. Both networks 
showed predominantly elastic behavior as was determined by frequency sweeps. 
Interestingly, in contrast to crosslinked NHS-PEG networks, crosslinked NHS-POx 
networks showed strain stiffening behavior as was demonstrated by strain sweeps, 
which indicates that NHS-PEG and NHS-POx formed different network structures. 
Overall, we explain the observations by the difference in polymer architecture 
between POx and PEG; the freely mobile NHS-ester groups of the NHS-PEG star 
polymer are more prone to react with different BSA molecules, which leads to the 
buildup of a more regular network structure, whereas, due the proximity of the NHS 
esters on NHS-POx one polymer chain can form multiple bonds with the same BSA 
protein. We furthermore observed that a pH optimum of 8.5 or higher was needed 
in order to obtain the strongest networks between NHS-POx and BSA, which can 
be used as useful tool for speeding up the hemostatic action of coated NHS-POx 
patches. Finally, both NHS-POx and NHS-PEG can be successfully utilized for the 
development of hemostatic polymers as they both formed networks (with BSA) with 
strengths in the same range as fibrin clots. 
 In Chapter 6, we studied the degradation and excretion of NHS-POx.  In this study, 
we were primarily interested in studying i) the excretion pathway of the degradation 
products of NHS-POx and ii) the possible accumulation of these degradation 
products in other organs.  We investigated the identity of the degradation products 
of NHS-POx by studying the stability of NHS-POx in physiologically relevant media. 
1H-spectroscopy revealed that the polymers bearing carboxylic acid groups in the 
side chain are the most likely degradation product of NHS-POx. After this, we 
synthesized this polymer containing a diethylene-triamine-pentaacetic acid (DTPA) 
ligand as an end-group which allowed chelation of radioactive isotopes (111In). After 
labeling and purification, the radiolabeled polymers were intravenously injected 
in Wistar-rats and the excretion was studied by Single Photon Emission Computed 
Tomography (SPECT) at different time points (1 hr, 6 hrs, 24 hrs and 7 days). After 
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hemostatic agents, because of the highly tunable degradation profile and excellent 
tunable structural properties. As a result, several groups have utilized the versatility 
of synthetic polymers for the development of wound dressing materials16, 17 (such as 
hemostatic agents). One of the most interesting manufacturing techniques for the 
design of these materials is electrospinning.
 Electrospinning is a manufacturing technique for the construction of polymeric 
fibers18, 19. During this process, a polymer solution is ejected through a needle, 
whereafter the ejected solution is charged by a high voltage source (typically 5-20 
kV) which results in the formation of a conical shape, a so-called Taylor cone (Figure 
1)20. By continuous ejection, the polymeric fibers can be collected on a metal surface 
(collector). 
 The quality and properties of the fibers which are formed are strongly 
determined by the experimental parameters which are used (e.g. solvent21, 
voltage22, concentration22), characteristics of the polymer and additives23 during 
the electrospinning process, which renders thic technique a highly tunable process. 
A wide range of fibers has been produced using electrospinning including solid24, 
hollow25 and porous26 fibers for a wide range of different polymers19, which allows 
design of fibers of various architectures.
 Electrospinning has also been applied in the field of poly(2-oxazoline)s. To 
date, several groups have reported electrospinning of poly(2-oxazoline)s, ranging 
from homopolymers such as poly(2-ethyl-2-oxazoline)24, 27 to side chain functional 
polymers28, thereby demonstrating the compatibility of poly(2-oxazolines) with 
electrospinning.   
Figure 1 Overview of the electrospinning process: A) Overview of an electrospinning setup, B) example 
of electospun fibers based on P(EtOx). Reprinted with permission27.  
these materials would involve introduction of additional hydrophilic moieties in 
the sidechains which would replace the hydrophilic functionalities described in 
Chapter 2. This would make the overall polymer structure more water soluble and 
the crosslinking groups more prone to reaction with primary amines. A final option 
would be to investigate dendritic structures based on POx, since these architectures 
can greatly enhance the availability of these crosslinking groups as well. The 
synthesis of dendritic POx has been reported7, 8, although care must be taken that 
the abovementioned modifications of the polymer structures should not impede 
their synthesis via robust procedures to allow sufficient quality. 
 Besides the adjustments that can be made in the polymer structure, several 
other improvements can be introduced, e.g. by using additives during production 
of hemostatic patches. In Chapter 5, it was demonstrated that the stiffness of the 
formed network between NHS-POx and BSA can be increased if the crosslinking 
reaction is performed at an elevated pH. Thus, an important parameter which can be 
tuned to enhance the crosslinking ability of NHS-POx is the pH of the hemostatic 
construct, for example by addition of a biocompatible basic component (such as 
sodium carbonate) onto the coated constructs. Upon contact of the hemostatic 
device with blood, the local pH would be slightly elevated to the desired pH which 
would facilitate crosslinking. Subsequently, the pH would be neutralized by the 
buffering ability of the blood after the crosslinking process has been finalized. This 
approach has already been suitably employed in various commercially available 
tissue adhesives in the biomedical field, such as Duraseal9 and Coseal10.
 Finally, a third improvement which could improve the development process is by 
getting a better understanding of the mechanism of action. Performing a systematic 
approach in investigating all the individual parameters in the process (e.g. polymeric 
structure, coating) in predictive model systems will ultimately lead to a more 
focused development process. An example of such a predictive model could be a 
suitable ex-vivo model to mimic profuse bleedings. Although in vivo efficacy remains 
the ultimate proof for a hemostatic agent, a suitable and predictive ex-vivo model 
would allow to obtain more understanding of the system, which can ultimately lead 
to a reduction of the number of animal experiments which have to be performed. 
To date, however, only a limited number of predictive ex-vivo models are reported, 
which compare the efficacy of hemostatic agents within one ex-vivo model11, 12.
Electrospinning 
While current topical hemostatic agents are generally still hybrid products 
(consisting both of natural and synthetic polymers), in the biomedical materials 
field, there is an increased interest towards the design of fully synthetic hemostatic 
materials13-15. These materials can offer multiple advantages over current topical 
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For the development of hemostatic materials based on POx, electrospinning 
is a particularly interesting platform, since it would result in a purely synthetic 
fibrous mat. The fibrous microstructure of this electrospun mat can have multiple 
advantages over current hemostatic products, e.g. a large surface area, which 
can greatly enhance the performance of these products. Moreover, this technique 
allows tuning of various parameters (fiber diameter29, pore size30, thickness31), 
which are important parameters for the hemostatic efficacy. Currently, in the 
field, electrospinning is mainly performed at lab-scale, although translation of this 
technology towards industrial applications is emerging16. 
 In conclusion, in this thesis we have successfully demonstrated the use of 
NHS-POx in hemostatic applications. We are convinced that that these polymers 
are excellent candidates for the design of hemostatic polymers. Evidently, the 
versatility of the polymers allows further finetuning of the polymer structure aimed 
at improved hemostatic efficacy. The opportunities are numerous as this class of 
polymers is compatible with manufacturing techniques such as electrospinning, 
which would lead to purely synthetic hemostatic products that might outperform 
currently available topical hemostatic agents on the market.
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uiteindelijk de hoeveelheid functionele groepen (NHS-esters) die uiteindelijk 
in het polymeren ingebouwd kunnen worden. In de tweede route (B) hebben we 
polymeren gemaakt, d.m.v. CROP met 2-methoxy-carbonyl-ethyl-2-oxazoline 
(MestOx) als functionaliseerbaar monomeer en 2-n-propyl-2-oxazoline (nPropOx) 
en 2-ethyl-2-oxazoline (EtOx) als niet-functionaliseerbare monomeren voor het 
regelen van de polariteit van de polymeren. Na de polymerisatie, hebben we de 
methylester groepen op het polymeer gehydrolyseerd en geactiveerd tot NHS-
esters wat resulteerde in een serie van NHS-ester gefunctionalizeerde polymeren 
met verschillende polariteiten.  In een derde syntheseroute (C) hebben we (net als in 
route B) gebruik gemaakt van CROP en post-polymerisatie-modificatiestrategieën 
(d.m.v. amidatie van de methyl ester groepen). In deze route hebben we de 
hydrofiele groepen en NHS-estergroepen ingebouwd d.m.v. modificatie van de 
methylesters. Nadat de polymeren gesynthetiseerd waren, zijn deze getest op 
enkele fysisch-chemische eigenschappen (zoals oplosbaarheid in water). We hebben 
geconcludeerd dat alleen routes B en C rendabele, robuuste syntheseroutes waren 
voor het maken van NHS-POx polymeren. Daarnaast waren de polymeren die via 
deze routes gemaakt zijn oplosbaar in water en organische oplosmiddelen, wat ze 
geschikt maakt als om als hemostatisch polymeer gebruikt en verwerkt te worden. 
Routes B en C zijn vervolgens gebruikt voor de synthese van POx polymeren die in 
de volgende hoofdstukken van deze thesis beschreven staan.
 In Hoofdstuk 3 hebben we een systematische studie gedaan naar het pH- en 
thermoresponsieve onderste kritische oplossingstemperatuur (LCST) gedrag 
van nPropOx bevattende copolymeren. Doordat deze polymeren naast nPropOx-
groepen ook carboxylzuur groepen of amine-groepen bevatten zijn deze gevoelig 
voor veranderingen in pH en temperatuur. Dit gedrag was bestudeerd door middel van 
turbidimetrie door te kijken naar de kritische oplossingstemperatuur (CP) van deze 
polymeren terwijl we verschillende parameters varieerden (polymeerconcentratie, 
zoutconcentratie en pH). We hebben gevonden dat de polymeerconcentratie 
een belangrijke parameter is voor het regelen van de CP. Verder vonden we dat 
er een lineair verband bestond tussen de hoogte van de CP en de hoeveelheid 
carboxylzuurgroepen op het polymeer. Het toevoegen van verschillende 
hoeveelheden zout (NaCl) leidde tot een verlaging van de CP wat verklaard kan 
worden door het uitzouten van het polymeer. Verder hebben we gevonden dat 
de pH van de oplossing een sterke invloed heeft op de lading van het polymeer, 
wat invloed heeft op de mate van oplosbaarheid in water en ook op de CP van de 
verschillende polymeren. Tenslotte hebben we turbiditeitsmetingen uitgevoerd in 
een fosfaatgebufferde zoutoplossing (PBS) om de CP onder fysiologische condities 
te onderzoeken. In deze experimenten hebben we gevonden dat de CP afhankelijk 
van de polymeerconcentraties kan worden ingesteld rond de lichaamstemperatuur 
1. Samenvatting
Operaties op zachte weefsels zoals lever en nieren gaan vaak gepaard met ernstige 
bloedingen, omdat deze weefsels goed doorbloed zijn. Hierdoor kunnen invasieve 
manieren om wonden te hechten (zoals hechtdraden en nietjes) niet gebruikt worden 
om deze, meestal hevige, bloedingen te stelpen. In dit werk zijn we geïnteresseerd 
om een niet-invasief hemostatisch hulpmiddel te ontwikkelen gebaseerd op poly(2-
oxazoline)s (POx) met N-hydroxysuccinimide-(NHS) esters (NHS-POx). De werking 
van deze polymeren is gebaseerd op de reactiviteit van NHS-esters met primaire 
amines, die veelvuldig voorkomen in bloedcomponenten (bijv. albumine) of weefsels 
(bijv. in een orgaan als de lever). Deze reactiviteit maakt deze polymeren geschikt 
als hemostatisch materiaal, doordat het de mogelijkheid geeft om een reactie aan 
te gaan met bloedcomponenten en zo een artificiele bloedprop te vormen en/of 
door als wondafsluitingsmiddel te werken door aan weefsel te hechten. Zoals is 
beschreven in hoofdstuk 1, worden NHS-ester gefunctionaliseerde polymeren al 
gebruikt in biomedische hulpmiddelen die gebaseerdeerd zijn op poly(ethyleen) 
glycol (PEG). Het nadeel van deze materialen is dat deze onvoldoende goed werken 
om hevige bloedingen te stelpen. Dit is mogelijk op te lossen door de polariteit 
en hoeveelheid NHS-esters op het polymeer aan te passen. Echter, voor PEG zijn 
deze twee parameters niet makkelijk aan te passen en zijn andere polymeerklassen 
beter geschikt. Vanwege de veelzijdige functionalisatiemogelijkheden en de 
biocompatibiliteit, hebben we in dit werk POx geselecteerd voor de ontwikkeling 
van hemostatische materialen.
 In hoofdstuk 2 hebben we verschillende synthetische routes besproken om 
NHS-POx te maken.  Een moeilijkheid is dat NHS-esters niet direct in polymeren 
kunnen worden ingebouwd tijdens kationische ring opening polymerisatie (CROP), 
de meest gebruikelijke manier om POx te maken, omdat deze functionele groep de 
polymerisatie verstoren. Daarom hebben we gebruik gemaakt van CROP en post-
polymerisatie-modificatiestrategieën voor het ontwikkelen van een schaalbare, 
robuuste methode om NHS-POx te maken. Daarnaast waren we geïnteresseerd 
in de fysisch-chemische eigenschappen van de gesynthetiseerde polymeren 
(zoals oplosbaarheid in water).  We hebben drie verschillende syntheseroutes (A-
C) ontwikkeld, welke alledrie gebaseerd zijn intermediaire polymeren die methyl-
esters bevatten. Deze methyl-ester groepen op de polymeren kunnen namelijk 
gemakkelijk worden omgezet naar NHS-esters. In de eerste route (A) hebben we 
gebruik gemaakt van gedeeltelijke, zuurgebaseerde hydrolyse van tertiaire amides 
in de skeletstructuur van commercieel verkrijgbaar poly(2-ethyl-2-oxazoline) 
(Aquazol®), wat resulteerde in de vorming van poly(ethyleen imine) (l-PEI) groepen. 
De hoeveelheid aan l-PEI groepen die tijdens de hydrolyse ontstaan, bepaalt 
167166
Chapter 8 Dutch summary and perspective view
8
PEG. Hierdoor hebben we gekeken naar de vernetting van deze polymeren met 
runderalbumine (BSA), een veelvoorkomend eiwit in (runder)bloed. In deze studie 
waren we geïnteresseerd in het effect van i) de positie van de NHS-esters op het 
polymeer (als zijgroepen (POx) of als eindgroepen (PEG)) en ii) het effect van 
het type hydrofiele groep (OH of N(CH3)2) op het polymeer, op de vorming van 
polymeer-eiwit netwerk. Daarnaast hebben de invloed van de pH op de snelheid 
en stijfheid van de gevormde netwerken onderzocht voor NHS-POx. We hebben 
gevonden dat NHS-POx en NHS-PEG beide instantaan een netwerk vormde met 
BSA, maar dat NHS-PEG stijvere netwerkstructuren vormde met BSA dan NHS-
POx. Verder zagen we dat beide soorten netwerken elastisch waren bij verschillende 
frequenties. Een andere interessante observatie was dat we zagen dat NHS-POx 
gebaseerde netwerken stijver werden nadat er meer spanning op de netwerken 
gezet werd, wat duidt op een andere netwerkstructuur die gevormd wordt bij 
PEG en POx gebaseerde netwerken. We kunnen dit verklaren door de verschillen 
in polymeerarchitectuur tussen PEG en POx. Omdat de NHS-ester in NHS-PEG 
heel mobiel zijn vormt NHS-PEG vooral bindingen tussen PEG met afzonderlijke 
eiwitmoleculen tot een homogeen netwerk. Bij NHS-POx zijn deze groepen minder 
mobiel, waardoor er hier (naast soortgelijke verbindingen als bij NHS-PEG) ook 
meerder bindingen van een polymeer met eenzelfde eiwitmolecuul mogelijk zijn. 
Dit resulteert in de vorming van een onregelmatig netwerk. Verder hebben we 
gevonden dat bij een pH-waarde van 8.5 de sterkste netwerkstructuren gevormd 
werden door NHS-POx. Daarnaast was het type hydrofiele groepen op het polymeer 
van weinig invloed op de gevormde netwerkstructuur. De sterkte de gevormde 
netwerken van NHS-PEG en NHS-POx zijn beide van sterker dan fibrinestolsels die 
gevormd worden in de bloedstollingscascade, wat deze polymeren geschikt maakt 
als wondafsluitingsmiddel/hemostaticum.  
 In Hoofdstuk 6 hebben we de afbraak en excretie van NHS-POx onderzocht. 
In deze studie waren we specifiek geïnteresseerd om te bestuderen hoe en of 
de afbraakproducten van NHS-POx geklaard worden. Daarnaast wilden we 
onderzoeken of deze afbraakproducten ongewenste ophoping in organen liet zien. 
Om dit te onderzoeken hebben we eerst de degradatie van NHS-POx onderzocht 
door incubatie van dit polymeer in PBS en bloedplasma te onderzoeken. In deze 
studie hebben we met behulp van 1H-NMR-spectroscopie bepaald dat bij deze 
polymeren de NHS-esters afbreken tot carboxylzuren en dat de ester binding in de 
zijgroep van het polymeer stabiel bleef onder de geteste omstandigheden. Hierna 
hebben we het dit polymeer gemaakt met een pentetinezuur (DTPA) eindgroep 
als een ligand voor het binden van radioactiviteve isotopen (zoals Indium-111). 
Na radiolabeling en zuivering hebben we dit gelabelde polymeer intraveneus 
geinjecteerd in de staart van Wistar-ratten. De excretie van de polymeren was 
(37 °C). Samenvattend hebben we in dit hoofdstuk laten zien dat het veelzijdige 
temperatuurgevoelige gedrag van deze polymeer voor meerdere toepassingen 
interessant kan zijn. Zo hebben we dit gebruikt voor het opzuiveren van polymeren 
in route B (beschreven in Hoofdstuk 2), maar verder kan dit gedrag ook gebruikt 
worden voor het ontwikkelen van materialen die gebruikt kunnen worden voor 
bijvoorbeeld medicijnafgifte. 
 In Hoofdstuk 4 hebben we de hemostatische activiteit van verschillende NHS-
POx polymeren (beschreven in Hoofdstuk 2) getest. We hebben dit zowel in vitro 
als ook in vivo getest en vergeleken met commercieel verkrijgbare hemostatische 
producten als controle.  In een eerste studie hebben we een serie van NHS-POx 
polymeren en een NHS-PEG controle laten reageren met humaan bloed. Door deze 
reactie werden covalente bindingen gevormd tussen bloedeiwitten en polymeer, 
wat resulteerde in een netwerkstructuur van polymeer en bloedeiwitten. We hebben 
gevonden dat deze vernetting alleen optrad als het polymeer NHS-esters bevatte. 
Bovendien trad de vernetting sneller op als het polymeer ook hydrofiele groepen 
bevatte, maar de vernetting met NHS-PEG verliep het snelste in dit experiment. 
Het NHS-POx polymeer wat het beste werkte in dit experiment werd vervolgens 
gespraycoat op gelatinesponzen, wat geresulteerde in een serie hemostatische 
sponzen met verschillende bedekkingsgraden (mg polymeer per cm2). Hierna werden 
de NHS-POx sponzen en Hemopatch (NHS-PEG) gecoate spons bestudeerd met 
een rasterelektronenmicroscoop (SEM).  We zagen dat het poreuze karakter van 
de NHS-POx sponzen behouden bleef en dat ze homegener gecoat waren dan 
Hemopatch, die gecoate en ongecoate domeinen bevat. De gecoate sponzen werden 
vervolgens getest op bloedopname en plakkracht. We hebben ontdekt dat een hogere 
bedekkingsgraad leidde tot verminderde bloedopname. In de plaktest zagen we dat 
sponzen met coating wel plakten en sponzen zonder coating niet plakten, maar er was 
geen duidelijk effect te zien van de hoeveelheid coating op de plakkracht. Vervolgens 
hebben we de hemostatische activiteit van een gecoate spons getest in een in vivo-
model voor zware bloedingen. Daarnaast hebben we een negatieve controle (spons 
zonder coating) en twee commerciële producten (Hemopatch gebaseerd op PEG-
NHS) en Tachosil getest in dit model. De NHS-POx gecoate spons, waarmee 7 van de 
8 bloedingen kon worden gestopt, presteerde beter dan de ongecoate spons (0 uit 4 
bloedingen) en Tachosil (1 uit 4 bloedingen). Ook in vergelijking met Hemopatch (5 uit 
8 bloedingen) presteerde de spons beter. Bovendien was bij Hemopatch (en niet bij de 
NHS-POx gecoate spons) bloeding aan de randen van de spons te zien, wat benadrukt 
dat ook een homogeneiteit van de coating een belangrijkere eigenschap is voor het 
ontwerpen van een hemostatische spons. 
 In Hoofdstuk 5 hebben we een systematische rheologische studie uitgevoerd 
om meer inzicht te krijgen in het verschil in werking tussen NHS-POx en NHS-
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kan deze reactie bespoedigd worden door de beschikbaarheid van deze groepen te 
vergroten. Dit kan geregeld worden door de afstand tussen het polymeerskelet en de 
elektrofiele NHS-esters te vergroten, waardoor de NHS-esters meer beweegruimte 
krijgen waardoor ze makkelijker kunnen reageren. Daarnaast zou er gekeken kunnen 
worden om een andere soort hydrofiele groep op de polymeer in te bouwen (via route B of 
C (Hoofdstuk 2)). Hierdoor kan het totale polymeer beter oplosbaar worden, waardoor 
de NHS-esters efficiënter kunnen reageren. Een laatste optie is door gebruik te maken 
van dendritische structuren gebaseerd op POx, omdat deze polymeerarchitectuur de 
beschikbaarheid van NHS-esters verbeterd. Een voordeel van deze laatste modificatie 
is dat de synthese van dendritische POx-polymeren reeds is beschreven in literatuur. 
Een belangrijke voorwaarde aan alle veranderingen die gedaan worden is wel dat ze via 
schaalbare, robuuste procedures ingebouwd kunnen worden.
 Naast structurele veranderingen aan de polymeerstructuur kunnen ook 
veranderingen kunnen gedaan tijdens de productie van de hemostatische sponzen om 
de prestaties te bevorderen, bijvoorbeeld door het toevoegen van additieven tijdens 
de productie. In Hoofdstuk 5 hebben we gezien dat de stijfheid van de netwerken die 
tussen NHS-POx en BSA netwerken gevormd worden verhoogd kan worden door de 
pH tijdens de koppelingsreactie te verhogen. Dit zou gerealiseerd kunnen worden door 
een biocompatibele basische component (zoals natriumcarbonaat) aan te brengen op 
de gecoate spons. Door contact van de gecoate spons met bloed zal de pH in de buurt 
van het grensvlak tijdens de koppelingsreactie tijdelijk verhoogd worden, waardoor 
koppeling efficient kan plaatsvinden. Hierna zal de bufferende capaciteit van het 
bloed, de pH normaliseren tot physiologische pH. De methode van het uitvoeren van 
koppelingsreacties bij verhoogde pH wordt al gebruikt bij commercieel verkrijgbare 
medische hulpmiddelen zoals Duraseal en Coseal.
 Naast veranderingen op basis van zou het nuttig zijn om meer inzicht te krijgen in 
de verschillende parameters die van belang zijn voor de werking van de hemostatische 
spons. Alhoewel verschillende belangrijke parameters voor de werking van NHS-
POx zijn beschreven in dit werk. Een systematisch onderzoek naar alle parameters 
(bijvoorbeeld de polymeerstructuur en de coating) in voorspellenende diermodellen 
zal uiteindelijk leiden tot een meer gefocuste ontwikkelingsproces. Een voorbeeld 
hiervan zou het ontwikkelen van een voorspellend ex-vivo modelsysteem dat hevige 
leverbloedingen kan simuleren. Alhoewel werking in vivo het ultieme bewijs blijft 
voor de werking van de hemostatische sponzen, zal het hebben van een voorspellend 
system kunnen leiden tot het verminderen van de te onderzoeken parameters in 
vivo. Hierdoor zullen minder proefdieren nodig zijn. Alhoewel er modelsystemen 
beschikbaar zijn die hevige bloedingen simuleren, bestaat er grote heterogeniteit 
tussen de systemen. Daarentegen zijn er weinig studies bekend die de werking van 
verschillende hemostatische producten binnen een simulatiemodel vergelijken. 
vervolgens bestudeerd met behulp van SPECT (computertomografie met behulp 
van uitstraling van enkelvoudige fotonen) door een afbeelding te reconstrueren na 1 
uur, 6 uur, 24 uur en 7 dagen (na injectie). Na 7 dagen werden de dieren opgeofferd. 
Vervolgens werden de organen operatief verwijderd, gewogen en geanalyseerd met 
behulp van een γ-counter. We hebben gevonden dat binnen 24 uur het merendeel 
van het geinjecteerde polymeer kon worden geklaard via de nieren. Niettemin, na 
7 dagen was ondanks een afname van het signaal, nog steeds 3.1 ± 1.1 % van de 
geïnjecteerde dosis per gram orgaan (%ID/g) (SPECT) of 9.5 ± 0.6 %ID/g (γ counter) 
te meten in de nieren. Geen ophoping van het polymeer in de andere organen was 
te zien. Concluderend hebben we gevonden dat het merendeel van de geïnjecteerde 
dosis van het polymeer kon worden geklaard via de nieren, echter dat een kleine 
hoeveelheid na zeven dagen nog steeds in de nieren te vinden was. Meer systematisch 
onderzoek is nodig om betrouwbare conclusies te trekken over de oorzaak van deze 
aanwezigheid van gelabelde afbraakproducten van NHS-POx in de nieren.   
 Tenslotte hebben we in dit werk laten zien dat NHS-POx in vele aspecten een 
veelbelovend alternatief is voor huidige hemostatische polymeren.   
2. Toekomstperspectieven
De laatste tientallen jaren hebben hemostatische materialen een geweldige 
ontwikkeling doorgemaakt. Traditioneel werd er in het veld voor gebruik gemaakt 
van hemostatische materialen van natuurlijke oorspong (zoals collageen en gelatine), 
omdat deze in groten getale beschikbaar zijn, goedkoop zijn en zeer snel afbreken. 
Deze materialen zullen in de toekomst nog wel gebruikt worden voor het behandelen 
van minder hevige bloedingen, maar deze materialen bieden geen passende oplossing 
voor het stelpen van hevige bloedingen tijdens operaties. Recentelijk zijn daarom 
meer geavanceerde hemostatische materialen ontwikkeld (zoals Hemopatch, Veriset 
en Tachosil) die beter geschikt zijn om zwaardere bloedingen te stelpen. Echter, ook 
deze materialen hebben specifieke nadelen (zoals beschreven in Hoofdstuk 1) wat vele 
groepen gestimuleerd heeft tot onderzoek naar nieuwe hemostatische materialen. 
Een voorbeeld hiervan zijn NHS-ester gefunctionaliseerde poly(2-oxazoline)s die 
beschreven zijn in dit werk.
 Ondanks dat de geschiktheid van deze materialen als hemostatisch materiaal 
is beschreven in dit werk, kunnen meerdere aanpassingen worden gedaan om de 
prestaties van deze materialen te verbeteren. Een soort aanpassingen die kan worden 
gedaan is structurele veranderingen op het polymeer toe te passen, zodat de polymeren 
efficiënter kunnen reageren met bloedeiwitten en zachte weefsels, waardoor het 
stoppen van bloedingen vergemakkelijkt wordt. Zoals, beschreven in Hoofdstuk 5 
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(zoals poly(2-ethyl-2-oxazoline)s) tot zijgroep-gefunctionaliseerde polymeren, wat de 
compatibiliteit van deze techniek met poly(2-oxazoline)s benadrukt. 
 Voor het ontwikkelen van hemostatische materialen gebaseerd op poly(2-
oxazoline)s is elektrospinnen een uitermate geschikt platform omdat het een 
volledig synthetische poreuze mat oplevert. De fijne microstructuur van de vezels, 
zorgt voor een groot contactoppervlak (in vergelijking met polymeerfilms). Dit 
grote contactoppervlak kan ervoor zorgen dat de hemostatische werking van 
deze polymeren verbeterd wordt. Daarnaast is het mogelijk om dit hemostatische 
effectiviteit te optimaliseren, door de eigenschappen van de polymeervezels aan te 
passen (zoals vezeldiameter, poriegrootte en vezeldikte). Ondanks dat elektrospinnen 
in het veld voornamelijk op laboratoriumschaal wordt uitgevoerd, zijn meerdere 
bedrijven bezig om deze constructietechniek te industrialiseren.
 In dit werk hebben we laten zien dat NHS-POx succesvol kan worden gebruikt 
voor hemostatische toepassingen. We zijn ervan overtuigd dat deze polymeren een 
uitstekend platform zijn voor de ontwikkeling van hemostatische materialen. Het is 
verder duidelijk dat de veelzijdigheid van deze polymeerklasse verder uitgebuit kan 
worden voor het verbeteren van de hemostatische activiteit. De compatibiliteit met 
constructietechnieken zoals elektrospinnen maakt het zelfs mogelijk om volledig 
synthetische hemostatische producten te maken, wat verdere mogelijkheden biedt 
voor het optimaliseren van dit platform als hemostatische materialen.   
Elektrospinnen
Ondanks dat het merendeel van de huidige hemostatische hulpmiddelen hydribe 
producten zijn (bestaande uit natuurlijke en synthetische materialen), zijn er 
verschillende groepen die onderzoek doen naar het ontwikkelen van volledig 
synthetische hemostatische materialen. Deze materialen hebben potentiele 
voordelen in vergelijking met natuurlijke materialen, zoals de uitstekend in te 
stellen afbreekbaarheid van deze materialen. Meerdere onderzoeksgroepen 
onderzoeken daarom de mogelijkheid om volledig synthetische polymeren als 
wondafdichtingsmaterialen te ontwikkelen. Een van de meest interessante 
constructietechnieken voor het maken van deze materialen is elektrospinnen. 
Elektrospinnen is een constructietechniek om polymeervezels te maken. Tijdens dit 
proces wordt een polymeeroplossing door een naald uitgedrukt. Deze uitgedrukte 
oplossing wordt elektrisch geladen door een hoge spanningsbron (5-20 kV), wat 
resulteert in een ‘kegel-vorm’, de zogenaamde Taylor kegel (Figuur 1). Door 
continue uitdrukking van het polymeer worden er polymeervezels gevormd, die 
kunnen worden opgevangen op een metalen oppervlak. 
Figuur 1 Overzicht van het elektrospinproces: A) Overzicht van de elektrospinning, B) voorbeeld van 
elektrogesponnen vezels gebaseerd op P(EtOx)  
De kwaliteit en eigenschappen van de vezels zijn sterk afhankelijk van experimentele 
condities die gebruikt zijn (zoals het type van het oplosmiddel), de eigenschappen 
van het polymeer en de additieven die worden gebruikt tijdens het elektrospinnen. De 
vele verschillende parameters die kunnen worden aangepast maakt elektrospinnen 
een veelzijdig en afstembaar proces. Mede hierdoor zijn verschillende soorten 
polymeervezels ontwikkeld, zoals massieve vezels, holle vezels of poreuze vezels. 
 Elektrospinnen is ook toegepast voor poly(2-oxazoline)s. Meerdere groepen hebben 
elektrogesponnen poly(2-oxazoline)s ontwikkeld, variërend van homopolymeren 
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